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1 Summary 
Toll-like receptors (TLR) recognize conserved molecular patterns of microorganisms and are essential 
for the activation of host immunity. Whereas the immune-stimulatory effects of TLR ligands are well 
described, the circumstances of TLR-mediated inhibition of immune responses are still largely 
unknown. In this thesis, it was investigated how ligands for TLR9 and TLR7 modulated cytotoxic T 
cell responses in mice infected with recombinant adenovirus or Plasmodium ssp. in vivo. The results 
of this thesis point out, that the anatomical site, dose, and time-point of TLR ligand application 
determined whether an immune response to an infection was stimulated or suppressed. In contrast to 
subcutaneous application of TLRs that stimulate adaptive immune responses, systemic application of 
TLR ligands in high doses prior to infection suppressed CD8 T cell cytotoxicity. TLR-ligand induced 
suppression of adaptive immune responses was characterized by reduced numbers of antigen-specific 
T cells and a (subsequent) lack of cytotoxicity and was crucially dependent on TLR expression. 
Importantly, by adoptive transfer of activated antigen-specific CD4+ T helper cells into TLR ligand-
treated mice it was possible to overcome TLR-ligand mediated suppression of CTL responses. This 
indicated that a block in CD4+ T cell activation is likely to account for insufficient CTL induction. 
Although TLR ligands caused functional impairment of dendritic cells, we doubt that DC paralysis 
was solely responsible for CTL suppression. An adoptive transfer of exogenously matured and antigen 
loaded DCs did not overcome CTL suppression in TLR ligand-treated mice, which further indicated 
that TLR ligand-induced CTL suppression was rather due to the induction of an inhibitory milieu than 
due to inability of DCs to activate T cells. In TLR7 ligand-mediated CTL suppression, inhibitory 
effects could be attributed to type I interferons. 
A physiological relevance of TLR-mediated suppression of effector immune responses was shown in 
mouse models of Plasmodium ssp. infection. Cerebral malaria (CM) is a severe immune-mediated 
complication in P. falciparum infection in humans. IFN! and T cells are among the few factors that 
are known to be essential in the pathogenesis of experimental CM (ECM) in mice upon P. berghei 
ANKA (PbA) infection. Here, we show by use of knock out mice that TLR2, -3 and -9 and IL-12 are 
crucial for the development of ECM upon PbA infection. PbA-infected mice were also significantly 
protected against ECM if they were depleted of DCs or were splenectomized. However, a key finding 
of this thesis was the observation that PbA parasites themselves were able to prevent detrimental 
effector responses. Wild type mice but not mice deficient in TLR2, TLR9, IL-12p40, IL-10 or iNOS 
were significantly protected against ECM upon infection with a highly enhanced dose of PbA. Also, 
systemic application of TLR9 ligand CpG protected PbA-low dose-infected wild type mice but not 
TLR9 deficient littermates from ECM. CpG blocked the production of pro-inflammatory mediators by 
DCs and prevented the generation of Plasmodium specific CD8+ T cell responses. These results 
strongly suggest that TLRs fulfill dual functions in regulation of immune responses in Plasmodium 
infection.  
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Overall, we conclude that the induction of immune suppression represents a sort of “emergency 
shutdown” that is induced if circumstances of TLR activation or infection due to excessive 
inflammation endanger the host’s life. Prevention of immune pathology ensures survival of the host. 
Pathogens such as Plasmodium ssp. may benefit from these mechanisms of TLR-mediated immune 
suppression as it offers a possibility of immune evasion or silencing that allows completion of their 
life cycle. 
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3 Abbreviations 
"  anti- 
A  Ampere 
Ab  antibody 
ABTA  2,2-Azino-bis-3-Ethylbenzothiazoline-6-sufonic acid 
AdOVA  recombinant Adenovirus type 5 expressing ovalbumin 
AdGFP  recombinant Adenovirus type 5 expressing GFP 
APC  antigen presenting cell; Allophycocyanin 
APC-Cy7 Allophycocyanin-Cy7 
 
B6  C57BL/6 mice 
bp  base pairs 
BSA  bovine serum albumin 
 
C  Celsius 
CD  cluster of differentiation 
CFSE  Carboxy Fluoroscein di-amino Succinimidyl Ester 
CpG-  Cytosin-phosphat-‚Guanin 
CM  cerebral malaria 
CM-R  cerebral malaria resistant 
CM-S  cerebral malaria susceptible 
CTL  cytotoxic T lymphocyte 
CQ  chloroquine 
 
D  Dalton (1D = 1,6601 x 10e
-27
 kg) 
DC  dendritic cell 
DEPC  Diethylpyrocarbonat 
DMSO  Dimethylsulfoxid 
DNA  deoxyribonucleic acid 
dNTP  2´-Desoxy-Nukleosidtriphosphat 
DOG  CD11c DTR Ovalbumin green fluorescent protein 
DTR  Diphtheria Toxin Receptor 
DTX  Diphtheria Toxin 
 
ECM  experimental cerebral malaria 
E.coli  Escherichia coli 
EDTA  ethylendiameintetraessigsäure 
ELISA  enzyme linked immuno sorbent assay 
et al.  et alteres 
EtOH  Ethanol 
 
FACS  fluorescence activated cell sorter 
FCS  fetal calf serum 
FITC  Fluorescein 
flg  Flagellin 
 
g  gram; acceleration of gravity (9,81m/s2) 
GFP  green fluorescent protein 
GpC  Guanin, phosphat, Cytosin 
 
h  hour 
HE  Hematoxylin-Eosin 
HK  heat killed 
HSP  heat shock protein 
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ICAM  intercellular adhesion molecule; CD54 
ICS  intra-cellular staining 
IDO  Indoleamine 2,3-dioxygenase 
IFN"  Interferon alpha 
IFNAR  Interferin alpha receptor; type I interferon receptor 
IFNß  Interferon beta 
IFN!  Interferon gamma 
Ig  Immune globuline 
IL  Interleukin 
iNOS  inducible nitric oxide synthase 
i.p.  intra-peritoneal 
IRF  interferon regulatory factor 
i.v.  intra-venous  
IVIS®200 In vivo imaging system (Xenogen)  
 
kB  kilo bases  
kD  kilo Dalton 
k.o.  knock out 
 
l  Liter 
LiCl  Lithiumchlorid 
LM-OVA recombinant Listeria monocytogenes expressing OVA 
LPS  lipopolysaccharide 
LTA  lipo teichonic acid 
luc  luciferase 
 
!  Micro- (10
-6
) 
m  meter, Milli- (10
-3
) 
M  molar 
mA  Milli-Ampère 
MACS® magnetic activated cell sorter (Miltenyi) 
MDP  muramyl dipeptide; NOD2 ligand 
min  minute 
MHC  major histocompatibility complex 
!MT  IgM transmembrane tail exons, deficiency in B cell k.o. 
mRNA  messenger RNA 
1-MT  1-Methyl-tryptophan 
MyD88  myeloid differentiation factor 88 
MW  Molecular weight 
MZ  marginal zone 
 
n  Nano-  (10
-9
), number 
nmol  Nanomol 
NaCl  Natrium chloride 
NaOH  Natriumhydroxid 
NF#B  nuclear factor kappa B 
NK  natural killer 
NKT  natural killer T cell 
NLR  NOD-like receptors 
NOD  nucleotide oligomerization domain 
 
Odx  optical density at x nm 
ODN  Oligodeoxynucleotide 
Oligo-d(T) Oligodeoxythymiylacid (= sequence of +thymidin nucleotides) 
OT-I H-2
b
 restricted CD8
+
 cells expressing transgenic TCR that recognizes OVA-
derived peptide SIINFEKL AA257-265 in the context of K
b
. 
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OT-II H-2
b
 restricted CD4
+
 cells expressing a transgenic TCR recognizing OVA-
derived MHC class II peptide AA323-339 in the context of I-A
b
.  
OVA  ovalbumin from chicken egg 
  
PbA  Plasmodium berghei ANKA 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PE  Phycoerythrin 
PE-Cy7 Phycoerythrin-Cy7 
Pf  Plasmodium falciparum 
PG  Prostaglandin 
PGN  Peptidoglycan 
pH  potentia hydrogenii 
p.i.  post infectionem 
p.o.  per os 
 
RAG  recombination activating gene 
RNA  ribonucleic acid 
RNAse  Ribonuclease 
rpm  rounds per minute 
RPMI Roswell Park Memorial Institute, cell culture medium developed by G.E. 
Moore et al. 
RT  room temperature 
 
S8L  SIINFEKL, OVA-derived MHC class I peptide 
S  supernatant 
SA  streptavidin; Staphylococcus aureus 
s.c.  sub-cutaneous 
SDS  sodium dodecyl sulphate 
siRNA  short interfering RNA 
sec  second 
shRNA  short hairpin RNA 
Spl-X  splenectomy 
sTAg  soluble Toxoplasma gondii antigen 
 
TAE  tris acetic acid EDTA 
Tab.  Table 
TCR  T cell receptor 
TEMED N,N,N´, N´,Tetramethylethylendiamin 
tg  transgenic 
TGFß  transforming growth factor beta 
TLR  Toll-like receptor 
TNF"  tumor necrosis factor alpha 
TRIF  TIR domain containing adapter inducing Interferon beta 
Tris  Tris(hydroxymethyl)aminomethan 
 
U  unit; international enzyme unit 
UV  ultraviolet light 
 
V  Volt 
VCAM  vascular-cell-adhesion molecule; CD106 
v/v  percent by volume 
 
XP  cross-presentation 
 
4  Introduction  
1 
4 Introduction 
4.1 The immune system and the task of defense 
 
The mammalian immune system represents an organization of cells and molecules with specialized 
roles for the defense against “danger” elicited by viruses, bacteria, or parasites but also by degenerated 
tumor cells to prevent harm of the organism. In mammals there are two fundamentally different types 
of responses that are provided by the innate and the acquired (or adaptive) part of the immune system. 
Innate defense mechanisms reduce pathogen load, whereas final clearance is achieved by the specific 
adaptive immune response. The innate immune system is the first line of defense characterized by 
phagocytes including macrophages and dendritic cells. Early detection of potentially harmful 
microorganisms is facilitated by a limited number of germline-encoded pattern recognition receptors 
(PRRs) that trigger inflammatory processes to kill the pathogens. Innate defense mechanisms initiate 
and provide time for the development of highly specific and long-lasting adaptive immune responses 
that are characterized by high diversity, specificity and memory. Acquired immunity is based on the 
activation of B and T lymphocytes and develops by clonal selection from a vast repertoire of 
lymphocytes bearing antigen-specific receptors that are generated via gene re-arrangement. The innate 
and the acquired immune system cooperate at several points to ensure an optimal protection of the 
host.  
 
4.2 Pathogens trigger inflammation 
 
Microorganisms causing disease are called pathogens. To establish an infection, a pathogen must first 
overcome numerous surface barriers, such as enzymes and mucus, that are either directly anti-
microbial or inhibit microbial attachment. Generation of an inflammatory response – a complex 
cascade of events – is the first reaction of an organism to pathogens induced by the infection or tissue 
injury. Important characteristics are migration of cells with defensive functions, alterations in vascular 
permeability and secretion of soluble mediators such as cytokines, chemokines and interferons. 
Inflammatory cells and soluble mediators have strong antimicrobial activities and constitute the 
effector phase of innate resistance. In turn, further immune cells are recruited and activated, which 
involves two major groups of cells, antigen-presenting cells and lymphocytes. The subordinate status 
of the adaptive immune response has been known since the 1960s, when it was shown that 
mononuclear phagocytic cells were required for an effective lymphoid response to antigens (Dutton, 
1967; Unanue and Askonas, 1968). It is now accepted that adaptive immune dependency on innate 
immune cells is based on the need for antigen presentation, a function performed by antigen-
presenting cells (APCs), especially dendritic cells (DCs). DCs are sparsely but widely distributed cells 
of haemato-poietic origin that are specialized for the capture, transport, processing and presentation of 
4  Introduction  
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antigens to T and B cells. At an “immature” stage of development DCs act as sentinels in peripheral 
tissues, continuously sampling the antigenic environment. Any encounter with microbial products or 
tissue damage initiates the maturation of DCs. The initial uptake and phagocytosis of microbial 
antigen by APCs is facilitated by receptor-mediated recognition of microbial molecules. Both 
scavenger receptors and receptors of the complement system are critical for this process. Upon 
maturation, DCs migrate to secondary lymphoid organs such as lymph nodes, the spleen and mucosa-
associated lymphoid tissue to initiate acquired responses. Antigen-specific interaction of DCs and 
lymphocytes via cell surface receptors triggers the activation and proliferation of antigen-specific B 
and T lymphocytes.  
A long time, the contribution of innate detection mechanisms that is based on a limited set of non-
clonal germline encoded receptors for the generation of an adaptive immune response was 
underestimated. In contrast, studies from the last decade support an important role of innate detection 
and effector mechanisms for translating microbial signals to antigen-specific T and B cells and to 
modulate the quality, strength and duration of the adaptive immune response (Pulendran & Ahmed, 
2006).  
 
4.3 Pattern Recognition via Toll-like receptors  
 
Pattern recognition receptors (PRRs) recognize conserved microbial components, described as 
pathogen associated molecular patterns (PAMPs) that are essential for the survival of the 
microorganism and are therefore difficult to alter. PRRs are expressed constitutively by the host; they 
are germline-encoded, non-clonal and expressed on all cells of a given type, and independent of 
immunologic memory. The discovery of several PRR families and the rapid expansion of knowledge 
in this field led to a reappraisal of the innate immune system. These studies suggested that pattern 
recognition receptors evolved to recognize conserved products of microbial metabolism produced by 
microbial pathogens, but not by the host. Janeway postulated that recognition of PAMPs allows the 
immune system to distinguish infectious “non-self” from noninfectious “self” (Janeway, 1989). The 
basic machineries underlying innate immune responses are highly conserved among species from 
plants and fruit flies to mammals.  
The family of toll-like receptors belongs to these detection systems that are critical for the activation 
of the innate immune system. Toll-like receptors (TLRs) are evolutionary conserved from the worm 
Caenorhabditis elegans to mammals and were originally identified in vertebrates on the basis of their 
homology with Toll, a molecule that was initially identified as a gene product essential for the 
development of embryonic dorso-ventral polarity in Drosophila (Anderson et al., 1985a; Anderson et 
al., 1985b). Later, experiments with Toll-deficient mutants demonstrated important roles of Toll in 
anti-fungal responses of the flies (Lemaitre et al., 1996).  
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4.3.1 Toll-like receptor ligands 
 
So far, 13 members of the TLR-family are known in vertebrates that recognize lipids, carbohydrates, 
peptide and nucleic acid structures that are broadly expressed by different groups of microorganisms 
(Figure 1). Some TLRs are expressed at the cell surface and recognize microbial patterns like 
lipopolysaccharide (LPS) via TLR-4 (Lien et al., 2000; Medzhitov et al., 1997; Poltorak et al., 1998), 
peptidoglycan and lipopeptides via TLR-2 (Takeuchi et al., 1999), bacterial flagellin through TLR-5 
(Hayashi et al., 2001). Further TLRs are expressed on membranes of endocytic vesicles or other 
intracellular organelles. Among those, TLR-3, -7 and -9 are intracellularly located and are described to 
recognize nucleic acids. TLR-3 detects double stranded RNA, and poly IC (Alexopoulou et al., 2001).  
Single stranded RNA and poly U rich sequences are sensed by TLR-7 (Diebold et al., 2004; Heil et al., 
2004). TLR-9 is essential for the recognition of invertebrate derived DNA, whose sequences are 
characterized by unmethylated CpG-rich motifs in contrast to DNA from vertebrates (Hemmi et al., 
2000).  
 
 
Figure 1 Toll like receptors and their ligands 
Toll-like receptor are expressed in cellular membranes at the cell surface or intracellularly. They 
recognize conserved molecules derived from pathogens. Upon binding, intracellular adapter 
molecules are recruited and initiate the activation of NF-kB and IRF-dependent target genes. 
 
 
 
The first hint that in addition to “non-self” ligands also endogenous ligands are sensed, was the 
description of TLR4 mediated recognition of heat shock protein 60 (HSP60) (Ohashi et al., 2000). 
Further on, TLR4-mediated recognition of Fibronectin was described (Okamura et al., 2001) and 
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Vabulas et al. demonstrated that recognition of HSP70 through TLR2/TLR4 triggered MyD88 
dependent signaling (Vabulas et al., 2002). These findings support the “danger” hypothesis postulated 
by Matzinger (Matzinger, 1994; Matzinger, 2002). According to this, the immune system is activated 
through “danger” signals released from damaged or stressed tissue rather than through detection of 
unknown antigens. Thus, if certain criteria of danger are met - i.e. during inflammation - also 
endogenous ligands can be recognized as appropriate ligands by immune cells and activate immunity. 
 
4.3.2 Toll-like receptors: structure and signaling 
 
TLRs are type I integral membrane glycoproteins characterized by their extracellular amino-terminal 
domains containing varying numbers of leucin-rich repeat (LRR) motifs that are responsible for the 
recognition of PAMPs, and a cytoplasmic carboxy-terminal domain homologous to that of the 
interleukin 1 receptor (IL-1R), termed the Toll/IL-1R homology (TIR) domain (Bowie and O'Neill, 
2000) that is required for initiating intracellular signaling (Takeda et al., 2003). All TLRs elicit 
conserved inflammatory pathways, culminating in the activation of transcription factors such as 
nuclear factor (NF)-kB that act as a master switch for inflammation. Subsequently, the expression of 
varying response genes is induced and regulated that are involved in immunity and inflammation. 
Each TLR activates similar signaling pathways, but some TLRs trigger their specific pathways. 
Cellular localization and composition of the individual TLR are likely to contribute to this kind of 
specificity. TLRs occur as dimers (Ozinsky et al., 2000). For example, TLR-1 and TLR-2 hetero-
dimerize and the resulting dimer senses bacterial triacylated lipo-peptides. TLR-2 hetero-dimerizes 
with TLR-6, which recognizes di-acylated lipopeptides. In contrast, TLR9 homo-dimerizes. This is 
presumably also the case for TLR3 and TLR5. It is assumed that the TLR dimers are pre-assembled in 
a low-affinity complex before ligand binding. Once the ligand binds, a conformational change is 
thought to occur that brings both TIR domains of each receptor in closer proximity. This complex then 
recruits TIR domain-containing adapter proteins. Differential induction patterns heavily depend on 
cytoplasmic adapter molecules that can associate with the TIR domain of TLRs (Akira and Takeda, 
2004). The discovery of at least five adapter proteins that are differentially recruited to TLRs has 
provided important hints for the molecular basis of this specificity (O'Neill and Bowie, 2007).  These 
adaptors are myeloid differentiation factor 88 (MyD88), MyD88-adaptor-like (MAL; also known 
asTIRAP), TIR-domain-containing adaptor protein inducing IFN-$ (TRIF; also known as TICAM1), 
TRIF-related adaptor molecule (TRAM, also known as TICAM2) and sterile "- and armadillo-motif 
containing protein (SARM). 
MyD88 was discovered in 1990 and later described as the first adaptor protein docking to the 
intracellular domain of an IL-1R and also to the TLR dimer through a TIR-TIR interaction (Lord et al., 
1990; Medzhitov et al., 1998; Muzio et al., 1997; Wesche et al., 1997). Upon binding of MyD88, 
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IRAK-4 is recruited, becomes activated and phosphorylates IRAK-1 that in turn activates Traf-6. A 
series of ubiquitinylation reactions then occur on Traf-6 itself and on the protein TAK-1, which is a 
candidate kinase for the activation of the inhibitor of NF-kB kinase (IKK) complex, leading to NF-kB 
activation, and activation of upstream kinases for p38 and JNK. 
Taken together, although the TIR domain is the common signaling domain, differences occur in the 
utilization of the different TIR-domain-containing adaptors, which might provide specific tailor-made 
responses to an invading pathogen.  
 
4.4 The adaptive immune response requires innate immune recognition 
 
Unlike antibodies or B cell receptors, T lymphocytes expressing "$ T cell receptors do not recognize 
pathogens and their antigens as such, but instead recognize only antigen that is processed and 
presented in the context of molecules encoded by the major histocompatibility complex (MHC). 
Higher vertebrates express three different classes of MHC encoding genes; two of them are relevant 
for antigen presentation and can be linked to two subtypes of T lymphocytes. Class I MHC genes 
encode glycoproteins expressed on the surface of all nucleated cells; class I presented peptides are 
derived from cytosolic antigens are presented to cytotoxic T cells expressing the CD8 co-receptor. 
Intracellular proteins are degraded into peptides by a proteolytic system in the cytosol – the 
constitutive proteasome – present in all cells. Recognition of MHC class I peptides plays an important 
role in detection and lysis of virus infected cells that display upon intracellular viral replication 
peptides derived from viral antigens on MHC class I. 
In contrast, class II MHC genes encode glycoproteins expressed primarily on antigen-presenting cells 
(macrophages, dendritic cells, B cells), which present processed antigenic peptides derived from 
exogenous antigens to CD4+ T helper cells. APCs internalize exogenous antigens by phagocytosis, 
endocytosis or both processes. Internalized antigen is then degraded into peptides within the 
compartments of the endocytic processing pathway. Within these acidic compartments, antigen is 
degraded to oligopeptides of about 13 to 18 residues, which bind to class II MHC molecules and then 
appear on the cell surface. Dendritic cells are the most effective of the APCs. Because these cells 
constitutively express MHC class II that is increased upon maturation, and have costimulatory activity, 
they can activate naïve CD4+ helper T cells. 
In addition to the presentation of endogenous antigen in the context of MHC class I molecules via the 
classical pathway mentioned above, it was recognized that some cells are able to internalize extra-
cellular antigen, which is shuttled to the cytoplasm, processed via the proteasome and then loaded on 
MHC class I molecules. This pathway was called cross-presentation (Bevan, 1976) and is an important 
process for the induction of CD8+ T cell immunity (called cross-priming) or CD8+ T cell tolerance 
(called cross-tolerance). 
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4.5 T cell activation, CD4 help and Memory 
 
Antigen-specific CD4+ and CD8+ T cells exist at very low frequencies in the naïve host. After 
immunization or infection, naïve T cells are activated and undergo clonal expansion, culminating in a 
higher frequency of antigen-specific cells that rapidly exhibit effector functions. Upon activation, 
naïve CD4+ T cells differentiate into different functional subsets called T helper 1 (TH1) cells that 
produce predominantly IFN! and T helper type 2 (TH2) cells that are characterized by production of 
IL-4. TH1 immune responses are essential for the protection against a variety of intracellular 
infections, whereas TH2 responses can be protective against certain extracellular parasites. CD8
+ T 
cells that mediate their effector functions through production of cytokines such as IFN!, TNF" and/or 
by cytolytic mechanisms are key players in a powerful TH1 response.  
The relevance of CD4+ T cell help and of activation, growth and survival signals provided by other 
cells such as DCs, in induction of an efficient CD8+ T cell response including clonal expansion, 
development of effector function and the generation of long-term memory is not entirely understood. 
A widely accepted theory postulates that the generation of long-lasting CTL responses require antigen-
specific interaction of CD4+ T cells and CD8+ T cells with the same DC (Behrens et al., 2004; 
Castellino and Germain, 2006). 
In most cases, naïve CD8+ T cells first encounter antigen being cross-presented by DCs in lymph 
nodes and the outcome depends on the maturation status of the DC. Immature DCs residing in the 
periphery are incapable of T cell priming. Presentation of antigen by immature DCs results in 
tolerance induction by mechanisms involving deletion, induction of unresponsiveness (anergy) or both 
(Mescher et al., 2007).  
According to the “two signal” theory, activation of T cells requires both antigen engagement by the 
TCR and signals provided by a co-stimulatory receptor such as CD28 binding to its B7 ligands 
(Janeway and Bottomly, 1994). In addition it has been shown that these classical two signals are not 
sufficient to support strong clonal expansion, development of effector functions or establishment of a 
long-lived memory population. The extended model postulates that the basic prerequisites for efficient 
priming of CD8+ T cells are antigen processing and presentation by activated DCs (signal 1), co-
stimulation (signal 2) and the so-called signal 3, which can be provided by IL-12 or IFN alpha/beta 
(Cousens et al., 1999; Curtsinger et al., 2005; Marrack et al., 1999; Mescher et al., 2007). TLR ligands 
or CD4 helper cells stimulate dendritic cells to produce these cytokines. Interaction of DCs with CD4+ 
helper cells via CD40-CD40L conditions these DCs to activate naive CD8 T cells (Ridge et al., 1998; 
Schoenberger et al., 1998). This process is also called “DC licensing”. Engagement of CD40 on DCs 
stimulates the cells to produce IL-12 and thus provision of the critical third signal for CD8+ T cell 
activation (Cella et al., 1996). Although IL-2 signals are required for sustained T cell proliferation and 
clonal expansion, there is currently no evidence to classify IL-2 as a helper cytokine provided by CD4 
T cells in vivo as this cytokine is unable to support the development of effector functions in naïve 
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CD8+ T cells (Curtsinger et al., 2005). The initial activation of CD8+ T cells is followed by the 
expansion phase that lasts for five to eight days, during which antigen-specific CD8+T cells numbers 
may increase by > 10,000-fold (Badovinac et al., 2002; Kaech et al., 2002). Clonal expansion is also 
associated with the differentiation to effector cells that migrate throughout the body. The third phase 
involves a contraction in number where 90-95% of effector cells are eliminated over the ensuing week 
(Badovinac et al., 2002; Sprent and Tough, 2001). The final phase is the initiation and maintenance of 
the CD8+ T cell memory pool by the cells surviving the contraction (Kaech et al., 2002). 
Whereas the contribution of CD4 help in the induction of primary effector responses is controversially 
discussed, an essential role for CD4 help in establishing long-term memory is commonly accepted. IL-
12 and IFN"/$ provide survival of the responding cells, as they become effector cells. A recent study 
showed that the death of the majority of the effector cells that occurs following the peak of clonal 
expansion is more rapid and profound in the absence of a third signal (Curtsinger et al., 2003). 
It has been postulated that the expression of costimulatory molecules needs to be inducible by 
microbial infection (Janeway, 1989). It is now known that PRRs of the innate immune system control 
many aspects of DC maturation such as expression of costimulatory molecules and cytokine 
production (Medzhitov, 2001). These stimulatory effects of pathogens are utilized in vaccination 
strategies by using adjuvants to boost TH1 immune responses followed by long-term protective 
memory responses. Discovery of TLR-mediated signaling as the underlying mechanism of infection 
helped to explain how adjuvants trigger inflammatory reactions to activate the immune system and 
thereby increase the immunogenicity of the co-administered antigen.  
 
4.6 Interleukin 12 and regulation of innate resistance and adaptive immunity 
 
IL-12 is a heterodimer formed by a 35-kDa light chain (=p35 subunit or IL-12") and a 40 kDa heavy 
chain (p40 subunit or IL-12$) (Kobayashi et al., 1989; Stern et al., 1990). It was identified in 1989 as 
a product of Epstein-Barr virus (EBV)-transformed human B cell lines. that can activate NK cells, 
generate lymphokine-activated killer cells (LAKs), and induce IFN-! production and T cell 
proliferation of pre-activated T cells and NK cells (Kobayashi et al., 1989; Stern et al., 1990). 
Subsequent studies indicated that IL-12 could boost the generation of cytotoxic T cells by promoting 
the transcription of genes encoding cytolytic factors including perforin and granzyme (Trinchieri, 
1998). Importantly, IL-12-induced IFN! mediates many of the pro-inflammatory activities of IL-12, 
whereas the ability to favor a TH1 response exemplifies its function as an immunoregulatory cytokine 
that bridges innate resistance and adaptive immunity (Hsieh et al., 1993). In B cells, IL-12 enhances 
the production of TH1-associated classes of immunoglobulins such as IgG2a. In 2000 it was 
discovered that IL-12p40 not only associates with IL-12p35, but also with another molecule, p19, to 
form a new heterodimer known as IL-23 (Oppmann et al., 2000). The main producers of IL-12 are 
phagocytes and DCs in response to microbial stimulation (D'Andrea et al., 1992; Macatonia et al., 
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1995).  In response to viral infections, both IL-12 and IFN" are produced by plasmacytoid DCs. The 
production of IL-12 is regulated strictly by positive and negative regulatory mechanisms. Microbial 
products are strong inducers of IL-12 production by APCs. The ability of IFN! to enhance IL-12 
production forms a positive feedback mechanism during inflammation and TH1 responses. 
Interestingly, IL-4 and IL-13 –two TH2 cytokines – are also potent enhancers of IL-12 production. In 
addition to IFN! and IL-4, T cells can trigger IL-12 production through direct cell-cell interactions, 
mostly through ligands of the TNF family such as CD40-CD40L. Negative regulation of IL-12 is 
performed by several cytokines. TGF $ reduces the stability of IL-12p40 mRNA. Although IFN" and 
IFN$ have some overlapping effects with IL-12 in terms of induction of IFN! production and TH1 
responses, they are also able to suppress IL-12 production as well as TNFa. Production of IL-12 is 
inhibited markedly by ligand binding to G"s-linked G protein coupled receptors (GPCR), mainly 
through their induction of cyclic AMP. IL-10 is a potent inhibitor of IL-12 by blocking transcription of 
both its encoding genes and is often induced when IL-12 is inhibited. It was postulated that the 
expression of IL-12 and IL-10 is reciprocally regulated which may have important implications on 
immune regulation. 
 
The IL-12 receptor family consists of IL-12R$1, IL-12R$2 and IL-23R (Cooper and Khader, 2007). 
The IL-12p70 receptor is a homo-dimer of IL-12-R$1 and IL-12R$2, whereas the IL-23 receptor is 
composed of IL-12R$1 and IL23R. The IL-12 receptor is mainly expressed by activated T cells and 
NK cells (Presky et al., 1996), but has been reported also for DCs (Grohmann et al., 1998) and B cell 
lines (Airoldi et al., 2000). On most resting T cells, IL-12R is undetectable but it is expressed at a low 
level by NK cells, which could explain the ability of these cells to respond rapidly to IL-12. T cell 
activation through the TCR up-regulates the transcription and expression of both IL-12 receptor 
chains. This up-regulation – in particular of the beta chain – is enhanced by IL-12 itself, IFN", IFN!, 
TNF" and co-stimulation through CD28. Regarding T cells, the expression of IL-12R$2 is assumed to 
be confined to T helper cells and its expression correlates with responsiveness to IL-12 (Rogge et al., 
1997; Szabo et al., 1997). Upon binding of IL-12, the heterodimeric IL-12 receptor recruits JAK2 
(Janus kinase) and TYK2, leading to phosphorylation of STAT-1, -3, -4 and -5 (signal transducer and 
activator of transcription); the specific biological effects of IL-12 are due mainly to activation of 
STAT-4. IL-23 induces the same JAK/STAT signaling pathway as IL-12, but induces different DNA 
binding STAT dimers (Parham et al., 2002). 
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4.7 Type I interferons 
 
Interferons (IFNs), which are only found in vertebrates, are a family of structurally related cytokines 
with a hallmark function in antiviral activity and. IFNs exhibit a diversity of biological functions such 
as antiviral activity, antitumor activity and immunomodulatory effects.  Type I IFNs are massively 
produced in most cells in response to viral and other microbial infections. A unique subset of DCs, the 
plasmacytoid DC, is endowed with a special capacity to produce high amounts of IFN" and IFN$ 
upon viral exposure or the activation of certain PRRs. By virtue of their potentiating effect on DC 
maturation, type I IFNs are currently recognized as pivotal cytokines bridging innate and adaptive 
immune system (Takaoka and Yanai, 2006).  Furthermore, type I IFNs are dominating in promoting 
conditions for IFN! production by T cells (Cousens et al., 1999). 
The type I interferons consist of IFN-",  -$, %, & and #. All IFN "/$ subtypes interact with the same 
receptor complex (IFNAR), which consists of at least two subunits, IFNAR-1 and IFNAR-2. Most cell 
types bind type I IFNs with a large variation in the number of binding sites and binding affinities. The 
intracellular domains of these two subunits are associated with JAK1 and Tyk2. Upon binding of IFNs 
to IFNAR, JAK-1/Tyk-2 are cross-activated and phosphorylate their downstream substrates, STAT-1 
and STAT-2. This leads to the activation of transcriptional activator complexes that translocated into 
the nucleus. The IFN stimulation of promoters containing ISRE results in the transcriptional induction 
of a large number of target genes to evoke multiple biological activities. IFNARs interact with a 
number of negative regulatory molecules, including SOCS-1 (suppressor of cytokine signaling 1) to 
limit the extent of signaling. 
 
 
4.8 Malaria  
 
Malaria is one of the most serious infectious diseases of humans in the world today, infecting nearly 
10% of the world population and causing one to two millions deaths, mostly of children, every year. 
Ninety percent of the deaths occur in sub-Saharan Africa and South East Asia, although malaria is 
endemic in more than 100 countries. Malaria is caused by infection with various species of the 
protozoa Plasmodium that are transmitted to the human host by the female Anopheles mosquito. Four 
different Plasmodium species - of which P. falciparum is the most virulent and prevalent - cause 
disease in humans. Serious pathological complications such as severe malarial anemia, metabolic 
acidosis and cerebral malaria (CM) represent life-threatening risks of infection. CM is multi-factorial 
and a complex syndrome. It is assumed that CM is a consequence of immune-mediated pathology due 
to overwhelming inflammatory processes. 
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4.8.1 Life cycle of Plasmodium  
 
The Plasmodium parasite that causes malaria is transmitted from mosquitos to men. The parasites 
spend part of their life cycle in the mosquito and part of it in the human host . The infective plasmodial 
sporozoites enter the bloodstream from the saliva of the female Anopheles mosquito during a blood 
meal. The Kupffer cells of the liver clear the sporozoites from the blood stream and kill many of the 
microorganisms. Some of the sporozoites escape destruction, and penetrate the hepatocytes where they 
take up residence. Within the hepatocytes, the parasites transform into a new form called schizonts. 
The nuclear genetic material in the schizonts replicates until the hepatocytes are totally filled with new 
forms called merozoites. A single schizont can produce thousands of merozoites. Then, hepatocytes 
burst and release the merozoites into the bloodstream where they invade circulating erythrocytes. This 
marks the end of liver-stage replication and initiation of the blood-stage infection, which is the main 
cause for disease.  After penetrating the erythrocytes the merozoites form a ring form called 
trophozoites. These organisms consume hemoglobin in erythrocytes and enlarge until they fill the cell 
completely. During their growth, the trophozoites transform into schizonts and produce new 
merozoites inside the erythrocytes. The red blood cells subsequently lyse and release merozoites that 
can penetrate new red blood cells and restart the pernicious process. 
Some of the trophozoites in the erythrocytes undergo a different developmental pathway and form 
gametocytes. Gametocytes are the sexual form of the parasite and do no lyse the red blood cells. A 
mosquito taking a blood meal from a person whose erythrocytes contain gametocytes acquires the 
malarial parasite. The sexual reproduction cycle then begins in the mosquito. The mosquito 
subsequently transmits the parasite when it attacks another human host. 
4.8.2 Murine models of Plasmodium infection 
 
The investigation of CM pathogenesis in humans is limited to analysis of biopsies due to ethical 
reasons. Post-mortem studies provide end-point findings, whereas the full extent of events leading to 
different syndromes remains largely unresolved. Therefore, the understanding of CM pathogenesis 
relies on the use of experimental models. Several animal models exist to study the different 
pathologies occurring during Plasmodium infection in humans. Infection of mice with Plasmodium 
berghei ANKA was established in 1966 (Vincke et al., 1966). The transfer of P. berghei ANKA (PbA) 
infected red blood cells into C57BL/6 mice induces experimental CM (ECM) and ranks among the 
lethal models of CM. Infected mice develop a neurological syndrome characterized by paralysis, 
deviation of the head, ataxia, convulsions and coma starting six to 14 days after inoculation with 
parasitized red blood cells. Infection leads to death in 60-100% of mice with relatively low 
parasitemia. Mice that do not develop CM die during the second or third week post infectionem from 
hyper-parasitemia and severe anemia (Engwerda et al., 2005a). Most data generated within the model 
of PbA infection in CM susceptible mice could be validated in humans.  
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4.8.3 Malaria pathogenesis as a result of immunological processes triggered by  
Plasmodium infection  
 
Severe malaria syndromes are assumed to arise from four basic processes: (1) the site-specific 
localization of parasitized red blood cells (PRBCs) among target organs, (2) the local and systemic 
action of bioactive parasite products, such as toxins, on host tissues, (3) the local and systemic 
production of pro-inflammatory and counter-regulatory cytokines and chemokines by the innate and 
adaptive immune system in response to the parasite products and (4) the activation, recruitment and 
infiltration of inflammatory cells (Schofield and Grau, 2005). The contribution of these events to the 
pathogenesis of CM is controversially discussed. 
 
4.8.3.1 Sequestration of parasitized red blood cells 
 
The mechanical (or sequestration) theory postulates that P. falciparum parasitized erythrocytes 
(pRBCs) bind to the post capillary venules that in turn causes obstruction of the blood flow, decreased 
perfusion of the tissue and decreased removal of waste products i.e. lactic acid (van der Heyde et al., 
2006). This is supported by the development of lactic acidosis of which the precise causes are not 
clear. The mechanical hypothesis was expanded by the assumption that pRBCs become less 
deformable during the progress of P. falciparum infection and, consequently, plug the small capillaries 
(Glenister et al., 2002). Evidence for capillary plugging in CM pathogenesis is provided by the 
observations that the extent of RBC deformability is an indicator of poor prognosis and that functional 
capillary density decreases markedly during ECM (Dondorp et al., 2000). However, pBRC 
sequestration in the brain is controversially discussed, as clinical studies and experimental models 
indicate only a low correlation between parasitemia and mortality. Individuals with parasitemia are 
sometimes asymptomatic, and symptomatic infected hosts can have low parasitemia. Furthermore, 
sequestration is not observed in post mortem analysis performed on tissue from patients who 
succumbed to P. falciparum malaria. Nevertheless, sequestration does occur during malaria, and the 
adherence of pRBCs probably signals within endothelial cells after binding to CAMs, eliciting a 
disruption of tight endothelial junctions and increased CAM expression. It is proposed, that the 
sequestration contributes interdependently from other processes to the development of pathology.  
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4.8.3.2 Toll-like receptors in Plasmodium infection 
 
It is supposed that the diverse organ-specific or systemic disease syndromes are end-stage processes of 
atypical inflammation cascades that are initiated in target organs by pathogen products. Several studies 
implicate that P. falciparum derived glycosyl-phosphatidyl-inositol (GPI) and hemozoin, a crystalline 
residue of parasite-mediated hemoglobin digestion are recognized as malarial PAMPs as these 
components were demonstrated to trigger the expression of pro-inflammatory genes. Plasmodium-
derived GPI is recognized by TLR2 and TLR4 (Krishnegowda et al., 2005). The finding that that 
hemozoin stimulates host cells via TLR9 was quite surprising (Coban et al., 2005), as TLR9 had been 
described as a receptor for CpG-rich DNA. A recent study demonstrated that it is plasmodial DNA 
instead that stimulates TLR9; the authors suggested that hemozoin may act as a carrier and amplify 
immune responses to AT-rich plasmodial DNA by targeting the DNA to TLR9 in the endosome 
(Parroche et al., 2007). TLR recognition activates monocytes to secrete several pro-inflammatory 
cytokines, including IL-1, IL-6, tumor necrosis factor (TNF) and lymphotoxin, which are suggested to 
trigger critical processes in malaria pathogenesis. However, the contribution of TLRs in development 
of ECM is still unclear. 
 
 
4.8.3.3 Inflammatory and anti-inflammatory cytokines 
 
The inflammation hypothesis, proposed by Maegraith in 1948, states that Plasmodium parasites elicit a 
systemic inflammatory response that causes multi-organ failure and death. Numerous studies support 
this hypothesis by showing that pro-inflammatory TH1 cytokines acting in a cascade are important 
determinants of malaria disease states. In particular, IFN! and lymphotoxin " are critical factors as 
depleting antibodies as well as genetic deficiency protected PbA infected mice from ECM. Non-
conventional lymphoid populations such as CD1d-restricted natural killer T cells that can recognize 
GPI as a natural ligand are supposed to account for IFN! production very early in infection. IFN! 
seems to be also the most important cytokine secreted from T cells. In response to TLR ligation, 
several inflammatory cytokines are produced such as IFN!, which in turn trigger the secretion of 
further effector cytokines, such as TNF that are boosting the cytokine cascade. The collection of 
inflammatory signals during malaria elicits vascular leak and, in combination with signaling through 
the CAMs, are assumed to contribute to microvascular disruption in several vascular beds, including 
the brain. The signaling pathways triggering IFN! effector responses particularly in ECM are not 
entirely known. IL-12 and TNF are assumed to contribute to the inflammatory response, whereas 
production of anti-inflammatory IL-10 is supposed to inhibit effector responses. Protective effects of 
IL-10 were concluded from PbA infection experiments in mice that received IL-10-depleting 
antibodies, or by treatment with recombinant IL-10 (Kossodo et al., 1997).  
4  Introduction  
13 
4.8.4  Adaptive immune responses in Plasmodium infection 
 
CM has been assumed to be a T cell-dependent disease since it was observed that several T cell 
deficient mice - such as nude, SCID, or RAG-deficient mice - are protected against ECM upon 
Plasmodium infection. This was supported by functional studies using antibodies that depleted T cells 
(Belnoue et al., 2002; Boubou et al., 1999; Finley et al., 1982; Grau et al., 1986; Nitcheu et al., 2003). 
In particular, an important role for CD8+ T cells in CM development was concluded from a recent 
study by Boubou et al., who showed a selective increase of sequestered CD8+ expressing "$ cells in 
CM positive mice. CM was prevented if PbA infected mice were specifically depleted of these T cells 
via antibodies (Boubou et al., 1999).  T cells represent a cellular source of IFN! and contribute to 
permeability changes of the murine blood-brain barrier through perforin-dependent mechanisms 
(Nitcheu et al., 2003; Potter et al., 1999). CD8+ T cells sequestered in the brain were proposed to be 
responsible for the neurological syndrome and for death, but direct evidence is still missing. 
Furthermore, the induction of parasite-specific CD8+ effector T cells has not yet been shown. 
 
 
4.9 Regulation of immune responses 
 
To protect the host from succumbing from infection, the innate immune system must rapidly detect 
and categorize the type of pathogen, which includes extra- or intracellular localization. Immediate 
activation of innate effector mechanisms ensures early defense and limitation of infection. These 
immediate decisions set the course for an appropriate adaptive immune response to eliminate the 
infection and prevent its recurrence. Immune activation is a double-edged sword for the host. It is 
essential for provoking the immune response and enhancing adaptive immunity against pathogens 
(Akira et al., 2001; Medzhitov, 2001), which basically aim clearance of infection by destructive 
mechanisms. The destructive potential requires strict control because the armory used against 
pathogens is also efficient and detrimental against the host. Self-inflicted damage is therefore 
inevitable during a protective response, either by direct lysis of infected cells by CTLs or indirectly by 
the release of antimicrobial factors (cytokines, free radicals) that are toxic to the host. Thus, excessive 
inflammation must be prevented.  
The regulation of immune responses involve multiple points of interaction and cross-regulation 
between pathogens, antigen-presenting cells (APC) and lymphocytes, which was defined by 
Bachmann and Kopf by the term “immunological ménage à trois” (Bachmann and Kopf, 2002). This 
implies several possibilities of interference in immune activation by negative feed back mechanisms 
induced by the host but also by mechanisms of immune modulation from the parasite.  
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5 Aims of this thesis 
 Toll-like receptors (TLR) are crucial for the detection of pathogens by recognition of their conserved 
molecular patterns. TLR signaling triggers activation of the vertebrate’s immune system and generally 
results in immunity. However, immune activation is a double-edged sword. For instance, while 
efficient combat of several bacterial and parasitic infections requires IFN!, regulation of 
overwhelming IFN! dependent immune response by induction of anti-inflammatory mechanisms is 
critical for survival. How excessive inflammation is counter-regulated is still largely unknown. 
 
The aim of this thesis was to determine the role of TLRs in immune regulation.  In particular, we were 
interested  
 
- how TLR stimulation influenced the induction of cytotoxic CD8+ T cell responses in mice 
infected with recombinant adenovirus, recombinant Listeria monocytogenes or Plasmodium 
ssp. and  
 
- how TLRs are involved in the induction and modulation of immuno pathology in the course of  
Plasmodium infection. 
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6 Material and Methods 
6.1 Material 
6.1.1 General laboratory equipment 
 
AutoMACS®     Miltenyi, Bergisch Gladbach 
Cell culture dishes 25cm2, 80cm2,  Nunc, Wiesbaden 
Cell strainer 40µm   BD, Heidelberg 
Centrifuge tubes 15ml, 50ml   Greiner Labortechnik, Frickenhauser 
Injection needle 25G, 27G   BD, Heidelberg 
Metal sieve     University of Heidelberg 
Multipipette     Dunn Labortechnik 
Microtiter plates 24/48/96 wells  Greiner BioOne 
Microwave     Bosch, Stuttgart 
Neubauer chamber    Brand, Wertheim 
Parafilm®     American National Can TM, Greenwich 
Pasteur glass pipettes 150mm, 230mm  Roth, Karslruhe 
Pipettes Gilson     Heidelberg 
Pipette-boy     Hirschmann Labortechnik, Eberstadt 
Reaction tubes 0.5-2mL   Eppendorf, Hamburg 
Scalpel     Aesculap, Tuttlingen 
Sterile filter 0.2µm    Nunc, Wiesbaden 
 
6.1.2 Machines 
 
Name Description Company 
AutoMACS® Magnetic cell separator Miltenyi, Bergisch Gladbach 
Calibur® Flow Cytometer BD Biosciences, Heidelberg 
Canto® Flow Cytometer BD Biosciences, Heidelberg 
Canto II® Flow Cytometer BD Biosciences, Heidelberg 
LSR II® Flow Cytometer BD Biosciences, Heidelberg 
DiVA® FACS-Sorter BD Biosciences, Heidelberg 
IVIS®200 In vivo Imaging Xenogen, San Francisco, USA 
ELISA reader ELISA reader Molecular devices 
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6.1.3 Analyzing software 
Name Description Company 
CellQuest Pro Acquisition of FCS files BD Biosciences, Heidelberg 
DiVA Acquisition + analysis of FCS files BD Biosciences, Heidelberg 
FlowJo Analysis of FCS files TreeStar 
SPF ELISA software Molecular Devices 
Living Image 2.5 IVIS Software Xenogen, San Francisco 
Prism Statistic software GraphPad Software 
 
6.1.4 Chemicals, reagents and kits 
 
ABTS       Sigma, Deisenhofen 
Acetic acid (C2H4O2, MW=60,05)    Roth, Karlsruhe 
7-Aminoactinomycin D (7-AAD)   Sigma, Deisenhofen 
Agarose       Invitrogen, Karlsruhe 
Albumin, Bovine serum- (BSA)    Gerbu, Gaiberg 
Ammoniumchlorid (NH4Cl, MW = 53,49)   Merck, Darmstadt 
Brefeldin A (C16H24O4, MW = 280,4)    Sigma, Deisenhofen 
Bromphenolblue (C19H10Br4O5S, MW = 670,0)   Sigma, Deisenhofen 
Collagenase A       Roche, Mannheim 
CFSE        Molecular Probes, Netherlands 
Dimethylsulfoxid (DMSO) ((CH3)2OS, MW = 78,13)  Merck, Darmstadt 
Dinatriumhydrogenphosphat (Na2HPO4, MW = 142,0)  Merck, Darmstadt 
DOTAP®      Roth, Karlsruhe 
DMEM       Invitrogen, Karlsruhe 
Ethanol, absolute (C2H5OH, MW = 46,07)   Merck, Darmstadt 
Ethidiumbromid (C21H20N3Br, MW = 394,3)   Sigma, Deisenhofen 
Ethylendiamintetraacetate (EDTA)   Sigma, Deisenhofen 
(C10H14N2O8Na2• 2H2O, MW = 372,2)    Gerbu, Gaiberg 
Foetal calf serum (FCS)     PAA, Cölbe 
GBSS (Gey’s balanced salt solution)   Invitrogen, Karlsruhe 
In vivo JET PEI®     Biomol/Polyplus, Hamburg 
L-Glutamine (200mM) (C5H10N2O3, MW = 146,1)  Invitrogen, Karlsruhe 
GM-CSF      Immunotools 
HCl, MW = 36,46)      Sigma, Deisenhofen 
Heparin       Amersham Pharmacia, Freiburg 
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HEPES 1 M (C8H18N2O4S, MW = 238,3)   Invitrogen, Karlsruhe 
Hoechst 33342       Molecular probes, Netherlands 
Isopropanol ((CH3)2CHOH, MW = 60,1)   Merck, Damrstadt 
Lymphoprep       PAA, Cölbe 
2-Mercaptoethanol (HS (CH2)2OH, MW = 78,13)  Sigma, Deisenhofen 
Natriumazid (NaN3, MW = 65,01)    Sigma, Deisenhofen 
Natriumbicarbonat (NaHCO3, MW = 84,01)   Sigma, Deisenhofen 
Natriumchlorid (NaCl, MW = 58,44)    Merck, Darmstadt 
Natriumchlorid (NaCl) 0.9%     B.Braun, Melsungen 
Natriumdihydrogenphosphat (NaH2PO4, MW = 120,0)  Merck, Darmstadt 
Natriumhydrogenphosphat (Na2HPO4, MW = 142)  Sigma, Deisenhofen 
Natriumhydroxid (NaOH, MW = 40,0)    Merck, Darmstadt 
Nycodenz      Axishield, Nycomed, Norway 
Ovalbumin, Grad V      Sigma, Deisenhofen 
Paraformaldehyde (PFA) (H (-OCH2)n-OH)   Serva, Heidelberg 
Penicillin      Invitrogen 
PBS        Biochrom, Berlin 
Percoll        Amersham Pharmacia, Freiburg 
Propidium iodide      Molecular probes, Netherlands 
RPMI        Invitrogen, Karlsruhe 
Saponin       Sigma, Deisenhofen 
Streptomycin      Invitrogen 
Sulfuric acid (H2SO4)     University of Heiderlberg 
Triton X-100       Sigma, Deisenhofen 
Trypanblue, 0,4% (C34H24N6O14S4Na4, MW = 960,8)  Biochrom, Berlin 
Trypsin/EDTA       Invitrogen, Karlsruhe 
Türcks solution      Merck 
 
6.1.5 Buffers and media 
    
Cell culture media (DC, T cells) 
RPMI 1640 incl. HEPES, 8% (w/v) FCS, 2mM Glutamine, 100 IU/ml Penicillin, 100µg/ml 
Streptomycin, 50µM 2-Mercaptoethanol was prepared and kept under sterile conditions at 4°C. 
 
CFSE stock: 
5,6-Carboxy-Succinimidyl-Fluoresceine-Ester (CFSE) was solved in DMSO (10mM) and stored in 
aliquots à 10µl at –20°C. 
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Collagenase A buffer 
GBSS (Ca2+ deprived) contained 0.05% (w/v) Collagenase A. 40ml Aliquots were stored at –20°C. 
 
EDTA 0.5M 
46,53g Ethylendiamintetraacetat (EDTA) (C10H14N2O8Na2 x 2H2O, MW = 372,2) was solved in 250 ml 
ultra-pure water and adjusted to pH 8.0 with NaOH. Solution was autoclaved and stored at room 
temperature. 
 
ELISA buffers 
-  Blocking buffer 1x PBS containing 1% (w/v) BSA  
-  Coating  0,1M NaHCO3, pH 8,2 (stored at 4°C) 
-  Detection buffer:  1mg ABTS per ml 0,1M citirc acid, pH 4,35 (stored at -20°C) 
-  Washing buffer 1x PBS containing 0.05% (w/v) Tween prepared freshly 
 
FACS buffer 
1x PBS containing 1% (w/v) FCS was stored at 4°C. 
 
MACS buffer 
1x PBS containing 1% (w/v) FCS and 2mM EDTA was stored under sterile conditions at 4°C. 
 
2-Mercaptoethanol stock solution 
178µl of 14.3 M 2-Mercaptoethanol was diluted in 500ml PBS (=0.005M). Solution was kept sterile 
and stored at 4°C. It was further diluted 1:100 in media. 
 
Permeabilization buffer incl. Saponin 
1x PBS containing 0.5% (w/v) saponin and 2% (w/v) BSA prepared freshly 
 
Permeabilization buffer incl. TritonX100 
Triton X-100  0.1 % diluted in 1x PBS, prepared freshly 
 
PBS (phosphate buffered saline) 
1x PBS (NaH2PO4 20 mM, NaCl 50mM) pH was adjusted to 7.4, then aliquoted à 500ml, autoclaved 
and stored at 4 °C. 
 
4% (w/v) PFA stock solution 
8g of PFA was solved in 200 ml PBS by incubation at 60°C in the water-bath. pH was set to 7.4. 
Aliquots were stored at –20°C.   
 
10% (w/v) Triton X-100 stock solution 
1ml Triton X-100 was mixed with 9ml ultra-pure water and stored at room temperature. 
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6.1.6 Synthetic oligonucleotides and TLR ligands 
 
CpG-rich Oligonucleotides were obtained from TIB MolBiol, Berlin, Germany. ODNs were delivered 
as lyophilized powder and dissolved in sterile 0.9% NaCl at a concentration of 1 nmol/µl, and 
incubated for 30 min at 37°C. Dissolved ODNs were stored at 4°C. Fluorescently labeled CpG-
ODN1668-Cy5 was obtained from Sigma-Aldrich. 
ODN Sequence Type Reference 
CpG-1668 TCC ATG ACG TTC CTG ATG CT CpG-B, murine (Krieg et al., 1995) 
  
Synthetic RNAs were obtained from Eurogentech® or Biomers® and delivered as lyophilized powder. 
RNAs were dissolved in sterile 0.9% Nacl (1µg/µl), aliquoted and stored at -80°C. 
RNA Sequence Target Reference 
9.2s n AGC UUA ACC UGU CCU UCA A human TLR9 (Hornung et al., 2005) 
9.2s R8A AGC UUA ACC UGA AAA AAA A Control to 9.2sn (Hornung et al., 2005) 
siMyD88 AAG GAG AUG GGC UUC GAG UAC dTdT; MyD88 (Flandin et al., 2006) 
siTRIF GAC CAG ACG CCA CTC CAA C TRIF (Li et al., 2005) 
 
Synthetic or purified TLR ligands  
Substance Derived from Ligand for Source 
Lipopolysaccharide (LPS) E.coli TLR4 InVivogen 
R848 Synthetic TLR7 InVivogen, 3M 
 
6.1.7 Peptides 
 
Peptides were obtained from Pineda, solved in DMSO for 20mM stock solutions and stored at -20°C.  
Peptide Amino acid sequence 
H-2kb OVA 257-264 peptide SIINFEKL 
H-2kd GFP200-208  peptide HYLSTQSL 
HLA A2 MSP-1  
• region 38/42  epitope 291 
                         epitope 609 
                         epitope 437 
• region 83/30  epitope 313 
                         epitope 674 
 
GLHHLITEL 
YLINLKAKI 
VIYLKPLAGV 
KLLDKINEI 
KLKEFIPKV 
 
 
 
6  Material and Methods  
20 
6.1.8 Antibodies 
 
- Antibodies used for cytokine ELISA 
All antibodies used for detection of murine cytokines via sandwich ELISA were purchased from BD, 
Heidelberg or eBioscience. Matching pairs of antibodies contained a primary unlabeled antibody and a 
biotinylated detection antibody that were used in previously titrated amounts according to the 
manufacturers guide. If not otherwise stated, monoclonal antibody derived from the following clones 
directed against murine cytokines were used: 
 
IL-2  JES6-1A12 (IgG2a, rat) and JES6-5H4 (IgG2b, rat) 
IL-6  MP5-20F3 (IgG1, rat) and MP5-32C11 (IgG2a, rat) 
IL-10  JES5-2A5 (IgG1, rat) and SXC-1 (IgM, rat) 
IL-12p70 C18.2 (IgG2a, rat) and C17.8 (IgG2a, rat) 
IFN!   AN-18 (IgG1 #, rat) and R4-6A2 (IgG1, rat) 
 
- Antibodies used for detection of antibody responses 
goat-anti mouse IgM  
goat-anti-mouse IgG conjugated with horseradish peroxidase 
 
- Antibodies coupled with magnetic beads 
Murine antibodies conjugated with magnetic beads (MACS® Beads) were purchased from Miltenyi, 
Bergisch Gladbach: anti CD4, anti CD19, anti CD11c. 
 
- Antibodies used for flow cytometry 
For FACS-staining of murine molecules at the cell surface or intracellularly, the following antibodies 
were purchased from BD Pharmingen or eBiosciences: All antibodies were either biotinylated or 
labeled with a fluorochrome (FITC, PE, PE-Cy-7, APC, Al488, Al647, Al405) and used in titrated 
amounts previously determined in the lab. The antibodies were directed against the following murine 
epitopes (clone names are given in brackets): anti CD4 (GK1.5), anti CD8a (53.-6.7), anti CD11b 
(M1/70), anti CD11c (HL3), anti CD19 ()1D3, anti CD40 (3/23), anti CD54 (3E2), anti CD69 
(H1.2F3), anti CD80 (16-10A1), anti CD86 (GL1), anti MHC class I /H-2kb (34-2-12), anti MHC 
class II / I-Ab (KH74), anti IFN! (R4-6A2), anti IL-12p40/p70 (C15.6), anti NK1.1(PK136), anti 
TNF" (MP6-XT22), anti TCR V"2 (B20.1), anti TCR V$5(MR9-4).  
Fc receptors were always blocked by adding 2.4G2 (rat) antibody. 
H-2kb/SIINFEKL tetramers labeled with fluorochromes were purchased from ProImmune or provided 
by Dirk Busch, Munich. 
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- Streptavidin conjugates for secondary staining 
Streptavidin (SA) conjugates that were labeled with different fluorochromes were used in combination 
with biotinylated primary antibodies for flow cytometric analysis. All conjugates were purchased from 
Molecular Probes, San Francisco, BD Heidelberg or eBiosciences In particular, the following 
conjugates were used in titrated amounts: SA-Al488, SA-phycoerythrin (SA-PE), SA-PE-Cy7, SA-
Al647, SA-APC-Cy7. Dilution was performed according to manufactures guide. 
 
6.1.9 Enzymes 
 
- Collagenase type I A (Clostridium histolyticum) (Boehringer, Mannheim) was used for the 
digestion of spleens 
- Horseradish peroxidase (Invitrogen) was used for sandwich ELISA. 
 
6.1.10 Cell lines 
 
All cell lines were available in the lab or obtained from the DKFZ, Heidelberg. 
Line Description and origin Reference 
B3Z CD8+ T cell hybridoma, recognizes Ova 257-264 
peptide presented on H-2kb 
(Van Bleek and Nathenson, 
1990) 
Mo4 melanoma / fibrosarcoma C3H  (Meyvisch and Mareel, 1982; 
Storme et al., 1981) 
RMA 
RMA-GFP 
NK lymphoma (H-2kb) 
transfected with GFP 
(Gays et al., 2000) 
 
6.1.11 Recombinant viruses, bacteria and parasites 
 
Recombinant adenoviruses are gutless vectors and kindly provided from other scientist: AdOVA, 
AdLucGFP (Dr. Andreas Untergasser, Prof. Dr. Ulrike Protzer; Cologne), AdLuc-OVA-GFP (Prof. 
Dr. Thomas Tüting; Bonn) and AdIL-12 (Dr. Volker Schmitz; Bonn). Wild type and recombinant 
Listeria monocytogenes (LM WT, LM-OVA, L-Luc) were provided by Dr. Stefanie Scheu and Prof. 
Dr. Klaus Pfeffer, Düsseldorf. Recombinant Escherichia coli strains (E.coli-luc, E. coli-lux) were 
generated by Timo Schwandt, Bonn. Dr. Natalija Novak, Bonn, provided staphylococcus aureus. 
Plasmodium berghei ANKA was available in the lab of Prof. Dr. Achim Hörauf, Bonn. P. berghei 
ANKA-expressing GFP was a gift from Dr. Friedrich Frischknecht, Heidelberg. All mentioned 
pathogens were used in vivo to study immune responses in wildtype or transgenic mice. 
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6.1.12 Mouse strains 
 
Wild type strains C57BL/6N, J (H-2kb), CB F1(H-2k
b x H-2kd), B6D2F1 F1(H-2
b x H-2kd) as well as 
Balb/c (H-2kd) were obtained from Charles River or Janvier. Mice were bred in animal facilites of the 
House for experimental Therapy (HET), University of Bonn under specific pathogen free conditions 
or in the IMMEI. Following knock out (ko) and transgenic (tg) animals backcrossed on C57BL/6 (I-
Ab) and Balb/c (I-Ad) were used:  
 
MHC haplotype (H-2kb /I-Ab)  Reference 
CD4-/- Deficient in CD4+ cells (Rahemtulla et al., 1991) 
CD40-/- Lack of CD40 expression  
CD11c-DTR-OVA-GFP tg* Express under CD11c promoter 
human Diphtheria toxin receptor 
and express OVA and GFP 
N. Garbi, Heidelberg 
HLA-A2 tg Express human MHC class I 
molecule HLA-A2 
(Ureta-Vidal et al., 1999) 
I-Ab-/- Lack CD4+ T cells and MHC 
class II 
(Cosgrove et al., 1991; 
Grusby et al., 1991) 
IL-10-/- IL-10 deficient (Kuhn et al., 1993) 
IL-12p35-/- IL-12 deficient (Cousens et al., 1999) 
IL-12p35/p40-/- IL-12 and IL-23 deficient Provided by G. Alber, 
Leipzig 
IL-23p19-/- IL-23 deficient Provided by G. Alber, 
Leipzig 
IFN!-/- IFN! deficient Provided by A. Hörauf, 
Bonn 
IFNAR-/- Lack type I IFN receptor (van den Broek et al., 1995) 
iNOS-/- iNOS deficient Provided by MPI Berlin 
OT-I transgenic OVA257-264 specific CD8
+ TCR 
transgenic line 
(Hogquist et al., 1994) 
OT-II transgenic OVA323-339 specific CD4
+ TCR 
transgenic line 
(Barnden et al., 1998) 
RAG1-/- Lack B and T cells Provided from DKFZ 
TLR3-/- TLR3 deficient (Alexopoulou et al., 2001) 
TLR4-/- TLR3 deficient (Hoshino et al., 1999) 
TLR7-/- TLR3 deficient (Hemmi et al., 2002) 
TLR9-/- TLR3 deficient (Hemmi et al., 2000) 
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6.2 Methods 
 
6.2.1 Experimental treatment of mice 
 
Mice were obtained from Charles River or Janvier and bred under specific pathogen-free conditions in 
the animal facility service of ZMBH Heidelberg and House for Experimental Therapy (HET), 
University of Bonn. Water and food were provided ad libitum.  
 
6.2.1.1 Splenectomy 
 
 
Surgical removal of the spleen was done prior to immunization or during the immune response. 
During surgery, mice received inhalational anaesthesia with isoflurane. An incision was made in the 
abdomen over the spleen, and the skin and muscles were pulled back. The spleen was located, and the 
blood vessels to and around the spleen, including the splenic artery and vein, were clamped or tied off, 
so that the organ was no longer attached. The spleen was removed and any bleeding was controlled by 
tying blood vessels. The wound was cleaned, the muscles and skin were closed with stitches. 
 
6.2.1.2 Generation of bone marrow chimeric mice 
 
For the generation of chimeric mice, recipient mice were !-irradiated with 9 Gy and reconstituted with 
bone marrow cells from each relevant donor strain. Bone marrow was isolated from hint legs taken 
from donor mice under sterile conditions, washed and filtrated. Each recipient mouse was injected 
with ~1x10e7 donor cells i.v.  At six to eight weeks after transplantion mice were used for subsequent 
experiments.  
 
6.2.1.3 Immunization protocols 
 
Reagents or pathogens or cells were diluted in 0.9% NaCl for experimental immunizations. 
Intravenous injections were performed with a maximal total volume of 250µl, subcutaneous injections 
with a volume of 100µl. 
 
• Immunization with soluble antigen 
For immunization with soluble OVA, C57BL/6 mice were injected i.v. or s.c. (intra ear pinna) 
with 100µg OVA. H-2kb SIINFEKL specific cytotoxicity was determined in the spleen (i.v.) or in 
draining lymph nodes (s.c.). H-2kb SIINFEKL specific CD8+ T cells were quantified by MHC 
tetramer staining (see below). 
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• Immunization with transduced BMDCs 
Mice were injected i.v. with 2x 10e6 AdOVA-transduced DC (see below). H-2kb SIINFEKL 
specific cytotoxicity was determined in the spleen five days later. 
 
• Infection with recombinant adenoviruses 
Mice were infected i.v. with 1x 10e7 PFU of recombinant adenoviruses expressing OVA, 
Luciferase and GFP or all three antigens. Viral load of AdLucGFP infected mice was monitored 
via In vivo imaging of bioluminescence at day 2 p.i..  H-2kb SIINFEKL or H-2kd HYLSTQSAL 
specific cytotoxicity was determined in the spleen or in the blood (in splenectomized groups). H-
2kb SIINFEKL specific CD8+ T cells were quantified by MHC tetramer staining (see below). 
Antibodies against adenovirus and OVA were determined at day 21 p.i. 
 
• Infection with recombinant Listeria monocytogenes 
Recombinant Listeria monocytogenes expressing OVA were cultured at 20°C over night in brain 
heart infusion medium in a shaker. Mice were infected intravenously with 1x10e5 bacteria. 
SIINFEKL or H-2kd HYLSTQSAL specific cytotoxicity was determined in the spleen. 
 
• Inoculation with P. falciparum infected red blood cells 
Human erythrocytes were cultured and infected with Plasmodium falciparum by members of the 
lab from Hermann Bujard in the ZMBH, University of Heidelberg. After formation of the “ring” 
stage, the infected erythrocytes were harvested, counted and incubated for 1 hour with 
chloroquine. HLA-A2 transgenic mice were immunized with 2,8 x 10e8 P. falciparum infected 
erythrocytes i.v. P. falciparum-derived MSP-1 specific cytotoxicity was determined six days later 
in spleen or blood. 
 
• Inoculation with RMA-GFP tumor cells 
Mice were injected i.v. with 5x10e5 RMA-GFP tumor cells. RMA-specific cytotoxicity was 
determined six days later in the livers by in vivo CTL assay (see below). 
 
• Inoculation with Mo4 tumor cells 
Mice were injected i.v. with 5x 10e5 Mo4 tumor cells expressing luciferase. Tumor growth in the 
lung was monitored by in vivo imaging of bioluminescence every other day (see below). 
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6.2.1.4 Preparation of P. berghei ANKA merozoites and infection of mice 
 
All Plasmodium infection experiments were performed in the Department of Parasitology, University 
of Bonn. Plasmodium berghei ANKA (PbA) parasites were obtained from a mouse previously 
infected with sporozoites. Blood was taken from highly parasitemic Balb/c mice. Parasitemia was 
determined in Giemsa-stained blood smears from tail blood. Giemsa stain is used to differentiate 
nuclear and/or cytoplasmic morphology of platelets, RBCs, WBCs, and parasites. Blood samples from 
donor mice were taken daily from day 4 post infection. 2-3 drops of blood were given on a slide and 
dispersed to obtain a thin blood film. After the blood has dried, the sample was fixed with methanol by 
dipping the film briefly in a Coplin jar containing absolute methanol. The sample was air dried again 
and then stained with diluted GIEMSA (1:20, vol/vol) for 20 minutes. It was briefly washed with PBS 
and then air dried in a vertical position. To determine parasitemia, 500 erythrocytes were counted and 
analyzed for parasites.  
Recipient mice were infected at the age of eight weeks or older with 5x10e4 parasitized red blood cells 
(merozoites). After infection, mice were monitored for parasitemia and survival. C57BL/6 mice 
develop 6-8 days cerebral malaria after infection with 5x 10e4 PbA parasites that is characterized by 
neurological symptoms, unconsciousness, coma and final death. 
6.2.1.5 In vivo application of TLR ligands 
 
- TLR9 ligand CpG-rich ODN, TLR4 ligand LPS, TLR8 ligand R848 
TLR ligands were diluted in 0.9% NaCl and injected i.v. in a maximal total volume of 250µl. 
Titration of the individual TLR ligands to determine sublethal doses that induce immune 
suppression were determined before. If not otherwise stated, the following doses were applied in 
vivo: TLR9 ligand CpG 100µg; TLR4 ligand LPS 1µg; TLR7 ligand R848 10µg. 
 
- TLR7 ligands single stranded RNA sequences 
siRNA sequences were injected i.v. or s.c. according to the experiment in a dose of 1 or 10µg per 
animal. siRNA requires complexation to a carrier to avoid premature degradation, if applied in 
vivo. Two different strategies were available for siRNA application in vivo. 
 
- Carrier: Cationic liposomes (CL) facilitates delivery into the endosome 
10µg siRNA was incubated 30µl DOTAP® for 20 minutes at room temperature under sterile 
conditions and then diluted with sterile 0.9% NaCl to obtain the final volume for injection. 
 
- Carrier: Polyethylene imines (PEI) facilitates siRNA delivery into the cytoplasm.  
This carrier condenses DNA into positively charged particles capable of interacting with 
anionic proteoglycans at the cell surface and entering cells by endocytosis 21. It is acting as a 
"proton sponge" that buffers the endosomal pH and protects DNA from degradation. 
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Continuous proton influx also induces endosome osmotic swelling and rupture which provides 
an escape mechanism for DNA particles to the cytoplasm (Kichler et al., 1995; Remy et al., 
1995). 
 
10µg siRNA are diluted in 50µl sterile 5% glucose solution and mixed with 2µl In vivo Jet PEI® 
diluted in another 50µl 5% Glucose solution. After incubation of 20 minutes at 37°C, the mixture is 
filled with glucose to obtain a final volume of 250µl per recipient.  
 
6.2.2  Ex vivo methods 
6.2.2.1 Enrichment of splenic dendritic cells for ex vivo analysis 
 
C57BL/6 mice were injected repeatedly with TLR9 ligand CpG. Two hours after the re-challenge, 
mice were sacrificed and spleens were taken out. To enrich splenic DCs, spleens were perfused in 
vitro with GBSS containing 0.5% collagenase A, then cut into small pieces and transferred back into a 
15 ml reaction tube. Spleens were incubated in 2 ml GBSS-collagenase buffer at 37°C for 20 minutes. 
Then, MACS buffer was added to prevent cell clumping. Spleen pieces were gently pressed through a 
metal sieve to obtain a single cell suspension. Splenocytes were washed with MACS buffer, 
centrifuged for 5 minutes at 4°C, 1500 rpm and resuspended in RPMI medium. Cells were counted 
and plated into 24 wells in a concentration of 5x10e6 cells per ml. To determine production of 
inflammatory cytokines, Golgi Plug® and Golgi Stop® was added. 
 
6.2.2.2 In vitro generation of myeloid dendritic cells from bone marrow and 
transduction with recombinant adenovirus 
 
C57BL/6 mice were immunized with AdOVA-transduced BMDCs to determine the OVA-specific 
CTL response in vivo. 
 
Preparation protocol 
Hind legs from mice were cut at the pelvis and disinfected with ethanol. Skin and muscle tissue were 
removed, blank bones were washed in sterile PBS. Bone ends were cut with a scissor, bone marrow 
was flushed with a PBS-filled syringe into a sterile 50 ml tube. Cells were filtrated through a 40 µM 
mesh and washed with PBS, spun down for 10 min at 4°C 1500 rpm. Cells were re-suspended in 
IMDM medium complemented with GM-CSF; the total cell number was determined. Cells were 
plated on sterile Agar plates with 5x10e6 cells per plate in a volume of 8 ml. Day 4 after preparation 
cells were washed and replated. Cells in suspension were transferred into a 50 ml tube. Adherent cells 
were incubated for 2 min with 2 mM EDTA at 37°C, then removed from the plates by PBS washing 
and transferred into 50 ml tubes. Cells were washed with PBS and re-plated in fresh IMDM medium at 
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a number of 5x10e6 per plate. At day 7 of culture, BMDCs were harvested and stained for CD11c, 
CD11b, CD80 and CD86.  
 
In vitro transduction of BMDCs 
BMDCs were cultured for 7 days in Petri dishes (ø 6 cm).  
Transduction with recombinant adenovirus was performed at an multiplicity of infection (MOI) of 250 
(i.e. 2.5 x 10e8 pfu/well). Cells were incubated for 4 h at 37°Cand 5% CO2. After this time, 1.5 ml of 
DC medium with 10% FCS was added. Transduction efficiency and expression of MHC class II (I-Ab) 
and CD86 was assessed using flow cytometry. Mice were immunized with 2x 10e6 Ad-transduced DC 
which were harvested, washed and resuspended in 250 !l of 0.9% NaCl. 
 
 
 
 
 
6.2.2.3 Isolation and adoptive transfer of splenic T cells 
 
- Isolation of splenic CD4+ T cells from OVA CD4+ TCR transgenic donors 
 
C57BL/6 mice received via adoptive transfer splenic CD4+ T cells isolated from OT-II transgenic 
donor mice that possess OVA-specific CD4+ TCR- transgenic T cells two days before immunization 
with recombinant adenovirus expressing OVA. 
 
Procedere 
A spleen of one OVA-specific CD4+ TCR transgenic (OT-II) was taken out, harvested and filtrated to 
obtain a single cell suspension. Splenocytes were diluted in 15 ml RPMI medium transferred into a 
75cm2 cell culture flask. To activate OVA-specific CD4 T cells, 1mg OVA per ml was added to the 
culture. The cells were maintained for 7 days at 37°C under sterile conditions and supplemented with 
new medium, if required. At day seven, the cells were washed with MACS buffer, centrifuged at 1500 
rpm for five minutes. The cell pellet was resuspended in 1 ml MACS buffer and filtrated. Isolation of 
CD4+ T cells was performed in a two-step selection process. First, CD19, CD11b and CD8+ 
contaminating cells were separated by MACS. The negative flow through was stained with CD4+ 
MACS beads and then positive selected. Purity of cell was confirmed by flow cytometry. For adoptive 
transfer of the cells, cells were resuspended in 0.9% NaCl, counted and titrated. Every recipient mouse 
was injected i.v. with 2,5 x 10e5 CD4+ cells. 
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- Isolation and adoptive transfer of splenic T cells from WT donors 
 
RAG1-deficient mice were reconstituted via adoptive transfer with splenic CD4+ T cells and CD8+ T 
cells isolated from wildtype donor mice seven days before immunization with recombinant adenovirus 
expressing OVA or infection with P. berghei ANKA. 
 
Procedere 
We calculated one donor spleen for one recipient spleen. Spleen of wild type mice were taken out, 
harvested and filtrated to obtain a single cell suspension. The cells were washed with MACS buffer 
and centrifuged at 1500 rpm for five minutes. The cell pellet was resuspended in 1 ml MACS buffer 
and filtrated. Isolation of CD4+ T cells and CD8+ T cells was performed in a positive selection process. 
The cells were stained with CD4+ MACS beads and CD8+ MACS® beads for 15 minutes at 4°C, then 
washed with MACS buffer and then positive selected with the help of the Auto®MACS. Purity of cell 
was confirmed by flow cytometry. For adoptive transfer of the cells, cells were resuspended in 0.9% 
NaCl, counted and titrated. Every recipient mouse was injected i.v. with 2,5 x 10e5 CD4+ cells. 
 
6.2.3 Analysis of innate and adaptive immune response 
6.2.3.1 Flow cytometric analysis of surface and intracellular molecules 
 
Principle of method 
The flow cytometer was designed to automate the analysis and separation of cells stained with 
fluorescent antibodies. The instrument uses a laser beam and light detector to count single intact cells 
in suspension. Every time a cell passes the laser beam, light is deflected from the detector, and this 
interruption of the laser signal is recorded. Those cells having a fluorescently tagged antibody bound 
to their cell surface antigens are excited by the laser and emit light that is recorded by a second 
detector system located at a right angle to the laser beam. The simplest form of the instrument counts 
each cell as it passes the laser beam and records the level of fluorescence intensity as the abscissa. 
More sophisticated versions of the instrument are capable of sorting populations of cells into different 
containers according to their fluorescence profile. Use of the instrument to determine which and how 
many members of a cell population bind fluorescently labeled antibodies is called analysis; use of the 
instrument to place cells having different patterns of reactivity into different containers is called cell 
sorting. It is possible to determine the absolute number of cells as well the percentage of cells within a 
certain population expressing the target antigen passing the beam. Analysis of stained cells allows also 
the distribution of cells in a sample population according to antigen densities as determined by 
fluorescence intensity. Information about the cell size is derived from analysis of the light-scattering 
properties of examined cells. Multi-color analysis facilitates differentiated conclusions about 
phenotype and functions of the examined cells.  
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Surface staining: 
Cells were transferred into a 96 round-bottom plate (circa 1x106 cells/well) and washed with FACS 
buffer (5 min 1500 rpm 4°C). Antibody mastermix was prepared in FACS buffer for staining in a 
volume of 50µl per sample. Cell pellet was carefully re-suspended in 50µl aliquot of antibody 
mastermix and incubated on ice for 15 minutes while covered with tin foil. Cells were washed with 
FACS buffer and stained if necessary with secondary antibodies to biotinylated primary antibodies 
again on ice. Cells were centrifuged and washed twice in FACS buffer before analyzing with a flow 
cytometer.  
 
Intracellular staining of cytoplasmic proteins (cytokines) 
Staining of intracellular antigens was always performed after cell surface staining and subsequent 
fixation of the cells. In case of intracellular cytokine staining, the cells were incubated in vitro for 5 
hours in RPMI containing 0.8µl each Golgi Plug® and Golgi Stop® per ml RPMI. Ex vivo analysis of 
splenic dendritic cells was performed under semi-sterile conditions. 
 
After completion of surface staining, cells were fixed with 2% (w(v) PFA for 10 min on ice. PFA was 
immediately washed off by centrifugation of the cells at 1800 rpm for 10 minutes. Cells were 
permeabilized with saponin buffer during an incubation of 20 min at RT. Cells were centifuged and re-
suspended in 50µl antibody solution (incl. Fc block) diluted in saponin buffer. Cells were incubated 
for 20 min at RT, then 150 µl of saponin buffer was added and cells were left for another 5 minutes at 
RT to allow unbound antibody to diffuse out of the cell. Cells were centrifuged and washed twice in 
FACS buffer before analyzing with flow cytometry. 
 
SIINFEKL Tetramer staining 
H-2kb –OVA (SIINFEKL)-specific CD8+ T cells were stained in the spleens of mice five days after 
immunization with AdOVA. A splenocyte single cell suspension was generated. The cells were 
washed in FACS buffer, centrifuged for five minutes 4°C 1500 rpm. The cell pellet of ~1x10e6 
splenocytes was resuspended in 30µl FACS buffer containing 2.5µl Fc blocking antibody and 5µl 
fluorochrome labeled SIINFEKL-MHC class I tetramers and incubated for 20 minutes at room 
temperature. Then, 20µl FACS buffer containing diluted fluorescently labeled anti-CD8a antibody 
was added and incubated for another 15 minutes on ice. Then, the cells were washed with FACS-
buffer, centrifuged five minutes 4°C 1500 rpm before analyzing with flow cytometry. 
 
Data acquisition and analysis 
Flow cytometry was performed on a FACS-Calibur®, FACS-Canto-II® or LSR II (BD). Doublets 
were excluded in a FCS-W/SSC-A gate. Data were analyzed using FlowJo software (TreeStar, 
Ashland, OR). 
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6.2.3.2 In vivo cytotoxicity assay 
 
Principle of method 
Cytotoxicity of antigen-specific CD8a+ T cells can be measured at day 5 following immunization. 
Intravenously applied splenocytes (= target cells) from syngenic donors which are labeled with 
antigen-specific class I peptide are killed by antigen-specific CTLs of the immunized animals. 
Labeling of these target cells with CFSE allows visualization of lyse via flow cytometry.  
 
Procedure: 
As target cells, splenocytes from syngenic donors were either labeled with the specific class I peptide 
(2µM, 30min 37°C; peptide see below) and with a high concentration of CFSE (1µM CFSE 15 min 
37°C; CFSEhigh). In parallel, reference cells were labeled with a low dose of CFSE without prior 
peptide loading (0.1µM CFSE 15 min 37°C; CFSElow). After CFSE labeling, cells were washed three 
times with PBS. Cell numbers were determined and mixed at a 1:1 ratio. Each mouse received 5x106 
target cells and 5x106 reference cells intravenously. Four hours later, organs (spleen, lymph nodes) 
were taken out under semi-sterile conditions and homogenized with the help of metal sieves. Cells 
were washed with FACS buffer and filtrated. Lyse of target cells and ratio of target (CFSEhigh) and 
reference cells (CFSElow) was determined by flow cytometric acquisition of CFSE positive cells. Data 
were analyzed using FlowJo®, Microsoft Excel® and Prism® software. To calculate specific lyses the 
following formula was used:  
specific cytotoxicity [%] = 100 – ((CFSEhigh / CFSElow) of immunized animal / (CFSEhigh / CFSElow) of 
naïve control) x 100). 
 
Target cells were pulsed according to the immunization protocol with the following peptides: 
OVA  (H-2kb) SIINFEKL 
GFP  (H-2kd) HYLSTQSAL 
MSP-1  (HLA-A2) GLHHLITEL, VIYLKPLAGV, KLLDKINEI, KLKEFIPKV, SLEVSDIVKL 
 
6.2.3.3 ELISA (enzyme linked immuno sorbent assay) 
 
Principle of method:  
Enzyme-linked immuno-sorbent assays (ELISAs) combine the specificity of antibodies with the 
sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed 
enzyme. The “sandwich ELISA” is used to determine the antigen concentration in unknown samples 
and requires two antibodies that bind to epitopes that do not overlap on the antigen. Plate-bound 
“capture” antibody immobilizes antigen of a sample. Then the binding of the “detection” antibody 
facilitates via biotinylation detection and quantification of antigen. Strepavidin-coupled horseradish 
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peroxidase binds to biotin and converts a colorimetric substrate to a soluble colored product. 
Substrates used with peroxidase include 2,2’-azo-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) 
and 3,3’5,5’- tetramethylbenzidine base (TMB), which yield green and blue colors, respectively. 
 
Material and solutions 
96 well “Maxisorb” micro-titer plate, flat bottom (NUNC Immunosorb); Multi-channel pipette, ELISA 
reader,  
 
Solutions 
coating buffer (0,1M Na2HPO4, pH 8,5), washing buffer (PBS, 0,05% Tween 20); blocking buffer 
(PBS, 1% (w/v) BSA); ABTS buffer (0,1M Na2HPO4, pH 4,2); detection solution ABTS buffer, 
(1mg/ml ABTS, 2ml/ml 30% H2O2) or TMB and 0.18M H2SO4. 
Buffers and samples were added in a volume of 50µl/well unless otherwise stated. 
 
Antibodies and enzymes 
Purified capture antibody, biotinylated secondary antibody, horseradish peroxidase 
Procedure of sandwich ELISA (cytokine detection) 
The micro-titer plate was coated with unlabeled capture antibody (1µg/ml) that was diluted in coating 
buffer and incubated at 4°C at least four hours or over night. Then unbound antibody was removed by 
extensive washing with washing buffer. To prevent unspecific binding, the micro-titer plate was 
saturated by incubation with blocking solution (100µl/ well) for 30 minutes at RT. Wells were washed 
three times with washing buffer. Antigen-containing samples and defined dilution series of the 
appropriate recombinant protein standard were added to the wells and incubated over night at 4°C. 
Cytokine standards were diluted in complete medium and covered a range from 80 ng/ml to 0.078 
ng/ml in " dilution steps. Wells were washed three times with washing buffer. The secondary 
biotinylated antibody was diluted in blocking buffer (1µg/ml) and incubated for four hours at 4°C. 
Wells were washed three times with PBS/1% Tween. Horseradish peroxidase was diluted in PBS and 
incubated for one hour at RT. Wells were washed three times with washing buffer. ABTS substrate 
was diluted in ABTS buffer (1mg/ml) and added to the wells. After suggested incubation time has 
elapsed, optical densities at 405 nm could be measured on an ELISA plate reader. Alternatively, TMB 
was used as a substrate. In those cases, commercial TMB solution was added to the well. Enzymatic 
products were quantified at 650 nm. The enzymatic reaction was stopped by addition of 50µl 0.18 M 
H2SO4/well. The end-point reaction delivered a yellow product, which could be read at 450 nm. Data 
analysis was performed with SPF software. 
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Sandwich ELISA for determination of antibody responses 
Serum titers of IgG specific for adenovirus or for OVA were quantified by coating plates with 
adenoviral particles or OVA, respectively and using POX-conjugated goat-anti-mouse-IgG and goat-
anti-mouse IgM antibodies (BD, Heidelberg; Jackson) 
 
6.2.3.4 In vivo detection of bioluminescence 
 
The AdLucGFP load in C57BL/6 mice and tumor load of mice inoculated with Mo4-luciferase tumor 
cells was quantified by in vivo bioluminescence using the real-time IVIS Imaging System 200 
(Xenogen Corp., Alameda, CA, USA). Mice were analyzed for bioluminescence measurement 24 h 
after infection or tumor cell inoculation. Five minutes before quantification of bioluminescence, mice 
were injected intraperitoneally with 2.5 mg luciferine (S039; Synchem, Kassel, Germany). Analysis 
was performed under inhalational anaesthesia with isoflurane. Data were analyzed using Living Image 
2.50 software (Xenogen Corp.). 
 
6.2.3.5 Statistical analysis 
 
Graphs displaying specific cytotoxicity show always the results are expressed as mean ± standard 
deviation (SD). Comparisons were drawn using a two-tailed Student's t-test (Prism 4, Graphpad 
Software Inc., San Diego CA USA). Statistical analyses for survival curves was performed using the 
Kaplan-Meier-Test. Each group was compared to the others to investigate statistical differences in 
survival. P values of less than 0.05 were considered significant and are signed with asterisks in the 
graphs. Significance of one group refers to all other groups, unless otherwise mentioned. 
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7 Results 
7.1 TLR ligands suppress adaptive immune response 
7.1.1 Characterization of TLR9 ligand induced CTL suppression 
7.1.1.1 Systemic injection of TLR9 ligand inhibited antigen-specific CTL 
response 
 
It is well established, that local application of TLR ligands – e.g. TLR9 ligand CpG-rich DNA – 
enhances the immunogenicity of co-administered antigens. This is utilized in vaccination strategies 
also already in humans for generation of efficient immune responses against infectious antigens 
(Krieg, 2006). 
In the present study, immune stimulatory effects of CpG-ODN1668 (CpG) were confirmed in a 
murine model of immunization against the soluble model antigen ovalbumin (OVA) in vivo. For this 
purpose, C57BL/6 mice were injected subcutaneously (s. c.) with 100µg OVA with or without 50µg 
CpG. The activity of OVA-specific cytotoxic lymphocytes (CTLs) was determined 5 days after 
immunization in the draining lymph nodes by performance of an in vivo cytotoxicity assay.  
The elimination of syngeneic target cells (H-2kb) loaded with OVA-derived class I peptide SIINFEKL 
(S8L) was ten times more efficient in CpG/OVA-treated animals than in mice that received OVA 
alone (Figure 2 A). Thus, co-administered CpG strongly enhanced OVA-specific CTL responses in 
draining lymph nodes of C57BL/6 mice following subcutaneous (s.c.) immunization. In contrast, only 
weak CTL responses were obtained in OVA-immunized mice without CpG (Figure 2A left panel). 
To analyze whether systemic immunization may also be influenced by TLR ligands, wild type mice 
were immunized with OVA intravenously (i.v.) with or without co-administration of CpG. Five days 
later, cytotoxic activity of OVA-specific CTLs was assessed with the help of an in vivo cytotoxicity 
assay in the spleen. Surprisingly, the cytotoxic activity of OVA-specific CD8a+ T cells in the spleen 
was markedly decreased by CpG application in comparison to control-immunized animals (Figure 2A, 
right panels). Thus, systemic co-injection of CpG and antigen inhibited antigen-specific cytotoxicity. 
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Figure 2: Systemic application of CpG-ODN1668 suppressed adaptive immune response 
and generation of antigen-specific T cells towards subsequent immunization. 
(see next page for figure legend) 
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- Figure legend for figure 2 - 
(a) C57BL/6 mice were immunized with 100!g OVA either s. c. or i. v. with (white bars) or without (black bars) 
CpG pretreatment (50!g). OVA specific CTL activity was analyzed 5 days p. i. in the draining lymph node (s. c.) 
or in the spleen (i. v.). (b, c) C57BL/6 mice were immunized with 1x10e7 PFU recombinant AdOVA i. v. with or 
without CpG pretreatment (100!g i. v.). OVA specific cytotoxicity was determined in vivo 5 days p. i. in the spleen 
(b). (c) Binding of splenic CD8a positive T cells to SIINFEKL-loaded MHC class I tetramers was assessed with 
flow cytometry. Numbers indicate percent of double positive cells. Data are representative results from more than 
three independent experiments with three or more mice per group. students t test: two asterisks represent p 
values <0.005, three asterisks represent p values <0.0001. (d) Determination of adenovirus specific IgG and 
OVA-specific IgG in sera of C57BL/6 after infection with recombinant AdOVA with or without CpG pretreatment 
according to (b). (e, f) C57BL/6 x BALB/c F1 mice were injected i.v. with the indicated doses of CpG-ODN 1 day 
before infection with 1x10e7 PFU recombinant AdLucGFP. (e) Determination of HYLSTQSAL-specific cytotoxicity 
in vivo 5d p.i. in spleens of AdLucGFP-infected animals. (f) Luciferase-related bioluminescence was quantified 3 
days after infection with AdLucGFP to determine viral load in the host. ROI= region of interest; ROI numbers 
indicate light intensity in the ROI. Results are expressed as mean ± standard error of the mean (SEM). 
Representative data are shown.  
 
 
7.1.1.2 Systemic injection of TLR9 ligand CpG prevented adaptive immune 
responses in vivo against AdOVA 
 
Systemic application of CpG inhibited cellular immune responses towards the soluble antigen OVA 
(Figure 2A). It was investigated next, whether CpG also influenced cellular immune responses 
towards viral infections. To study this question, mice were infected i. v. with replication-deficient 
recombinant adenoviruses with or without systemic CpG-pretreatment. Recombinant adenoviruses 
were chosen as immunization model because recent studies by Harui et al. demonstrate the induction 
of strong CTL and antibody responses towards adenoviral expressed transgenes (Harui et al., 2004).  
Here, experiments were performed primarily with recombinant adenoviruses expressing OVA 
(AdOVA) or luciferase and green fluorescent protein (GFP, AdLucGFP). OVA-derived MHC class I 
peptide S8L is presented on H-2kb that allows determination of cytotoxic activity of S8L-specific 
CTLs in C57BL/6 after infection AdOVA. Infection with AdLucGFP allows monitoring of luciferase-
caused bioluminescence via in vivo imaging as well as determination of cytotoxic activity of GFP-
specific CTLs recognizing the GFP-derived MHC class I peptide HYLSTQSAL (H9L) presented on 
H2-kd.  
In the present study, mice were injected i. v. with 100µg CpG one day prior to infection with 
recombinant AdOVA. Antigen-specific CTL responses were determined five days post infection with 
the help of an in vivo cytotoxicity assay in the spleens of the infected mice. 
Systemic pre-treatment of mice prevented generation of antigen-specific CTL responses in C57BL/6 
mice after i. v. infection with AdOVA (Figure 2B). In addition, we used the MHC class I tetramer 
technology to quantify S8L specific CTLs by flow cytometry. In spleens of CpG treated C57BL/6 
mice, the amount of S8L-specific T cells was reduced by factor 3 compared to control-infected 
littermates (Figure 2C). Furthermore, systemic CpG injection affected also the generation of virus-
specific antibodies. In the sera of control-infected mice, high levels of OVA- and adenovirus-specific 
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immunoglobulins were detected 21 days after AdOVA immunization, whereas both types of 
antibodies were lacking in CpG-treated animals  (Figure 2D).  
It is well described, that CpG can stimulate innate immune cells resulting in antiviral effects, which 
may cause reduced viral load. It is possible that the lack of both CTL and antibody responses were the 
result of CpG-induced activation of innate phagocytic mechanisms that may cause removal of the 
antigen. To rule this out, the infection rate was investigated in mice 24 hours after infection with 
AdLucGFP by in vivo imaging of luciferase bioluminescence. In addition, activity of H9L-specific 
CTLs in spleens of the infected (C57BL/6 x Balb/c) F1 mice was assessed by an in vivo cytotoxicity 
assay 5 days post infection and compared to the infection rate. To determine influences of CpG 
application, mice received 0,5µg, 5µg or 50µg CpG 24 hours before infection with AdLucGFP. All 
three doses of CpG strongly reduced bioluminescence (Figure 2F). 
However, CpG-induced inhibition of CTL responses was dose-dependent; only high doses equal or 
above 50µg of CpG suppressed the GFP-specific CTL response, whereas low doses were immune 
stimulatory and enhanced GFP-specific CTL responses (Figure 2E).   
Thus, inefficient T cell priming cannot be explained by complete clearance of antigen due to increased 
activation of innate immune mechanisms. The anatomic site of CpG application influenced (and 
determined) the outcome of the subsequent immune response. CpG injection prior to immunization 
with soluble or virally expressed antigen led to a dose-dependent inhibition of antigen-specific CTL 
responses. Thus, systemic application of CpG in high doses did not amplify the adaptive immune 
response, but rather prevented the generation of antigen-specific T cells towards adenoviral infection. 
 
7.1.1.3  CpG induced immune suppression is dependent on TLR9 
 
TLR9 recognizes CpG-rich DNA as a natural ligand (Hemmi et al., 2000). To investigate whether 
CpG-mediated suppression is dependent on TLR9, experiments were performed in mice that were 
either competent or deficient in TLR9 expression. To answer the additional question, whether CpG-
induced suppression is dependent on TLR9-expression by cells of the hematopoietic system, TLR9-
bone marrow chimeric mice were generated. For generation of TLR9-chimeric mice, sub-lethally 
irradiated wild type mice were reconstituted with bone marrow (BM) purified from TLR9-deficient 
mice. As a control, wild type mice were reconstituted with BM from wild type littermates.  
All mice were infected with AdOVA with or without systemic CpG pretreatment; OVA-specific CTL 
responses were determined 5 days p. i. in the spleen. 
TLR9-deficient animals generated a CTL response against OVA equally well compared to wild type 
littermates (Figure 3A). Importantly, CpG-induced inhibition of the OVA-specific CTL response was 
abrogated in TLR9-deficient mice (Figure 3A). Analysis of TLR9-BM chimeric animals revealed that 
CpG-induced suppression was dependent on TLR9 expressed by BM-derived cells. Wild type 
recipients that were reconstituted with TLR9-/- BM generated strong OVA-specific CTL responses 
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whether or not CpG was injected before immunization (Figure 3B). In contrast, wild type recipients 
reconstituted with BM from wild type littermates, CpG treatment prior to AdOVA immunization 
suppressed OVA-specific CTL responses (Figure 3B).  
Thus, CpG mediated suppression was dependent on TLR9 expressed by BM-derived cells. 
 
 
Figure 3  TLR9-dependent suppression induced by CpG 
(a) TLR9 deficient and wild type littermates were pretreated with 50!g CpG before infection with 1x10e7 PFU 
recombinant AdOVA. Cytotoxic function of OVA class I peptide S8L-specific CTLs was determined five days after 
immunization in a 4h in vivo cytotoxicity assay. Specific lysis of target cells in the spleens was calculated and is 
shown as percentage. (b) TLR9-BM chimeric mice were generated and analyzed for suppression. WT recipients 
received either BM from syngenic TLR9 deficient donors (middle) or from TLR9 competent donors (right), 
Representative data of two independent experiments are shown with three or more mice per group. (D) donor (R) 
recipient. BM bone marrow 
 
 
 
7.1.2 Mechanistic requirements for the induction of CTL responses against 
antigens expressed by recombinant adenovirus 
7.1.2.1 Importance of the spleen and CD4 help for the generation of CTL 
responses 
 
Observations in patients who underwent surgical removal of the spleen imply that the spleen is of 
major importance for the generation of protective and functional adaptive immune responses towards 
several infections (Mebius and Kraal, 2005). Indeed, experiments performed in our laboratory in 
splenectomized mice supported this hypothesis for the mouse model. C57BL/6 mice were 
splenectomized either one day before or four days after immunization with AdOVA and an OVA-
specific in vivo cytotoxicity assay was performed 5 days after infection. Antigen specific CTL 
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responses against OVA were lacking in all splenectomized animals, as determined in blood and liver 
(Figure 4A, data not shown). This is remarkable, as recombinant adenovirus is reported to primarily 
infect hepatocytes of the liver in mice and to induce activation of liver DCs (Zhang et al., 2001). This 
result strongly implies that despite high infection rate of the liver and low infection rate of the spleen, 
antigen-specific CTL responses were not generated in the liver, but required the spleen. 
 
 
 
Figure 4  The induction of functional immune responses towards AdOVA infection is 
dependent of the spleen  
(a, b) In vivo SIINFEKL-specific CTL responses in mice were determined five days after AdOVA infection. (a) 
Comparison of naïve C57BL/6 mice and splenectomized littermates. Splenectomy was performed either prior to 
or after i. v. immunization with 1x10e7 PFU AdOVA, analysis of blood. (n=3 per group). (b) Analysis of S8L-
specific cytotoxicity in the spleen of wild type and RAG1
-/- 
mice. RAG1
-/-
 received CD4+ and CD8a+ splenocytes 
purified from syngenic naïve wild type donors seven days before AdOVA infection.  
 
It was investigated next, whether the generation of a productive CTL response towards AdOVA 
required intact spleen architecture. Due to its localization in the circulatory system and its unusual 
structure of its lymphoid compartments, the spleen is a unique lymphoid organ. Functional disruption 
of the RAG-1 gene by homologous recombination leads to the absence of B and T cells in RAG-1-/- 
mice, and thus to a disorganized micro-architecture of the spleen. (Mebius and Kraal, 2005). We 
investigated, whether RAG1-/- mice were able to generate CTL responses towards AdOVA infection 
after reconstitution with splenic T cells from syngeneic donors. CD4+ and CD8a+ T cells cells were 
isolated from naïve C57BL/6 and purified via MACS technology, then pooled and adoptively 
transferred into RAG1-/- recipients. All mice were infected with AdOVA seven days after transfer. It 
was not possible to detect cytotoxic activity of S8L-specific CTLs in RAG1-/- mice after substitution 
with splenic CD4+ and CD8+ T cells isolated from naïve wild type donors (Figure 4B). 
These results indicate that not only the lack of certain cell populations, but also a disintegrated 
architecture of the spleen was responsible for inefficient generation of adaptive immune responses. 
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7.1.2.2 Induction of antigen specific CTL responses in AdOVA infection 
requires CD4 help and CD40 signaling 
 
Additionally, we investigated the role of CD4 help in the model of AdOVA infection. It is well 
known, that for generation of CD8 responses towards some viral infections CD4 help is required 
(Ahmed et al., 1988; Cardin et al., 1996; Kast et al., 1986). Therefore, the generation of OVA-specific 
CTLs was investigated in wild type mice that were injected i. p. with a CD4 depleting antibody before 
AdOVA infection. In addition, CD4-/- or MHC class II-/- (=I-Ab-/-) deficient mice that lack CD4+ cells 
(Bevan, 2004) were infected with AdOVA and examined in this experiment. Five days after infection, 
the cytotoxic activity of OVA-specific CTLs was determined in spleens of these mice. Neither of the 
groups generated productive OVA-specific CTL responses (Figure 5 A,B).  
CD4 help requires a productive interaction between DC and CD4+ T cell via CD40-CD40L 
(Schoenberger et al., 1998). We investigated whether CD40 deficient mice were able to induce an 
OVA-specific CTL response upon AdOVA infection. OVA-specific CTL responses were determined 
five days after infection in the spleens, but were not detected in CD40-deficient mice (Figure 5C). 
Thus, CD4 help was critical for the induction of functional immune responses towards AdOVA 
infection. 
 
 
 
 
Figure 5 CD4 help and CD40 signaling are required in CTL induction 
S8L specific cytotoxicity in spleens of AdOVA infected mice at day 5. (a) Analysis of spleen of AdOVA-infected 
wild type and MHC class II deficient mice (I-A
b-/-
). (b) Analysis of spleen of C57BL/6 wild type, CD4-depleted wild 
type and CD4 deficient littermates (c) . Analysis of spleen of AdOVA-infected wild type and CD40 deficient mice 
n=4 per group. Results are median ±SEM. 
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7.1.3 Cellular phenomena of CpG induced suppression  
7.1.3.1 Injection of CpG induced an initial immune activation 
 
Production of inflammatory cytokines is a hallmark during immune activation and described to be a 
consequence of TLR ligation in vivo and in vitro (Kawai and Akira, 2005). Upon ligation, TLRs 
trigger the production of NF-kB-dependent gene products like IL-6 and IL-12 (Doyle and O'Neill, 
2006). In the present study, the question arose whether the dose of CpG that induced suppression of 
CTL responses towards subsequent infections, initially also leads to activation of immune cells.  
To examine immune activation due to CpG application, mice were injected i. v. with 100µg CpG. Sera 
and splenocytes were analyzed for production of IL-6 and IL-12. Furthermore, splenic DCs were 
stained for the surface expression of molecules that are important for antigen presentation and co-
stimulation and indicate DC maturation.  
Indeed, whereas in sera of naïve C57BL/6 mice neither IL-6 nor IL-12 could be measured, sera of 
CpG-injected littermates contained elevated levels of IL-12p70 and IL-6 2 hours after single CpG 
injection (Figure 6A). In addition, increased levels of IL-12p40p70 were detected in CD8+CD11c+ 
splenocytes of CpG-injected mice but not samples of naïve mice as determined by intracellular 
staining (ICS) and analyzed via flow cytometry (Figure 6B). Flow cytometric analysis 24 hours after 
CpG injection showed further that splenic dendritic cells of CpG-injected mice expressed enhanced 
levels of CD40, CD80 and I-Ab in comparison to naïve mice (Figure 6C). Thus, systemic application 
of TLR9 ligand CpG induced a phenotypic and functional activation of splenic dendritic cells. 
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Figure 6  Systemic CpG application activated splenic dendritic cells 
(a) Sera taken from ± CpG (100!g i.v.) injected C57BL/6 were analyzed for IL-6 and IL-12 via sandwich ELISA. 
n=2. (b) Intracellular detection of IL-12 produced by splenic CD8a
+
 CD11c
+
 cells isolated from Balb/c (upper row) 
and C57BL/6 (lower row). Mice received 100!g CpG i. v. and were sacrificed 2 hours later. n=2 per group, 
representative data from one mouse from more than 3 independent experiments are shown.(c) Splenic dendritic 
cells isolated from C57BL/6 24 hours after systemic injection of 100!g CpG. Cells were gated on CD11c (open 
histograms = naïve control; tinted histograms = TLR-L treated). n=2 per group, representative data from one 
mouse are shown. 
 
 
 
7.1.3.2 Multiple TLR stimulation is followed by paralysis and altered 
composition of DC subpopulations 
 
The primary finding showed that systemic injection of TLR9 ligand CpG inhibited the generation of 
CTL responses towards subsequent AdOVA infection. This contrasts the observation that CpG 
treatment triggered systemic immune activation and maturation of splenic dendritic cells (Figure 6). 
Therefore, we asked whether a second TLR stimulation could re-elicit production of pro-inflammatory 
cytokines in mice previously injected with CpG in comparison to single CpG-injected mice. To mimic 
CpG injection and subsequent AdOVA infection, mice were given two CpG injections of 100µg each 
24 hours apart. All mice were sacrificed 2 hours after the last injection. Systemic levels of IL-12p70 
were determined in the sera of all mice by sandwich ELISA. The production of inflammatory 
cytokines was examined by intracellular FACS staining for IL-12p40p70, TNF" and IFN!. To 
distinguish different splenocyte subsets, CD11c+ splenocytes were gated for CD8", CD11b and NK1.1 
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(Figure 8). Figure 8 illustrates the amount of cells that were stained positive for each cytokine and for 
the subset-marker. The relative amount of double positive cells was calculated and stated as percent 
corresponding to the individual subset (Figure 8). 
In splenocytes of mice that received a single injection of CpG briefly before analysis, strong signals 
for IL-12p40p70, TNFa and IFNg were detected. In particular, almost 50% of CD8a+CD11c+ were 
stained for IL-12p40p70, whereas in the same splenic DC subset of naïve controls no reasonable 
amount of this cytokine was detected (left column #1 and #2, Figure 8A). In addition, more than 7% of 
splenic CD11b+CD11c+ splenocytes were stained for TNF" (middle column #1 and #2, Figure 8 B) 
and almost 30% of NK1.1+CD11c+ splenocytes were stained for IFNg (right column #1 and #2, Figure 
8C). Again, in splenocytes of naïve mice, signals for TNF" and IFN! were almost undetectable or 
very low. Systemic activation as a result of CpG injection was concluded from increased IL-12p70 
levels detected in sera of CpG-injected mice compared to lacking signals in sera of naïve mice (D). 
These results corresponded to the data shown in 7.1.3.1 where a primary immune activation was 
observed following a single injection of CpG. 
In contrast, in CpG re-injected mice, levels of IL-12p40p70 detected in CD8a+CD11c+ splenocytes 
were greatly impaired, as determined by ICS (Figure 7 left column). Compared to splenocytes from 
single injected mice, the amount of CD8a+CD11c+ splenocytes stained positive for IL-12p40p70 was 
reduced by 80% following repeated CpG treatment. In addition, production of TNF" by CD11b+ 
CD11c+ as well as IFN! production by NK1.1+CD11c+ was greatly impaired in this group (Figure 7 
middle and right panel). A quantification of ICS results revealed, that only 50% of CD11b+CD11c+ 
were positive for TNF" and only 20% of NK1.1+CD11c+ were positive for IFN! (Figure 8).  Most 
importantly, the expression of all examined splenic subset marker molecules was remarkably reduced 
in these splenocyte-samples of mice that received repeated CpG injection within 24 hours. CD8a and 
NK1.1 were decreased about twofold whereas expression of CD11b was only marginally reduced. To 
determine whether the induction of DC paralysis in the spleen results also in systemic suppression, 
levels of IL-12 were measured in the sera of CpG treated or untreated mice. Samples of mice that 
received CpG prior to a secondary CpG stimulus contained markedly reduced levels of IL-12 
compared to single-injected mice (Figure 8D).  
Thus, primary CpG application induced paralysis of splenocytes and changed the composition of 
cellular subsets in the spleen. This resulted in abrogated cytokine production in response to a 
secondary TLR stimulation in the spleen, but was also detected systemically. 
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Figure 7 Systemic CpG injection rendered splenic DC inactive 
C57BL/6 were pretreated in vivo with 100!g CpG i. v. at indicated time points. 2 hours before analysis, mice were 
restimulated in vivo with 100 !g CpG i.v. Then spleens were isolated and digested with collagenase. 5x10e6 cells 
were incubated in vitro for 4 hours with 0.8 !l Golgi Plug® and Stop® per ml medium. Production of IL-12p40p70/ 
TNF"/IFN! was assessed by ICS. CD11c
+
 gated splenocytes are displayed. Representative data from 1 out of 2 
mice are shown. 
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In order to determine the duration of CpG induced paralysis, the kinetic of restoration of the response 
to CpG was studied in previously paralyzed animals. Table 1 gives an overview about the treatment 
schedule. Mice received a first systemic injection of CpG on different days prior to CpG re-challenge 
and were compared to littermates injected once with CpG as well as naïve mice. 
 
 
 
Table 1  Treatment schedule for ex vivo 
analysis 
C57BL/6 were injected twice with 100!g CpG-ODN1668 
i. v. at the indicated time points. The individual groups 
are indicated. Exceptions: Naïve mice did not receive 
CpG treatment (=group #1) and group #2 received only 
one-time CpG injection 2 hours before analysis. 2 hours 
after the last CpG injection, mice were sacrificed for 
analysis. (# =group). 
 
 
 
 
Complete abrogation of IL-12 production by CD8a+ DCs lasted for 3 days (Figure 7 left column, 
Figure 8A). Five days after the initial challenge, a slight restoration of the response towards CpG was 
observed as an increased amount of CD8a+CD11c+ splenocytes that were positive for IL-12p40p70 
was detected. The full response to CpG was restored in CpG-re-challenged mice if the initial CpG 
injection dated back longer than seven days. Similar results were obtained by the determination of 
intracellular levels of TNF"  in CD11b+CD11c+ and of IFN! in NK1.1+CD11c+ cells. The amount of 
splenic CD11b+CD11c+ cells that were stained positive for TNF", was strongly decreased when CpG 
injection was repeated within 24 hours but was completely recovered, when the initial CpG injection 
was given seven days prior to CpG re-challenge (Figure 8B). Similarly, less NK1.1+CD11c+ 
splenocytes were stained for IFN! immediately upon CpG re-challenge, but increased the more 
primary CpG application dated back (Figure 7 middle and right panel). This indicates a re-population 
of these splenic CD11c+ subsets into the spleen. 
Kinetics of systemic paralysis reflected the results obtained from the spleen as sera of CpG-treated 
mice contained less IL-12p70 after consecutive CpG treatment. Systemic levels of IL-12p70 triggered 
by CpG increased concomitantly and were comparable to values from the positive controls if the 
primary challenge dated back seven days or more (Figure 8D). These data suggest, that TLR ligation 
alters splenic CD11c+ subpopulations as they are temporarily refractory towards repeated microbial 
signals. This is not only detected locally but also systemically. 
 
7  Results  
45 
 
Figure 8 Quantification of CpG-induced DC paralysis. 
(a, b, c) Calculation of cytokine production by CD11c+ splenocyte subsets, all data and groups correspond to 
figure 7 (a) Calculation of CD8a
+
CD11c
+
 splenocytes stained for IL-12p40p70 (b) Calculation of CD11b
+
CD11c
+
 
splenocytes stained for TNF" (c) Calculation of NK1.1
+
CD11c
+
 splenocytes stained for IFN! (d) Determination of 
systemic production of IL-12p70 detected in sera of CpG treated mice corresponding to figure 7 via Sandwich 
ELISA.  
 
As mentioned above, in CpG treated mice subpopulations of CD11c+ splenocytes were fundamentally 
altered regarding the cellular composition. This remarkable change was also observed during the 
kinetic experiment. Particularly splenic CD11c+ subsets expressing CD8" or NK1.1 were markedly 
decreased upon repeated CpG injection, whereas the fraction of CD11b+CD11c+ was decreased to a 
lesser extent. The amount of CD8"+CD11c+ was mostly decreased in spleen of mice that were injected 
with CpG at d-3 and d0. The longer the time-span was between primary and secondary injection of 
CpG, the higher the amounts of CD8"+CD11c+ splenocytes were detected by ICS. If more than 5 days 
elapsed between primary and secondary CpG application, levels of CD8"+CD11c+ splenocytes 
reached numbers that were comparable to those determined in spleens of naïve controls. Similar 
findings were made for NK1.1+CD11c+ splenocytes. Here, the lowest amount of NK1.1+CD11+ was 
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detected in spleens of mice that received the primary CpG injection at d-5, d-3 or d-1. Importantly, the 
amount of this splenic subpopulation did not recover until a period of 10 days to levels that were 
equivalent to naïve controls. This suggested, that not only production of pro-inflammatory cytokines 
by individual splenocyte subsets was decreased but also the relative amount of this specific splenocyte 
subpopulation was reduced.   
To examine whether this loss of distinct splenocyte subpopulations was a result of primary CpG 
injection, mice were injected with CpG and splenocytes were examined 24 hours later in respect to 
their expression of CD11c and CD8a, NK1.1, CD11b or CD19. The amount of the different subsets 
were determined by flow cytometric analysis and calculated as relative proportion of CD11c+ cells.  
CD11chigh cells were almost absent in spleens of CpG-treated mice, which constituted a clearly 
confined population in spleens of naïve animals (Figure 9A). CD11c expression by splenocytes was 
rather decreased to intermediate levels. Furthermore, whereas the fraction of CD11c+ splenocytes 
stained positive for CD8" or NK1.1 was decreased by factor 3 and 4, respectively, the proportion of 
CD11b+CD11c+ splenocytes differed only marginally (Figure 9B).  Interestingly, the amount of 
CD19+CD11c+ splenocytes was more than twofold increased in CpG treated mice (Figure 9D). 
These findings show that systemic CpG injection does not only impair DC function but also results in 
loss /disappearance of certain DC subpopulations. We assume that this will contribute to the impaired 
immune responses towards further microbial challenge in vivo.  
 
 
Figure 9  CpG altered composition of splenic DC subpopulations 
(a) Staining of CD11c+ splenocytes regarding CD8a (left column) and CD19 (right column) expression of naïve 
C56BL/6 (upper panel) and 24h after CpG (100!g i.v.) lower panel). Representative data of one mouse out of two 
are shown. (b) Quantification of relative proportion of splenic CD11c+ subsets isolated in naïve mice compared to 
CpG-injected littermates after flow cytometric analysis (100!g CpG-ODN1668 i.v. 24 hours before analysis) Mean 
± standard deviation of n= 2. 
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7.1.3.3 Exogenously matured DCs are unable to restore CTL response in CpG 
pretreated recipients 
 
The previously presented data described the inhibition of adaptive immune responses induced by CpG 
(Figure 2B). This suggested two different possibilities of CpG-induced suppression. CpG could either 
directly inhibit DC maturation and antigen presentation or indirectly by induction of an inhibitory 
local milieu. To distinguish between these two possibilities, an adoptive transfer of in vitro infected 
bone marrow-derived DCs (BMDC) was performed. Efficient activation and re-localization of 
transferred BMDC into the spleen could be confirmed in vivo recently by Schweichel et al. 
(Schweichel et al., 2006).  
 
 
Figure 10 Treatment schedule for adoptive transfer of AdOVA- transduced BMDCs into 
syngenic naïve or CpG-1668 pretreated recipients 
 
Therefore, BMDC derived from syngenic donors were transduced with AdOVA in vitro. 24 hours 
later, the transduced DCs were adoptively transferred into C57BL/6 that were either naïve or were 
systemically injected with 100µg CpG-ODN1668 at the previous day according to Figure 10. An 
OVA-specific cytotoxicity assay was performed six days after transfer and clearly showed a strong 
CTL response in the control group, whereas in spleens of mice that were systemically injected with 
CpG before transfer of AdOVA-transduced BMDC, the OVA-specific CTL response was significantly 
reduced (Figure 11A).  In a second approach, mice received BMDCs that were incubated in vitro with 
CpG or not one day before in vitro transduction with AdOVA. Cells were adoptively transferred 
another 24 hours later in naïve syngeneic C57BL/6 recipients. An in vivo cytotoxicity assay was 
performed 5 days after transfer and revealed that in vitro incubation of BMDC with CpG did not 
inhibit OVA-specific CTL responses (Figure 11B). 
Thus, insufficient maturation and/ or antigen presentation possibly caused by CpG cannot exclusively 
be made responsible for impaired T cell responses.  
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Figure 11  Systemic CpG pretreatment prevented efficient T cell priming by exogenously 
matured DCs 
(a) S8L-specific CTL response was determined in spleens of C57BL/6 mice after immunization with 2x10e6 
AdOVA-transduced BMDCs at day 6. One group of mice was pretreated with 100!g CpG-ODN1668 24 hours 
before immunization. (b) C57BL/6 received BMDCs, that were incubated over night with 10nmol CpG in vitro or 
not 24 hours before in vitro transduction with AdOVA. 2x10e6 BMDCs were injected per mouse i.v. 24 hours later 
into naïve recipients. Cytotoxic activity of S8L specific CTLs were determined in the spleen at day 5 p.i. and 
calculated in %. 
 
7.1.3.4 Exogenous CD4 help abrogated CpG-induced CTL suppression 
 
It was shown that for an efficient generation of CTL responses towards AdOVA infection spleen and 
CD4 help are required. In addition, systemic CpG treatment prevented the generation of immune 
responses. As adoptive transfer of fully matured DCs could not compensate for the inhibitory effects 
of previously administered CpG, this led to the suggestion, that provision of exogenous activated CD4 
helper cells might circumvent the suppression. Therefore, experiments were performed with the help 
of OT-II transgenic mice, which express a transgenic CD4 T cell receptor specific for OVA MHC 
class II derived 323-339 peptide presented on I-Ab (Barnden et al., 1998).  
To examine the influence of naïve or activated antigen-specific CD4+ T cells, naïve or in vitro 
activated MACS-purified CD4+ splenocytes from OT-II transgenic mice were adoptively transferred 
into naïve wild type recipients. Indicated groups received CpG 24h later and were infected with 
AdOVA according to Figure 12.  
 
Figure 12 Time schedule of adoptive T cell transfer 
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A CTL response was lacking in spleens of mice that received naïve CD4+ cells from OT-II mice and 
CpG, whereas transfer of activated CD4+ T cells from OT-II mice completely restored the activity of 
S8L-specific CTL (Figure 13). 
Thus, CpG-induced inhibition of CTL responses can be abrogated by the provision of exogenously 
activated antigen-specific CD4 T cells. These results further support the hypothesis, that the amount of 
antigen presented by DCs is sufficient for T cell priming. 
 
Figure 13  Transfer of Exogenously activated 
CD4+ helper cells restored CTL activity in CpG 
pretreated mice 
Transfer of in vitro activated CD4+ cells from OT-II 
transgenic mice restored CTL activity in CpG treated mice. 
C57BL/6 mice received either 2,5 x10e5 in vitro activated 
OT-II (OT-II*) or naïve OT-II (n-OT-II) or were left untreated 
(Ø) 24 hours before i.v. injection with 100!g CpG-1668. n=3 
per group. Mean ±SEM of S8L specific lysis is shown. 
 
 
 
 
 
7.1.4 Summary of chapter 7.1 
The data presented so far showed that systemic, but not local injection of high doses of CpG 
suppressed the generation of innate and adaptive immune responses. CD8 and CD4 T cell responses 
against the model antigen OVA were completely abrogated by CpG application in a dose-dependent 
manner. Furthermore, the generation of specific CTL responses against specific model antigens 
expressed by recombinant adenoviral vectors required the spleen, CD4 help and CD40 signaling. 
CpG-induced suppression could not solely be attributed to a direct inhibition of DC maturation or 
antigen presentation. Nevertheless, CpG treatment induced paralysis of splenocytes that resulted in 
strongly reduced secretion of pro-inflammatory mediators and fundamental alteration of CD11c+ 
splenocyte subsets. We assumed that CpG rather induced an inhibitory milieu that resulted in block of 
CD4 help. This hypothesis was further supported by the observation that CpG-induced suppression 
was abrogated through adoptive transfer of activated antigen-specific CD4+ T helper cells.  
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7.2 The role of the TLR system for the control of host immune responses induced 
by infection with Plasmodium ssp.  
 
Cerebral malaria is a fatal neurological complication in humans infected with Plasmodium falciparum 
(Pf) and is mainly caused by the host immune response. Infection of C57BL/6 with Plasmodium 
berghei ANKA (PbA) infected red blood cells (iRBC) induces experimental cerebral malaria (ECM) 
and ranks among the acknowledged experimental models of malaria (Greenberg and Kendrick, 1957a; 
Greenberg and Kendrick, 1957b).  
It has been shown by experiments in genetically deficient mice or by use of depleting antibodies, that 
inflammatory cytokines (IFN!, lymphotoxins) and activated CD8 T cells recognizing parasite-derived 
antigens are essential for ECM development (Belnoue et al., 2002; Yanez et al., 1996) Production of 
inflammatory cytokines and activation of T cells implies requirement for detection of parasite-derived 
molecular patterns by sensors of the host immune system and subsequent DC activation.  
Recently, immune activation upon recognition of Plasmodium-derived GPI was linked to TLR2 and 
recognition of hemozoin/Plasmodium ssp.-derived DNA to TLR9. However, a role of TLRs for 
development of ECM was not determined until recently. Therefore, the question was addressed 
whether TLRs, in particular TLR2 and TLR9 are critically involved in ECM development. 
Furthermore, as the first part of the present thesis revealed that systemic injection of TLR9 ligand CpG 
suppressed TLR9-mediated immune responses, it was hypothesized that CpG application could 
prevent development of ECM in PbA infected mice. These questions were investigated with the help 
of transgenic mice that were genetically deficient for relevant/individual TLRs. 
 
7.2.1 Mechanistic requirements for ECM development in PbA-infected 
C57BL/6 mice 
7.2.1.1 Importance of TLR2, TLR3 and TLR9 for ECM induction 
 
The role of TLR during PbA infection was unclear in the beginning of this project. However, basic 
necessity for sensors that detect the presence and trigger the response towards Plasmodium infection 
in the host was assumed. As mentioned earlier on, recent studies by other groups describe recognition 
of Plasmodium-derived components GPI and hemozoin /Plasmodium-derived DNA by TLR2 and 
TLR9. Until then, recognition of bacterial lipopeptides by TLR2 and TLR9-specific detection of CpG-
rich DNA was known.  
To decipher the relevance of TLRs for development of ECM upon infection with PbA in the present 
study, survival after PbA infection was compared between mice that were genetically deficient for 
TLR2 or TLR9 and wild type littermates. In addition, mice that were deficient for TLR4 or TLR3 
were infected with PbA to investigate possible relevance of those receptors for ECM induction. TLR3 
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is until now described to bind nucleic acids like double-stranded RNA or poly IC and is intracellularly 
located in the endosome like TLR9 (Alexopoulou et al., 2001). Among the multitude of TLR4 ligands 
that were discovered so far, lipopolysaccharide is the most prominent example. Both TLR3 and TLR4 
were not yet associated with Pf or PbA infection. 
 
 
Figure 14  TLR2
-/-
, TLR9
-/-
 and TLR3
-/-
 mice are significantly protected against ECM after 
PbA infection 
Survival of C57BL/6 and TLR-deficient littermates after i. v. infection with 5x10e4 PbA-iRBC is shown. n=6-10 per 
group. Statistical analysis by Kaplan-Meier. 
 
C57BL/6 mice developed ECM 6-8 days after infection with 5x10e4 PbA-iRBCs (Figure 14A).  
TLR2-/- mice and TLR9-/- mice developed significantly less often ECM after infection with 5x10e4 
PbA iRBC than wild type littermates (Figure 14A).  
TLR4 deficient mice showed no difference in survival after PbA infection compared to WT (data not 
shown), whereas TLR3-/- survived PbA infection significantly better than WT controls (Figure 14B).  
These results provide strong evidence, that the TLR system is essential for induction of ECM after 
PbA infection; in particular TLR2, TLR3 and TLR9 are critically involved. 
 
7.2.1.2 ECM induction after PbA infection is dependent on the spleen 
 
The spleen is the central organ involved in the generation of immune responses towards systemically 
circulating antigens. Several studies postulate that the spleen is a crucial site for removal of parasitized 
erythrocytes as well as for generation of parasite-directed immune responses during infection with 
different Plasmodium parasites (Engwerda et al., 2005b). To investigate the importance of the spleen 
for ECM development during PbA infection, two approaches were conducted. In the first instance 
RAG1-/- mice were examined regarding ECM development upon adoptive transfer of splenic T cells 
from wild type donors. Mice deficient in RAG1-/- or RAG2-/- exhibit an abnormal a disorganized 
architecture of the spleen (Mebius and Kraal, 2005). Furthermore, RAG2-/- mice are described to be 
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resistant against ECM development, which is mainly ascribed to lack of effector T cells. In a study 
from Nitcheu et al., RAG1-/- mice were rendered ECM susceptible by transfer of effector T cells 
purified from PbA-infected immuno-competent wild type donors after induction of ECM (Nitcheu et 
al., 2003).  
We analyzed whether reconstitution of RAG1-/- mice with splenocytes derived from naïve WT 
littermates prior to PbA infection was capable to induce host immune responses that result in ECM. 
For this purpose, CD4+ and CD8a+ cells were isolated via MACS® from spleens of naïve WT donors 
and adoptively transferred into RAG-/- recipients seven days before PbA infection. It was impossible to 
induce immune-mediated damage in reconstituted RAG1-/- mice as all mice were still protected against 
ECM (Figure 15A). In part 4.1 of this study it was shown, that RAG1-/- did not generate CTL 
responses towards AdOVA infection despite reconstitution with splenic T cells derived from wild type 
donors seven days prior to AdOVA infection (Figure 4B). This suggested that simple reconstitution of 
RAG1-/- with naïve T lymphocytes may be insufficient for induction of host immune responses also 
during PbA infection. 
It was investigated next whether surgical removal of the spleen could influence the development of 
ECM during PbA infection. C57BL/6 mice were infected with 5x10e4 PbA-iRBCs two days after 
surgical removal of the spleen. Compared to intact littermates infected with PbA, splenectomized 
animals did not develop ECM  (Figure 15B). Taken together, these data support a major relevance of 
the spleen and its unique architecture for generation of host-derived immune responses causing severe 
pathologies during the course of PbA infection. 
 
 
Figure 15  Intact spleen is required for generation of ECM pathology 
(a) Survival of C57BL/6 and RAG1-/- after infection with 5x10e4 PbA-iRBC i.v. 7 days before experimental 
infection with 5x10e4 PbA iRBCs, one group of RAG1
-/-
 was reconstituted with splenic CD4+ and CD8a+ from 
wild type donors (1 donor/1 recpipient); n=10 mice per group (b) Survival of splenectomized C57BL/6 and intact 
littermates after infection with 5x10e4 PbA-iRBC i.v. Splenectomy was performed 2 days before infection. n=10 
mice per group. 
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7.2.1.3 Depletion of DCs prevents ECM in PbA infected C57BL/6 mice 
DCs link innate and adaptive parts of the immune system during an infection. Recognition of 
pathogens via TLRs leads to activation and subsequent production of pro-inflammatory mediators and 
up-regulation of co- stimulatory molecules that amplify antigen presentation towards T cells and T cell 
priming. During infection, DCs are permanently exposed to parasite-derived antigen, as parasite-
infected red blood cells are mainly trapped in the spleen. It was assumed that targeted elimination of 
DCs could prevent ECM, as they maintain a key role during early phases of infection in T cell 
priming, but may contribute to pathology during late stages by production of inflammatory cytokines. 
Furthermore, mice that were genetically deficient for TLR2, TLR3 or TLR9 showed increased 
survival towards PbA infection, which supports a critical role for DCs in induction of PbA-directed 
immune responses, because expression of several TLRs is a particular characteristic of this cell subset.   
Jung et al. recently described efficient depletion of DCs in CD11c transgenic mice that express the 
human Diphtheria toxin receptor under control of the CD11c promoter. Intra-peritoneal injection of 
diphtheria toxin (DTX) is followed by almost complete elimination of DCs in the spleen (Jung et al., 
2002). Natalio Garbi (DKFZ Heidelberg) generated similar mice that express the human Diphtheria 
toxin receptor under control of the CD11c promoter together with OVA and GFP. These CD11c-DTR-
OVA GFP transgenic mice were designated as DOG mice1. 
 
Figure 16  Depletion of DCs prevents ECM in PbA-infected DOG mice 
(a) Survival of C57BL/6 and CD11c-diphtheria-Toxin-Receptor transgenic mice after PbA infection. DTR 
transgenic mice received either daily injections of 40ng DTX/g mouse or not. n=5 mice per group (b) Analogous to 
(a) with different DTX treatment schedule: Mice received DTX either from d0 until d+4 post PbA infection or from 
d+4 until d+7 post PbA infection. n=10 mice per group 
 
To investigate the relevance of DC elimination for ECM induction, PbA infection experiments were 
performed in DOG mice. Daily intra-peritoneal application of 40ng Diphtheria toxin (DTX) per gram 
animal weight is followed by almost complete depletion of DCs in the spleen (data not shown) 
                                                      
1 DOG transgenic mice= CD11c-Diptheria toxin receptor-Ovalbumin-green fluorescent protein (Natalio Garbi) 
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Importantly, DOG mice can be injected repeatedly with DTX to prevent presence of DCs. In the first 
approach, DTX was given daily during PbA infection of DOG transgenic mice and compared to WT 
controls as well as non-depleted DOG tg mice infected with PbA. DTX treatment led to increased 
survival of DOG mice (Figure 16A). In the second approach it was determined whether the presence 
of DCs was critical in the early or the late stage of infection. For this purpose, DOG tg mice were 
depleted either from day 0 to day 4 post infection or from day 4 till the end of the experiment. Only 
early DTX treatment resulted in significantly enhanced survival of infected mice, whereas late DTX 
treatment only partially protected mice from ECM (Figure 16B). These experiments provide evidence, 
that dendritic cells are key players during the early phase of murine PbA infection for induction of 
pathogenic immune responses. 
7.2.1.4 IL-12 and IL-23 confer ECM susceptibility 
So far, mice that were deficient in single TLRs or were injected with DTX to deplete DCs, did not 
develop ECM after infection with PbA. An important result of TLR ligation is the production of the 
pro-inflammatory cytokine IL-12, which is a prerequisite for T cell activation. Therefore it was 
hypothesized that abrogated production of IL-12 may result in impaired generation of host responses 
directed against PbA and consequently give rise to increased survival of IL-12 deficient mice after 
PbA infection. 
Bioactive IL-12 is a hetero-dimer p70 consisting of a p35 and a p40 subunit. In addition, p40 is part of 
the hetero-dimer p19p40 (Trinchieri, 2003). In the present study, survival of IL-12p35-deficient 
animals and IL-23p19-deficient animals after PbA infection was monitored. IL-12p35-deficient 
animals were significantly protected against ECM; only 30% of PbA infected mice died in contrast to 
WT control-infected mice that all succumbed to ECM (Figure 17). In comparison, IL-23p19 deficient 
mice died after PbA infection, but death was significantly delayed in comparison to WT controls 
(Figure 17). Thus, pro-inflammatory mediators IL-12 and IL-23 are also involved in ECM induction 
after PbA infection. 
 
 
Figure 17:  Lack of IL-12p35 or IL-23p19 leads 
to increased survival of PbA infected mice 
Survival of C57BL/6 WT mice or littermates deficient 
in IL-12p35 or IL-23p19 after infection with 5x10e4 
PbA iRBC. N=10 per group. 
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7.2.2 CpG prevented ECM in PbA infected mice 
7.2.2.1 Prophylactic CpG injection before PbA infection prevents ECM 
development in C57BL/6 mice 
In section 7.1 of this thesis it was shown, that systemic application of CpG inhibited the generation of 
CTL responses towards AdOVA and led to paralysis of DCs. Accordingly, Reis e Sousa et al. 
demonstrated in a model of parasite infection that repeated triggering of the innate immune system by 
components of Toxoplasma gondii induced DC paralysis. They concluded that limitation of the 
inflammatory responses by DC paralysis led to prevention of tissue damage (Reis e Sousa et al., 
1999). Based on these observations, we hypothesized that systemic injection of mice with CpG could 
inhibit the generation of detrimental innate and adaptive effector molecules and cells, thereby 
preventing ECM upon PbA infection.  
To investigate possible suppression of host immune responses towards PbA infection, C57BL/6 mice 
received 100µg CpG i.v. 1 day before (d-1) PbA infection and survival was monitored in comparison 
to control-infected littermates. Most importantly, CpG-treated mice survived and did not develop 
ECM (Figure 18). Thus, systemic CpG treatment inhibited cytopathological consequences of PbA 
infection. 
 
 
 
 
Figure 18:  CpG treatment prevented 
ECM development in PbA infected 
C57BL/6 mice 
Survival of C57BL/6 mice after PbA infection 
(5x10e4 PbA iRBC i.v.) with or without systemic 
pre-treatment with 100!g CpG-ODN1668 i.v. n=8 
per group 
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7.2.2.2 Early CpG treatment prevents ECM, whereas late CpG injection 
accelerates ECM in PbA-infected C57BL/6 mice 
To dissect time-dependent consequences of TLR ligation and subsequent activation of DCs, C57BL/6 
mice were injected intravenously with 100µg CpG either 1 or 5 days after PbA infection (d+1, d+5) 
and survival was monitored (see Figure 19). D+1 CpG treated mice survived and did not develop 
ECM (Figure 20A). In contrast, CpG application five days post infection had detrimental 
consequences and led to an accelerated development of neurological symptoms, coma and death 
(Figure 20A).  
 
Figure 19:  Time schedule for CpG-treatment of PbA-infected mice 
 
Additionally, parasitemia of early treated mice was significantly lower than in control-infected and 
late treated animals (Figure 20 B). Sera were taken from different groups and analyzed for the 
presence of inflammatory cytokines. CpG treatment elicited an immediate IL-12 peak, regardless of 
the time point of application after PbA infection (Figure 20 C). Strict dependence of CpG-induced 
protection on TLR9 was confirmed in TLR9 deficient animals. CpG-treatment prevented induction of 
ECM only in WT mice but not TLR9-/- (data not shown).  
 
 
 
Figure 20  CpG treatment of infected mice protected mice from ECM in a TLR9 dependent 
manner 
(a, b) Survival of C57BL/6. (a) Mice were injected i.v. with 100!g CpG either at d+1, d+5 or d+1 and d+5 following 
injection of 5x10e4 PbA iRBCs. n=10 mice per group (b) Parasitemia of C57BL/6 mice with or without CpG 
treatment. C57BL/6 mice were CpG treated at indicated time points. ** p<0.005 to CpG d+1 (c) IL-12 ELISA from 
sera of PbA infected C57BL/6 with or without CpG treatment. Serum samples were taken every day and analyzed 
for cytokines by ELISA. Analysis of survival is shown and calculated as percentage. 
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To examine whether protection against ECM by d+1 post infectionem (p.i.) CpG application could be 
abrogated, PbA-infected C57BL/6 that were already injected with CpG i. v. at day 1 after PbA 
infection received an additional CpG injection at d+5 p.i. However, twice-injected mice were still 
protected against ECM and survival was comparable to CpG d+1 p. i. sinlge injected mice (Figure 
20A). In conclusion, early CpG treatment prevented ECM, which was dependent on TLR9, whereas 
late CpG application accelerated pathological incidences resulting in death. Furthermore, primary CpG 
application prevented death of PbA-infected mice that were re-challenged with CpG at day 5.  
 
7.2.2.3 Role of IL-10 in CpG induced protection from ECM 
We speculated, that CpG-induced prevention of ECM in PbA-infected mice may be due to induction 
of anti-inflammatory mediators i.e. interleukin 10 (IL-10). To investigate a possible role of IL-10 
during CpG-induced protection against ECM, survival of PbA-infected IL-10-deficient mice that were 
injected with CpG one day before infection was monitored. Importantly, IL-10-deficient PbA infected 
mice died within the following hours after CpG injection (Figure 21), whereas those IL-10-deficient 
mice, that did not receive CpG application, developed to a similar time ECM as WT littermates 
(Figure 21).  
Thus, we could not exclude a role for IL-10 during CpG-induced prevention of ECM after PbA 
infection. 
 
 
Figure 21 Subsequent death of PbA-infected IL-10-deficient mice after systemic injection 
of CpG 
Survival of IL-10
-/-
 and WT littermates after i.v. infection with 5x10e4 PbA-iRBC; indicated groups received 100!g 
CpG-ODN1668 i.v. 24 hours after infection. IL-10
-/-
 deceased within 6 hours after CpG injection. n=10 per group. 
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7.2.2.4 CpG injection prevents generation of Pf-specific CTLs in the spleen of 
HLA A2  transgenic mice 
 
Systemic injection of C57BL/6 with TLR9 ligand CpG suppressed CTL responses towards subsequent 
infections (Figure 2B). During Plasmodium infection, T cell responses are generated and are supposed 
to be a major cause of immune pathology as depletion of CD8a+ cells by injection of neutralizing 
antibodies protected mice from death, even if depletion was performed proximate to ECM (Hermsen 
et al., 1997; Yanez et al., 1996).  
So far, direct investigation of Plasmodium-specific T cell responses in vivo was impossible due to the 
lack of an appropriate experimental model. The laboratories of Hermann Bujard and Hans-Georg 
Rammensee identified merozoite-surface protein 1 (MSP-1)-specific CTL epitopes derived from 
Plasmodium falciparum (Pf) that bind to human MHC class I molecules HLA A2 (personal 
communication). This allowed the design of specific MSP-1-derived peptide sequences and facilitated 
the exploration of MSP-1 specific CTL response in humanized transgenic mice expressing HLA A2 
(HLA A2 tg) (Ureta-Vidal et al., 1999). Therefore, it was speculated that inoculation of HLA A2 tg 
mice with Pf-infected iRBC should induce a MSP-1 specific CTL response. The HLA A2 tg mice 
received 2,8 x 108 Pf iRBC i. v. Six days later, the activity of MSP-1 specific CTL was examined by 
an in vivo cytotoxicity assay. Indeed, in the blood of immunized animals significant lysis of syngenic 
target cells loaded with MSP-1 derived MHC class I peptides was measured (Figure 22). The data 
show that pre-treatment of mice with CpG or splenectomy significantly reduced the activity of MSP-1 
specific CTL as measured in the blood (Figure 22). Thus the generation of specific CTLs against Pf-
iRBC in HLA-A2 tg mice was dependent on the spleen and could be inhibited by systemic CpG 
injection. 
 
Figure 22  CpG inhibits Pf-specific 
CTL responses 
In vivo cytotoxicity assay against P. falciparum 
derived MSP1 in the blood of HLA-A2  
transgenic C57BL/6. Mice were injected with 
2.8x10e8 Chloroquine-treated P. falciparum 
infected human red blood cells; one group was 
pre-treated with 100!g CpG-ODN1668 at d-1. 
MSP-1 specific kill was performed 6 days later. 
n=5 per group. students t test 
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7.2.3 Role of TLRs for ECM development and induction of immune suppression 
by PbA parasites 
7.2.3.1 High dose infection with PbA prevents ECM in C57BL/6 mice 
C57BL/6 mice developed within 6-8 days after infection with 5x104 PbA-iRBC ECM. In order to 
accelerate ECM, WT mice were infected with 1x107 – a greatly increased number – of PbA-iRBC. 
Interestingly, WT mice infected with high dose PbA did not develop ECM but were rather protected 
from death (Figure 23B). This provided strong evidence that PbA itself was able to induce immune 
suppression, probably to evade detection of the immune system and subsequent induction of 
inflammatory responses. To decipher a possible role for TLRs during Plasmodium-induced immune 
suppression, survival after infection with PbA high infection was studied in mice that were genetically 
deficient in TLR2 or TLR9 in comparison to WT controls. Importantly, 30% of TLR2-deficient mice 
as well 30% of TLR9-deficient mice died following PbAhigh infection, whereas WT littermates 
survived PbAhigh infection completely (Figure 23A). This suggested that several TLRs collaborate with 
and/or compensate for each other. To investigate whether PbAhigh induced protection against ECM 
might also be dependent on expression of TLR2/3/9, survival of triple-deficient mice was monitored. 
Upon infection with PbAhigh, circa 40% of TLR2/3/9-triple deficient mice survived and did not develop 
ECM (Figure 23B). From these results, a dual role of TLRs during PbA infection was concluded. On 
the one hand, TLR2, TLR3 and TLR9 were involved in development of ECM after infection with a 
low dose of PbA, whereas on the other they also play a role during induction of immune suppression 
elicited by high dose infection. 
 
 
Figure 23 TLR2, TLR3 and TLR9 are involved in PbA-induced immune suppression  
Survival of C57BL/6 wild type and TLR deficient littermates upon PbA infection (a) Survival of wild type, TLR2
-/-
 
and TLR9
-/-
 littermates following i.v. infection with 1x10e7 PbA-iRBC (=high), n=10 per group. (b) Survival of wild 
type and TLR2
-/-
/3
-/-
/9
-/-
 mice after infection with 5x10e4 or 1x10e7 (=high) PbA-iRBC; n=10 per group. 
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7.2.3.2 PbA-induced immune suppression required IL-12 and IL-23 
 
To examine a possible negative role of IL-12 or IL-23 in induction of immune suppression by PbAhigh 
infection, survival and ECM development after PbA high infection was monitored in IL-12p35p40 
double-deficient mice. Importantly, PbAhigh-induced protection against ECM was completely 
abrogated in IL-12p35p40 double deficient mice (Figure 24A). In contrast, mice that lacked 
expression of either IL-12p35 or IL-23p19 were still protected against ECM (Figure 24B). This 
suggested involvement of the p40 subunit that is present in both IL-12 and IL-23. Thus, IL-12/IL-23 
were important for induction of protective factors that prevented ECM after PbAhigh –infection.  
 
 
Figure 24  IL-12 and IL-23 are critically involved in protection against ECM induced by PbA 
high dose infection. 
(a) Survival of C57BL/6 WT and IL-12p35
-/-
p40
-/-
 mice after infection with 1x10e7 PbA-iRBCs i.v. n=10 per group 
(b) Survival of IL-12p35-/- or IL-23p19-/- mice compared to WT after infection with 1x10e7 PbA-iRBCs i.v. n=10 
per group. Statistics refer to WT controls. 
 
7.2.3.3 Relevance of IL-10 and iNOS in PbA high-dose induced protection 
from ECM 
IL-12 was required for the induction of protective mechanisms that prevented ECM development upon 
infection of mice with a high dose of PbA. IL-12 is described to induce IL-10 and inducible nitric 
oxide synthase (iNOS) that triggers production of nitric oxide (NO) (Gerosa et al., 1996; Huang et al., 
1996; Koblish et al., 1998). Both IL-10 and iNOS are suggested to represent negative regulators in 
immune activation and were also linked to protection of PbA-infected mice against ECM by induction 
of neuro-protective factors and by blocking of neuro-toxic factors (Hunt and Grau, 2003; Pamplona et 
al., 2007). Negative regulation is assumed to result in stabilizing the integrity of the blood-brain 
barrier by neutralizing inflammatory mediators. This finally prevents infiltration of parasitized RBC 
into the brain and subsequent attack by parasite-specific effector cells. Therefore, it is assumed that 
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survival of PbA infection depends on the ratio between neuro-protective versus neuro-toxic factors. To 
determine the relevance of IL-10 and iNOS regarding the capacity to mediate protection against ECM 
in PbAhigh-infected mice, survival of IL-10-deficient mice and iNOS-deficient mice was monitored 
following infection with a high dose of PbA. Circa 50% of IL-10-deficient and 40% of iNOS-deficient 
mice were protected against ECM after infection with PbAhigh dose, whereas 75% of WT mice 
survived PbAhigh dose infection (Figure 25). From this experiment a critical role of IL-10 and iNOS for 
the induction of mechanisms that prevented ECM was concluded. 
 
 
Figure 25 Participation of iNOS and IL-
10 in PbA-high dose induced protection 
against ECM. 
Survival of WT C57BL/6, IL-10-/- mice and iNOS-/- 
mice after PbA infection. 1 group of WT mice was 
infected with 5x10e4 PbA iRBC as a control 
(indicated as “low”), all other groups reveived 
1x10e7 PbA iRBC i.v. n= 10 per group. Statistics 
refer to WT PbA low group. 
 
 
 
 
7.2.4 Summary of chapter 7.2 
Induction of inflammatory innate and adaptive immune responses towards Plasmodium infection is 
assumed to cause immune pathologies that may result in life-threatening complications like cerebral 
malaria. Detrimental immune responses causing ECM were less prevalent in mice deficient in TLR2, 
TLR3 or TLR9. Complete prevention of ECM was observed if PbA-infected mice that were 
splenectomized or depleted of DCs. 
Systemic application of CpG also protected PbA-infected mice against ECM. This was attributed to 
DC paralysis and suppression of parasite-specific T cells. Importantly, infection of C57BL/6 WT with 
a high dose of PbA prevented ECM as well. The regulation of this protection required several factors. 
Detection via TLR2 and TLR9 were involved that mediated protection via IL-12. Finally, IL-10 and 
iNOS were suggested to have negative regulatory roles in inflammatory pathways. 
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7.3 TLR7 ligands inhibit antigen-specific CTL responses via type I interferon 
 
Systemic application of TLR9 ligand CpG induced suppression of innate and adaptive immune 
responses towards a subsequent AdOVA infection in C57BL/6 mice. In particular, prevention of 
antigen-specific CTL responses was one of the basic findings. It might be reasonable that the 
induction of immune suppression by several TLR ligands is a general mechanism to limit 
overwhelming immune activation thereby prevention of tissue damage. On the other side it was 
hypothesized that TLR-ligand-induced inhibition of CTL responses might also result in lack of 
protection against infectious agents. As TLR ligands are used therapeutically in progressive rate 
because of their immune-stimulatory effects, this implies that in vivo application of TLR ligands 
harbor substantial risks of subsequent immune suppression.  
Therefore, questions were addressed whether apart from TLR9 ligand CpG also ligands of other TLRs 
have the potential to inhibit CTL responses towards subsequent infections. In addition, the question 
was addressed whether TLR ligation after AdOVA infection influenced also the generation of immune 
responses. Finally, it was investigated, whether therapeutic application of TLR ligands in two different 
tumor models in mice can interfere with the generation of antigen-specific CTL responses.  
 
7.3.1 TLR7 ligand siRNA induces suppression of adaptive immune responses 
7.3.1.1 Other TLR ligands also suppress adaptive immune responses 
 
It was hypothesized that apart from TLR9 ligand CpG also other microbial-derived patterns that are 
recognized as TLR ligands might influence the generation of immune responses directed against 
AdOVA infection in mice. Lipopolysaccharide (LPS) is recognized by TLR4 expressed on the cell 
surface of many immune and non-immune cells, whereas the imidazoquinoline derivate R848 – also 
known as Resiquimod – was identified as ligand for TLR7. Like TLR9, TLR7 is also intracellularly 
expressed in the endosome of immune cells but its expression is limited to few DC subsets (Heil et al., 
2003; Kadowaki et al., 2001).  
In addition, as application of TLR9 ligand prior to AdOVA infection resulted in inhibition of immune 
responses, the consequence of TLR ligation after AdOVA infection was investigated. 
Here, ligands for TLR4, TLR7 or TLR9 were compared with respect to the generation of OVA-
specific CTL towards AdOVA infection. C57BL/6 mice were injected i. v. with LPS, R848 or CpG 
and then infected with AdOVA 24 hours later. OVA-specific CTL responses were determined five 
days after AdOVA infection by an in vivo cytotoxicity assay in the spleen. LPS and R848 also induced 
suppression of OVA-specific CTL responses in the spleen, if they were injected i. v. into C57BL/6 
mice before AdOVA immunization (Figure 26A, B). Furthermore, suppression of OVA-specific CTL 
responses by LPS and R848 was induced in a dose-dependent manner as it was already observed for 
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CpG. Only high doses inhibited the generation of OVA-specific CTLs whereas low doses did not 
influence the CTL response (Figure 26B, data not shown). In contrast to TLR ligand injection before 
AdOVA infection, the OVA-specific CTL response was not inhibited but rather enhanced, if CpG or 
LPS were injected i. v.  one day after AdOVA infection (Figure 26A).  
Suppression of OVA-specific CTL responses by LPS or R848 was abrogated in TLR4-deficient and 
TLR7-deficient mice, respectively (Figure 26C, D).  
Importantly, TLR ligation after AdOVA infection elicited immune stimulation rather than suppression.  
 
Figure 26:  Several TLR ligands induce suppression of adaptive immune responses 
(a, b, c, d) Mice were infected with 1x10e7 PFU AdOVA and subjected to an in vivo S8L-specific cytotoxicity 
assay; spleen was analyzed. (a) C57BL/6 wild type mice were injected i. v. 24h before (black bars) or 24h after 
(white bars) AdOVA immunization with 1!g LPS or 100!g CpG. Grey bar represents AdOVA control.(b) Dose-
dependent suppression elicited by R848. C57BL/6 received 0.1!g, 1!g or 10!g R848 i.v. 24 hours before AdOVA 
infection. (c) TLR4 deficient and wild type littermates were injected with 1!g LPS (white bars) or not (black bars) 
before immunization. (d) TLR7 deficient mice and wild type littermates received 10!g R848 i v. (white bars) or not 
(black bars) 24 hours before AdOVA infection. n=3 or 4 animals per group 
 
7.3.1.2 Inhibition of immune responses induced by small-interfering RNA  
TLR7 is an intracellular pattern recognition receptor and binds in addition to primary identified 
ligands R848 and R837 also uridin-rich single-stranded (ss) RNA derived from human immune 
deficiency virus (HIV) and influenza virus (Diebold et al., 2004; Heil et al., 2004; Hemmi et al., 
2002). In addition, TLR7 recognizes poly U sequences and certain small-interfering RNA (siRNA) 
(Hornung et al., 2005). As several TLR ligands were shown here to elicit immune suppression, it was 
hypothesized that also TLR7-mediated recognition of siRNA harbors the risk to inhibit immune 
responses. 
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We analyzed possible inhibitory effects of systemically injected siRNAs concerning generation of 
CTL responses against Listeria monocytogenes (L.M.) or adenovirus in vivo. Therefore, three different 
siRNA sequences were investigated. First, a previously published siRNA-sequence targeting MyD88 
(siMyD88) was chosen (Flandin et al., 2006). For generation of immune responses towards both 
bacterial and viral infection in vivo, MyD88 represents a central adapter molecule for the transmission 
of TLR signals and triggering adaptive immune responses (Lord et al., 1990; Muzio et al., 1997; 
Wesche et al., 1997). Secondly, we chose the siRNA sequence designed as 9.2s that targets human 
TLR9 and was previously shown by others to elicit immune-stimulatory effects in mice in a TLR7 
dependent manner (Hornung et al., 2005). Finally, the control sequence 9.2s-R8A, lacking any 
immune stimulatory qualities was used (Hornung et al., 2005). These experiments were done in 
cooperation with the group of Gunther Hartmann. 
OVA-specific CTL response was determined by an in vivo cytotoxicity assay in the spleens five days 
post infection. OVA-specific CTL responses were markedly decreased in spleens of mice treated with 
MyD88-specific siRNA before AdOVA or LM-OVA infection (Figure 27A, B). This indicated that 
application of MyD88-siRNA caused gene silencing that prevented transduction of TLR signal and 
subsequent generation of an immune response. However, systemic injection of 10µg 9.2s siRNA 
suppressed OVA-specific CTL responses in C57BL/6 mice equally well compared to siMyD88 
(Figure 27A, B) and was also observed after i. v. injection of 5µg; this dose was reported by Hornung 
et al. to exert immuno-stimulatory effects (data not shown) (Hornung et al., 2005). It was concluded, 
that inhibition of OVA-CTL depended on the presence of immune stimulatory motif, as the sequence 
9.2s-R8A lacking that motif did not influence the CTL response towards AdOVA infection. These 
results suggested that the siRNA-induced suppression did not (only) result from target-specific gene 
silencing, but must have been due to intrinsic properties of single stranded immune-stimulatory RNA.  
 
Figure 27   siRNA mediated suppression 
S8L specific cytotoxicity was determined in spleens of C57BL/6 mice at day five post infection with (a) AdOVA or 
(b) L. monocytogenes expressing OVA. Indicated groups of mice received 24 hours before infection (1x10e7 PFU 
AdOVA; 2x10e4 LM-OVA) 50!g siMyD88, 10!g 9.2s or 10!g 9.2s-R8A. RNA was complexed with 30!l CL per 
animal. n=4 per group. 
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7.3.1.3 Immune stimulatory RNA inhibited CTL responses in a TLR7-
dependent manner 
 
So far, 9.2s-n siRNA was demonstrated to strongly stimulate type I interferon responses in a TLR7 
dependent manner as work by Hornung et al. showed, but was not yet associated with immune 
suppression (Hornung et al., 2005).  
Inhibition of OVA-specific CTL responses towards AdOVA infection by prior injection of 9.2s RNA 
could be the result of three different scenarios. First, human and murine TLR9 show 75.5% homology 
regarding the amino acid sequence (Hemmi et al., 2000). Thus, inhibitory effects due to gene silencing 
could not be completely excluded in the previous experiment. Secondly, if the suppression was caused 
by TLR7-mediated recognition of 9.2s RNA, this should be abrogated in TLR7 deficient mice. 
Accordingly, if CTL suppression was due to silencing of TLR9, suppressive effects elicited by 9.2s 
application should be still observed in TLR7 deficient mice. Thirdly, recognition of siRNA-duplex 
structures by TLR3 represents another possibility for TLR-mediated interference.  
Therefore, WT, TLR3-deficient and TLR7-deficient mice were injected i. v. with 9.2s siRNA one day 
prior to infection with AdOVA. The OVA-specific CTL response was determined 5 days later in the 
spleens by an in vivo cytotoxicity assay. Importantly, in spleens of both WT and TLR3-deficient mice 
that were pre-treated with 9.2s RNA before AdOVA infection OVA-specific CTL response was 
completely absent. In contrast, 9.2s-induced suppression of CTL responses was abrogated in TLR7-
deficient mice (Figure 28A).  
These results provide strong evidence, that 9.2s-induced immune suppression of AdOVA-directed 
CTL responses in mice cannot be attributed to siRNA-caused gene silencing of TLR9 but rather by 
recognition via TLR7. In addition, these results suggested that systemically circulating nucleic acids in 
general are able to induce immune suppression. 
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Figure 28 9.2s-induced immune suppression requires TLR7 and targeting to the 
endosome 
S8L specific cytotoxicity was assessed in the spleens of mice 5 days post immunization. (a) Indicated groups of 
C57BL/6 WT, TLR3
-/-
 or TLR7
-/-
 littermates, respectively, received 10!g 9.2 24 hours before AdOVA infection 
(1x10e7 PFU i.v.). All RNAs were complexed to 30!l cationic liposomes (CL) (=DOTAP) per 10!g RNA per 
mouse (b) Indicated groups of C57BL/6 WT mice received 10!g 9.2 siRNA 24h before i. v. infection with 1x10e7 
PFU recombinant AdOVA. siRNA was either complexed to 30!l CL per 10!g RNA or to PEI. n=3-4 per group, 
representative data of two or more independent experiments are shown. 
 
 
7.3.1.4 Intracellular targeting of TLR7 ligand siRNA has stimulatory or 
suppressive consequences 
TLRs that bind nucleic acids are predominantly localized intracellularly in the endosome. Efficient 
delivery of RNA into different sub-cellular compartments requires association to vehicles, particularly 
in cases of non-stabilized nucleic acids to prevent premature degradation. For in vivo therapies, RNA 
samples are either complexed with cationic liposomes (CL) or polyethylene imines (PEI), in case they 
lack special stabilization. RNA complexed to CL is exclusively targeted to the endosome whereas PEI 
facilitates delivery into the cytoplasm after osmotic rupture of the endosome (Kichler et al., 1995). 
Application of siRNA in the previous experiments was performed with CL complexation. 
The relevance of siRNA application bound to different vehicles regarding the influence on the 
generation of CTL responses towards AdOVA infection was investigated in vivo. C57BL/6 mice were 
injected with 9.2s RNA either complexed with CL or PEI one day before AdOVA infection. OVA-
specific CTL responses were determined 5 days after infection by an in vivo cytotoxicity assay in the 
spleen. Only 9.2s RNA complexed to CL induced immune suppression, whereas binding to PEI did 
not inhibit CTL responses towards subsequent AdOVA infection (Figure 28B). Thus, delivery of 
nucleic acids into the cytoplasm prevented induction of suppression.  
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7.3.2 Experimental therapeutic application of TLR7 ligand 9.2s induces 
suppression of adaptive immune responses towards subsequent AdOVA 
infection 
7.3.3  
The association of siRNA with immune suppression was unexpected as siRNA application is 
commonly expected to induce immune stimulation due to its capability to induce high amounts of type 
I interferon. Therefore, we asked whether experimental therapeutic application of isRNA as cancer 
treatment could exert adverse effects on subsequent infections in murine models. This is of major 
interest as the connotation of RNA-caused gene silencing with its type I interferon-inducing capability 
is currently supposed to be favorable in anti-tumor therapy.  
In particular, three questions were addressed. First, does systemic application of siRNA after 
inoculation of mice with tumor cells influence the anti-tumor CTL response or tumor growth? 
Secondly, does siRNA treatment inhibit a CTL response directed against a subsequent infection with 
recombinant AdOVA? Thirdly, does anatomical site of application as well as the dose of siRNA 
determine the outcome of the OVA-specific CTL response towards the subsequent AdOVA infection?  
In the present study, experimental siRNA treatment was applied in two different tumor models to 
analyze whether siRNA-induced anti-tumor effects were accompanied by an inhibition of adaptive 
immune responses towards subsequent infection with recombinant adenoviruses.  
 
7.3.3.1 9.2s-n siRNA enhances CTL response against RMA tumor but 
suppressed immune responses against subsequent AdOVA infection 
To study the influence of siRNA application on tumor-specific CTL responses experimentally, 
C57BL/6 mice received i. v. RMA tumor cells expressing eGFP (RMA-GFP); RMA tumor cells 
predominantly localize in the liver upon systemic injection, whereas local i.e. subcutaneous injection 
of tumor cells leads to local growth.  
To mimic therapeutic application of siRNA in an experimental tumor treatment, tumor-inoculated 
mice received 9.2s RNA i. v. two days after injection of RMA-eGFP. The tumor-specific CTL 
response was determined 6 days after tumor cell injection by an in vivo cytotoxicity assay in the liver 
(see Figure 29 for overview about the treatment schedule). As shown in Figure 30, RMA-GFP-specific 
CTL responses in siRNA-treated mice were minimally stronger than in tumor-bearing mice that did 
not receive siRNA. Thus, siRNA-treatment did not inhibit CTL responses against RMA tumor cells.  
We next addressed the questions, whether in RMA-tumor bearing mice local versus systemic 
application or the doses of 9.2s siRNA were decisive for generation of OVA-specific CTL towards a 
subsequent AdOVA infection. The treatment schedule is shown in Figure 29. 
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Figure 29 Time schedule of RMA-GFP tumor experiments 
 
C57BL/6 mice received RMA-eGFP tumor cells either s.c or i. v. Two days later, mice received 
experimental treatment with siRNA 9.2s.  9.2s siRNA was injected either s. c. in mice that had 
received RMA-GFP tumor cells also s. c., or i. v. in mice that were injected with RMA-GFP tumor 
cells i.v., respectively. To decipher the role of high or low dose 9.2s, mice were injected either with 
1µg or 10µg siRNA. 
Three days after tumor inoculation mice were infected i. v. with recombinant AdOVA to mimic a 
secondary infection. OVA-specific CTL responses were determined five days after AdOVA infection 
in the spleen. OVA-specific CTL responses against AdOVA were strongly reduced in mice that had 
received high doses of 9.2s isRNA i.v. In contrast, low dose or s.c. injection of 9.2s isRNA did not 
inhibit OVA-specific CTL responses (Figure 30B).  
Taken together, our findings show that systemic (i.v) rather than local (s.c.) application of high doses 
of CpG or siRNA induced immune suppression (Figure 2A), (Figure 30B). This indicated that immune 
suppression was only associated with the systemic route and was not dependent on the TLR-ligand 
itself. Importantly, the time point of TLR ligation in respect to antigen application was also critical 
whether the induced CTL response was stimulated or suppressed. 
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Figure 30  Systemic injection of 9.2s siRNA into RMA-GFP tumor bearing mice prevented 
the generation of CTL responses towards subsequent AdOVA infection 
(a) C57BL/6 received 5x10e5 RMA-GFP cells i. v. and were injected with TLR ligands 2 days later. RMA-specific 
cytotoxicity assay was performed in vivo 6 days later and lysis of target cells was determined in the spleen. (b) 
S8L-specific cytotoxicity of AdOVA-infected C57BL/6 that received three days before AdOVA 5x10e5 RMA-GFP 
cells i. v. and were injected with 1!g 9.2s or 10!g 9.2s RNA 2 days later. Spleen was analysed, n=4 per group. 
 
 
7.3.3.2 TLR7 ligand 9.2s-n siRNA inhibits growth of melanoma but also 
cellular immune responses towards AdOVA infection 
Systemic application of Mo4 cells, which is a weakly immunogenic B16 melanoma, leads to tumor 
growth in the lung (Meyvisch and Mareel, 1982). In the present study, Mo4 transfected with luciferase 
(Mo4-luc) was utilized, which allowed monitoring of tumor growth with the help of in vivo imaging of 
bioluminescence. Here, the question was addressed whether experimental treatment with siRNA 9.2s 
reduced tumor growth and concomitantly influenced CTL responses against subsequent infection with 
recombinant AdOVA. To investigate this question, C57BL/6 WT mice were injected with Mo4-Luc i. 
v. and received experimental siRNA treatment two days later by i.v. injection of either with a low dose 
or a high dose of 9.2s siRNA ( see Figure 31 for treatment schedule). At day 3, mice were infected i. 
v. with recombinant AdOVA. In vivo imaging of bioluminescence of anaesthetized mice was started at 
day 4 and then performed every other day to monitor tumor growth. OVA-specific CTL responses 
were determined at day 8 in the spleen by an in vivo cytotoxicity assay. Treatment of Mo4-luc tumor 
cell-injected mice with a low dose of 9.2s siRNA did neither induce significant reduction in tumor 
growth nor inhibition of OVA-specific CTL responses towards AdOVA infection (Figure 32A, B). In 
contrast, injection of high dose 9.2s siRNA caused a significant reduction in tumor growth but 
prevented OVA-specific CTL responses towards AdOVA infection (Figure 32A, B).  
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Thus, these results support the relevance of 9.2s siRNA dose. Although systemic application of high 
doses of 9.2s siRNA reduced growth of Mo4-luc tumor cells, it also inhibited CTL responses directed 
against subsequent infection with recombinant AdOVA. 
 
 
 
Figure 31 Time schedule for inoculation of mice with Mo4 tumor cells and subsequent 
AdOVA infection 
 
 
 
 
Figure 32  Systemic injection of 9.2s siRNA inhibited growth of Mo4 tumor, but suppressed 
also CTL response towards subsequent AdOVA infection. 
(a) S8L specific cytotoxicity was determined 5 days in the spleen after infection of C57BL/6 with 1x10e7 PFU 
AdOVA. Before, C57BL/6 had received x Mo4-luciferase expressing tumor cells i.v. and were treated 2 days later 
with 1!g (L) or 10!g (H) 9.2s siRNA complexed to CL. AdOVA infection was performed at d3. (b) Multiplication of 
luciferase expressing tumor cells was monitored via In vivo Imaging (IVIS®200) every other day starting 2 days 
after inoculation of mice with 9.2s siRNA. 
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7.3.4 TLR7 ligand siRNA induced suppression of adaptive immune responses 
can be abrogated by exogenous CD4 help and is dependent on type I IFN   
 
7.3.4.1 Restoration of cytotoxicity by provision of CD4 help  
 
In the present study it was figured out, that OVA-specific CTL responses were very weak or almost 
absent in AdOVA-infected CD4 cell-deficient mice, suggesting that CD4+ T cells are necessary for 
primary CD8 T cell responses towards infection with recombinant AdOVA (Figure 4C). Moreover, 
CpG-induced suppression of CTL responses towards infection with recombinant AdOVA was 
abrogated by provision of exogenously activated antigen-specific CD4+ cells purified from TCR-
transgenic OT-II mice (Flandin et al., 2006). To investigate the capacity of exogenous CD4 help to 
abrogate 9.2s siRNA-induced CTL suppression, two groups of C57BL/6 mice were adoptively 
transferred with in vitro activated CD4+ cells that were isolated before from CD4-TCR transgenic OT-
II mice. Indicated groups received 9.s siRNA 24h later and were infected with recombinant AdOVA. 
OVA-specific CTL responses were determined in all groups five days after AdOVA infection in the 
spleen. A strong OVA–specific CTL response was detected in spleens of AdOVA-infected mice that 
had received in vitro activated OVA-specific CD4+ T cells from OT-II mice by adoptive transfer. 9.2s 
siRNA treatment did not abrogate S8L-specific cytotoxicity when activated CD4+ T cells were present 
(Figure 33). Thus, provision of exogenously activated antigen-specific helper cells rescued the CTL 
response suppressed by 9.2s siRNA (Figure 33). This result strengthened the role of CD4 T cells in 
siRNA induced suppression and provided evidence that TLR-ligand induced inhibition of CTL 
response cannot be explained exclusively by insufficient antigen-presentation. 
 
 
Figure 33 Adoptive transfer of 
exogenously activated CD4 cells abrogated 
9.2s siRNA-induced CTL suppression 
S8L specific cytotoxicity was measured in spleens of 
AdOVA infected C57BL/6 mice d+5 p.i. 2x10e5 in vitro 
activated CD4+ cells from transgeneic OT-II donors 
were adoptively transferred into indicated groups (+ 
OT-II*) 2 days before AdOVA infection (1x10e7 PFU 
i.v.). Indicated groups were injected with 10!g 9.2s per 
mouse at d-1 and infected i. v. with 1x10e7 PFU 
AdOVA at d0. 
 
 
 
 
7  Results  
72 
 
7.3.4.2 siRNA-induced suppression is dependent on type I interferon 
 
Hornung et al. reported induction of high levels of type I interferon upon systemic injection of 9.2s 
siRNA (Hornung et al., 2005). Induction of immune activation is one of the main characteristics that 
are attributed to type I IFNs (Curtsinger et al., 2005). In contrast, other studies demonstrate inhibitory 
functions of type I IFNs (Billiau, 2006). We asked whether the generation of antigen-specific CTL 
responses might be inhibited through the induction of type I IFN. This was investigated in IFNAR-
deficient mice, which cannot respond to type I interferons alpha and beta due to a lack of the receptor 
(van den Broek et al., 1995).  
To further investigate the influence of 9.2s siRNA on viral load, mice were infected with recombinant 
adenovirus expressing luciferase, OVA and GFP (AdLOG) that allowed in vivo analysis of luciferase 
expression by determination of bioluminescence. WT and IFNAR-deficient mice were injected with 
9.2s siRNA or not one day before infection with recombinant AdLOG. One day after infection, 
luciferase-caused bioluminescence was determined in all groups by in vivo imaging and OVA-specific 
CTL responses were determined 5 days after infection in the spleen.  
Most importantly, siRNA did not inhibit OVA-specific CTL responses in IFNAR deficient mice 
(Figure 34A); this demonstrated clearly a negative regulatory role of type I interferons. Analysis of 
viral load by determination of bioluminescence revealed that the application of 9.2s siRNA did not 
significantly influence luciferase-expression in WT mice in comparison to control-infected littermates. 
In contrast, bioluminescence was 4 fold stronger in AdLOG infected IFNAR-/- mice than in WT 
controls. siRNA treatment reduced luciferase expression in AdLOG infected IFNAR-/- mice compared 
to control-infected IFNAR-/- mice (Figure 34B, C). As the OVA-specific cytotoxicity was not 
influenced by siRNA in IFNAR-/- mice, these results strongly support irrelevance of TLR-L induced 
reduction of antigen dose for efficient generation of CTL responses. 
To specify the contribution of interferon beta to the suppressive effect of type I IFNs, IFN-$-/- (H2-kd) 
mice were infected with AdLOG after pretreatment with 9.2s siRNA. Five days later, the GFP-specific 
CTL response was determined in the spleens of those animals. 9.2s-induced suppression of CTLs was 
still present in IFN beta-/- mice (Figure 34D). Thus, IFN-$ can be excluded to participate in type I IFN-
mediated immune suppression. This suggests that IFN-" is critically involved in siRNA-mediated 
immune suppression. 
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Figure 34  siRNA induced CTL inhibition required type I interferon. 
(a) Determination of S8L-specific cytotoxicity in C57BL/6 wild type or IFNAR
-/- 
mice after infection with 
recombinant AdLOG with or without systemic 9.2s-n pre-treatment. (b, c) In vivo Imaging of C57BL/6 WT or 
IFNAR
-/-
 mice 24 hours after AdLOG infection; mice were injected with 10!g 9.2s siRNA complexed with 30!l 
DOTAP 24 hours before AdLOG infection or not. Numbers indicate photons per mm2 per second x10e7 detected 
in the regions of interest. Representative animals are shown. (c) Bioluminescence was quantified by photons per 
mm2 per second, n=3 per group. (d) H9L-specific CTL response was determined in Balb/c WT and IFN beta-/- 
mice 5 days after infection with 1x10e7 recombinant AdLOG i.v. Indicated groups of mice were injected with 10!g 
9.2s siRNA i.v. one day before AdLOG infection. Each bar represents the mean ±SEM;  n=3 per group.   
 
7.3.5 Summary of chapter 7.3 
Systemic injection of ligands for TLR4 or TLR7 also inhibited CTL responses towards infection of 
mice with recombinant AdOVA, as it was previously observed for CpG. Importantly, siRNA-induced 
CTL suppression, which was dependent on TLR7. The observation that TLR7 ligand siRNA 
suppressed CTL responses raised the hypothesis that therapeutic application of siRNA might inhibit 
the generation of CTL responses towards subsequent infections. Indeed, experimental therapeutic 
application of siRNA inhibited CTL responses directed against subsequent infections of mice with 
recombinant AdOVA in two different tumor models, although siRNA treatment positively influenced 
the anti-tumor response. Most importantly, siRNA-induced inhibition of immune responses could be 
attributed to negative regulatory effects of type I IFN. 
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8 Discussion 
The aim of this thesis was to investigate how Toll-like receptor (TLR) ligands regulate effector 
immune responses towards viral or parasitic infections. TLR recognize conserved molecular patterns 
of microorganisms and are essential for the activation of host immunity. Whereas the immune-
stimulatory effects of TLR ligands are well described, the circumstances of TLR-mediated inhibition 
of immune responses are still largely unknown. The results within this thesis point out a key function 
of TLRs in negative regulation of inflammatory immune responses. In contrast to subcutaneous 
application of TLRs that stimulate immune responses, systemic application of TLR ligands in high 
doses prior to infection suppressed innate and adaptive immune responses. The results demonstrate a 
dual role of TLRs as that the anatomical site, dose and time-point of TLR ligand application 
determined if an immune response was stimulated or suppressed. TLR-ligand mediated suppression of 
adaptive immune responses – i.e. antigen-specific CTL responses, was mediated by inhibition of CD4+ 
T cell help. Physiological relevance of TLR mediated suppression of spleen dependent-immune 
responses was demonstrated in two different mouse models of infectious diseases. TLR-dependent 
negative regulation suppressed CTL responses in mice following infection with recombinant AdOVA 
and protected Plasmodium berghei infected mice against lethal inflammatory processes. However, the 
data emphasize the risk of TLR ligand mediated bystander suppression of unrelated immune responses 
targeted against subsequent infections, which may have important implications for future therapeutic 
application of TLR ligands.  
Immune activation is a double-edged sword for the host. The destructive potential of the effectors has 
to be strictly controlled because the armory used against pathogens may also exert detrimental effects 
to the host. Self-inflicted damage is inevitable during a protective response, either by direct lysis of 
infected cells by CTLs or indirectly by the release of antimicrobial factors (cytokines, free radicals) 
that are toxic to the host. Thus, excessive inflammation causing immune damage must be prevented. 
Therefore, we addressed the question how TLR ligand-mediated inflammatory immune responses are 
regulated and in particular, how TLR-L influenced the generation of antigen-specific CD8+ T cell 
cytotoxicity in response to various infections, such as adenoviral vectors, Listeria monocytogenes or 
Plasmodium ssp. All these infections required the spleen for the induction of CD8+ T cell responses 
against antigens expressed by these pathogens (Figure 4,Figure 15). 
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8.1 TLR ligand-mediated inhibition of adaptive immune responses 
 
8.1.1 TLR7-ligand and TLR9 ligand-mediated inhibition of T cell activation by 
interfering DC-T cell interaction 
 
Interestingly, we observed that TLR-L differently affected CTL responses if given locally or 
systemically. While subcutaneous injection of the TLR9 ligand CpG enhanced specific CTL responses 
towards co-administered antigen (Figure 2A), intravenous injection of TLR ligands in high doses 
inhibited the generation of adaptive immune responses (Figure 2, Figure 26, Figure 27). The 
stimulatory effect of local administration of TLR-L together with antigen is in line with many reports 
where TLR-L are used as adjuvans in the induction of adaptive immunity (Krieg, 2006).  
Largly unexpected though was the finding that intravenous injection of TLR ligands in high doses 
inhibited the generation of adaptive immune responses (Figure 2). TLR ligand-mediated immune 
suppression was characterized by strongly reduced numbers of antigen-specific T cells and a lack of 
antigen-specific cytotoxicity (Figure 2B, C). Importantly, this effect was strongly dependent on TLRs, 
as TLR deficient mice generated normal CTL response even upon injection of the ligand (Figure 3, 
Figure 26, Figure 28). 
It is assumed that cellular responses to TLR ligands are influenced by an individual expression pattern 
of single TLRs in respect of the cell type, localization and tissue (Kawai and Akira, 2005). The 
striking finding demonstrating that subcutaneous application of CpG enhanced CTL responses 
whereas intravenous application of CpG inhibited CTL responses suggests that the circumstances of 
immune activation determine whether a CTL response was induced or not.  
In particular, we observed that the time point of TLR ligation in respect to immunization/application 
of antigen and the dosage of TLR-L injected determined whether CTL induction was successful or 
not. With respect to the time point, systemic injection of TLR-L prior to immunization inhibited the 
CTL responses whereas injection of TLR-L one day after infection enhanced the CTL response 
(Figure 26). In this line, low doses of systemic TLR-L were stimulatory, while doses above a certain 
threshold inhibited CTL responses. 
To determine the mechanisms underlying the suppressive effect of TLR-L on the generation of CTL 
responses, one has to carefully look at the factors known to be essential for the activation of CD8 T 
cells: Firstly, DC have to take up antigen and present it to T cells (signal1). Secondly, DC have to be 
licensed by TLR stimulation and/ or CD40-CD40-Ligand interaction provided by CD4+ T cells. 
Thirdly, activated DC have to provide co-stimulation in form of receptors (signal 2; CD80/86) or 
cytokines (signal 3; IL-12, type I interferon). Finally, activated CD4 T cells have to provide help to 
CD8 T cells either by licensing DC, i.e. by maximizing costimulation or by providing IL-2 (Bennett et 
al., 1998; Ridge et al., 1998; Schoenberger et al., 1998). 
8  Discussion  
76 
We first investigated whether TLR-L impeded antigen presentation. As it is known that TLR 
triggering enhances the antiviral activity of innate cells (Blander and Medzhitov, 2004), TLR ligands 
could have diminished the viral load in a way that CD8 T cell activation was inhibited. We can 
exclude this possibility, as our results indicate that although CpG decreased the amount of antigen, the 
strength of the CTL response did not correlate with viral load. In particular, both high and low doses 
of CpG reduced the viral load equally strong (Figure 2F). But while the systemic application of CpG 
in high doses suppressed the CTL responses directed against a subsequent AdOVA infection, low 
doses of CpG even stimulated the CTL response compared to control-infected mice (Figure 2E). A 
recent study by the group of Villadangos demonstrated impaired phagocytosis and strongly reduced 
cross-presentation of OVA class I antigen by splenic CD8a+ DCs upon systemic injection of CpG 
(Wilson et al., 2006). In agreement with Wilson et al., we also detected decreased cross-presentation 
of OVA class I antigen after systemic application of CpG (data not shown). However, our results 
demonstrated that reduced cross-presentation did not affect CD8 T cell activation and therefore was 
not responsible for CpG induced CTL suppression.  
We could further exclude an inhibitory effect of TLR-L on antigen presentation based on transfer 
experiments. Adoptive transfer of exogenously antigen-loaded and matured APCs did not overcome 
the CTL suppression in TLR ligand treated mice, although untreated control mice generated a strong 
CTL response (Figure 11). These results rather supported the theory that TLR-L induced an inhibitory 
milieu, which was responsible for the observed block of T cell activation. Although TLR ligand- 
induced impairment of IL-12 and other pro-inflammatory cytokine production was a major 
characteristic of immune paralysis (Figure 7, Figure 8), the data suggest that although direct negative 
effects of TLR ligands on APCs can not be excluded, these effects can not exclusively be responsible 
for inhibition of endogenous T cell responses.  
 
CD8+ T cell activation greatly depends on the activation of DC (“licensing”), which either occurs by 
provision of CD4+ help via CD40 or TLR stimulation. As CD4+ T cells are important factors in the 
induction of CD8 T cell responses, we investigated whether systemic TLR-L blocked the generation of 
CD8+ T cell cytotoxicity via inhibition of CD4+ help. The importance of CD4+ help for the generation 
of cytotoxic CD8+ T cells against adenoviral antigens was demonstrated by two experiments. First, 
lack of OVA-specific CTL response in CD40-deficient animals upon infection with recombinant 
AdOVA demonstrated that the generation of OVA-specific CTL responses required CD40 co-
stimulation. Second, mice genetically deficient CD4+ T cells or MHC class II did not generate OVA-
specific CTL responses upon infection with recombinant AdOVA (Figure 5). These findings support 
current models postulating that CTL responses require CD4+ T cell help (Behrens et al., 2004; Bevan, 
2004)Castellino et al., 2006).  
Indeed, data presented in this thesis provide evidence that systemic TLR ligands negatively affected 
CD4 help. This was concluded from the observation that an adoptive transfer of activated antigen-
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specific CD4+ T helper cells restored antigen-specific CTL response in mice treated with ligands for 
TLR9 and TLR7 (Figure 13; Figure 33). This transfer experiment strongly indicated that systemic 
application of TLR ligands mainly affected CD4+ T cell help, whereas impairment of DCs seemed to 
be less important as otherwise activation of CD8 T cells by antigen presenting DC would not have 
been possible. Even if TLR ligands caused sub-optimal conditions of T cell priming by reducing the 
levels of class I presented antigen and lack of costimulatory cytokines such as IL-12, these deficits had 
been clearly overcome by the adoptively transferred exogenously activated CD4+ T cells.  
In summary, the transfer experiments imply two major facts: (1) inhibition of adaptive immunity could 
not solely be attributed to a functional impairment of DCs; the amount of antigen that is presented on 
class I must be sufficient for T cell activation and (2) a possible inhibitory milieu can be bypassed by 
transferring the activated CD4+ T cells. Also here, a hyper-reactivity of the transgenic T cells cannot 
be completely excluded.  
Future experiments are required to examine the role of CD40-CD40L triggered DC-T cell interaction 
during TLR ligand-induced suppression. To investigate this question, TLR ligand treated mice could 
be injected with a stimulatory anti-CD40 antibody or receive DCs that were in vitro transduced with a 
recombinant adenovirus expressing CD40L via an adoptive transfer. This may help to determine 
whether DC licensing via CD40-CD40L is affected during TLR ligand induced suppression. 
 
8.1.2 TLR7 ligand but not TLR9 ligand-mediated CTL suppression is 
dependent on type I interferons 
 
In addition to TLR9 ligand CpG, also systemic application of TLR7 ligand siRNA prior to AdOVA 
infection suppressed antigen-specific CTL responses in mice (Figure 27, Figure 28). In agreement 
with the results obtained in TLR9 ligand experiments, also the transfer of activated antigen-specific 
CD4+ helper cells rescued the CTL response in TLR7 ligand treated mice. In contrast to TLR9 ligand 
CpG, induction of immune suppression by TLR7 ligand siRNA was mediated by type I IFNs (Figure 
33). This finding contrasts the general association of type I IFNs with immune stimulation, as type I 
IFN can enhance maturation of DCs and provide signal 3 for T cell activation (Curtsinger et al., 2005). 
Besides the well described stimulatory effects of type I interferons, anti-inflammatory functions of 
type I IFN are observed in several models of autoimmunity (Hron and Peng, 2004; Katakura et al., 
2005; Touil et al., 2006; Yarilina et al., 2007). Type I IFN were shown to protect neonates from acute 
inflammation by induction of IL-10 producing B cells (Zhang et al., 2007). Furthermore, a report by 
Lehner et al. demonstrated induction of apoptosis in monocyte-derived DCs by type I IFN (Lehner et 
al., 2001). The groups of Welsh and Reimann demonstrate negative regulation of CTL responses by 
type I IFNs (Bahl et al., 2006; Dikopoulos et al., 2005). IFN$ interferes with CD25 expression and is 
also described to induce CD95 (Noronha et al., 1993; Rep et al., 1999).  
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How type I interferon influences DC mediated T cell activation plays a similar role in the TLR-L 
induced suppression of CTL responses, as described here, needs to be analyzed in future studies. This 
involves investigation of the cellular source, which produces high levels of type I interferon. In a 
preliminary experiment depletion of plasmacytoid dendritic cells as a primary responder to TLR7 
ligand and source of type I IFN was performed. Antibody mediated pDC depletion abrogated siRNA-
induced CTL suppression significantly, but not completely (data not shown). Although pDC are 
considered to be the most important source of type I interferons following TLR7 stimulation, our 
experiment suggests that other cells might produce type I interferons following challenge with TLR7-
L. Possible candidates are B cells as these cells express TLR7 and TLR9. Preliminary experiments that 
were performed in B cell deficient µMT-/- mice did neither indicate a role for B cells in TLR9 ligand 
nor in TLR7 ligand-mediated suppression (data not shown). However, µMT-/- mice still express pre-B 
cells (B1, B2) that may be involved in suppression. In addition, the use of genetically deficient 
animals may be limited to draw conclusions as these animals may compensate for the genetic lack of a 
certain molecule or cells by increased activation of other mechanisms. 
 
8.1.3 Therapeutic application of TLR ligands harbors possible risks of immune 
suppression 
Our data show that an intravenous injection of siRNA can suppress CTL responses in a TLR7 
dependent manner if siRNA is complexed to a carrier that targets the endosome. Importantly, the 
experimental dose of siRNA that induced suppression of adaptive immune responses in our 
experiments, was previously reported to exert immune stimulatory effects (Hornung et al., 2005). Our 
data demonstrate a relevance of siRNA-mediated suppression of immune responses against a 
secondary adenoviral infection in two experimental models of tumor therapy (Figure 30, Figure 32). In 
addition to previously described immune-stimulatory consequences that are mainly attributed to 
induction of high levels of type I interferon (Hornung et al., 2005), our data point out a critical role for 
type I interferons in immune suppression. 
Immune stimulatory properties of TLR ligands provide a promising tool for therapeutic application. 
Induction of pro-inflammatory cytokines facilitates the attraction of lymphocytes and a “productive” 
encounter with APCs. This is favored in circumstances of insufficient immunogenicity or actively 
induced “tolerance”, which may be induced by persistent infections or tumors in order to evade attack 
by the immune system. CpG and siRNA treatment currently represent a highly interesting approach of 
tumor therapy (Lu et al., 2005; Muller and Scherle, 2006; Xie et al., 2006). Certain RNA sequences 
are described to elicit immune stimulatory properties in a TLR7 dependent manner (Hornung et al., 
2005). Data from this thesis provide evidence that siRNA can suppress adaptive immune responses 
towards subsequent infections if circumstances of the application meet the criteria of a potential  
“danger” signal. Here, we define “danger” as the risk to induce systemic overwhelming inflammation 
that may be dangerous for the host.  
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We recommend that therapeutic application of TLR ligands should be carefully considered in order to 
prevent “accidental” T cell suppression towards subsequent infections during therapeutic application 
of immune-stimulatory TLR ligands. Our data indicate an increased risk of systemic application 
whereas local application did not inhibit immune responses. Our data show that intracellular targeting 
of siRNA into the cytoplasm instead of the endosome by choosing the appropriate carrier may offer a 
possibility to prevent “accidental” immune suppression due to systemic application of TLR ligands 
(Figure 28B). These observations may be the basis of future research to improve success and safety of 
TLR ligands in therapeutic applications. 
 
8.2 The role of TLRs in the induction of experimental cerebral malaria (ECM) 
8.2.1 Induction of pro-inflammatory effector mechanisms during Plasmodium 
infection is dependent on TLRs 
 
It is yet unresolved how immune effector mechanisms during Plasmodium ssp. infection are regulated 
that are necessary to efficiently combat parasites but may cause detrimental consequences due to 
excessive immune activation. Cerebral malaria (CM) is a major life-threatening complication due to P. 
falciparum infection in humans and is assumed to be a complex inflammatory syndrome. CM 
pathogenesis may be partially explained by a long-standing hypothesis postulating that immuno-
pathology is caused by inflammatory responses, leading to the disruption of the blood-brain barrier. 
Vascular leakage facilitated infiltration of parasitized erythrocytes and immune cells into the brain that 
harbors the risk of brain damage due to sequestration of parasitized erythrocytes or due to immune 
damage caused by parasite-specific CD8+ T cells. In humans, the examination of postmortem tissue or 
tissue biopsies exerts the only way of evaluating pathological processes. Thus, experimental studies in 
animal models are essential to identify biological processes during Plasmodium infection causing 
cerebral malaria. Among many different experimental malaria model systems, Plasmodium berghei 
ANKA (PbA) infection of C57BL/6 mice is the most accepted model to study the pathogenesis of 
experimental cerebral malaria processes in vivo, as most of the data generated in this system are 
considered to be similar to the human situation (Schofield and Grau, 2005).  
In the PbA infection, IFN! and T cells have been identified to be among those factors that are essential 
for the pathogenesis of ECM. This was concluded from experimental approaches performed in 
genetically deficient animals or by use of depleting antibodies (Yanez et al., 1999; Belnoue et al., 
2002; Hermsen et al., 1998) and was confirmed in this study (Figure 15).  
Until recently, the role of TLRs in the pathogenesis of ECM was unknown. First hints that 
Plasmodium-derived components are recognized through TLRs and induce immune activation are 
based on three recently published studies. TLR-mediated recognition of plasmodial components GPI 
occurs through TLR2, whereas TLR9 recognizes hemoglobin-degradation product hemozoin /parasite-
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derived DNA (Coban et al., 2005; Krishnegowda et al., 2005; Parroche et al., 2007). However, the 
biological relevance for TLRs in ECM pathogenesis was not examined up to now. 
We investigated the role of TLRs and their contribution to IFN! dependent effector mechanisms in the 
generation of innate and immune responses following Plasmodium berghei ANKA (PbA) infection. 
Mice deficient in TLR2, TLR3 or TLR9 were significantly protected against ECM upon PbA 
infection, which suggested that detection of PbA through TLR2, TLR3 and TLR9 leads to induction of 
detrimental inflammatory responses (Figure 14). These data are in line with a recent study from Coban 
et al., who attributed TLR2, TLR9 and MyD88 to the induction of ECM following PbA infection 
(Coban et al., 2007). Contradictory results were published by two other groups, that either excluded 
any relevance of TLRs in PbA infection (Togbe et al., 2007) or limited it to MyD88 (Lepenies et al., 
2007). A possible explanation for these discrepant observations may be that clones of PbA used in 
these studies differ in their ability to induce CM (Amani et al., 1998).  
For a long time it has been speculated where pathogenic T cells and inflammatory cytokines causing 
ECM are generated. Among direct effects on the brain, the spleen has been considered to play a role in 
ECM induction (Engwerda, 2005; Hermsen et al., 1998). Therefore, we studied whether and how the 
spleen influenced ECM induction. Interestingly, splenectomized animals were completely protected 
against developing ECM after PbA infection (Figure 15). Similar observations were published before 
in an infection model utilizing the related strain P. berghei K173 in mice (Hermsen et al., 1998; 
Kamiyama et al., 1987),  suggesting that a requirement of the spleen represents a general mechanism 
for priming of T cell responses following infection by different Plasmodium species (Engwerda et al., 
2005b). Additionally, our data indicate relevance for an intact micro-architecture of the spleen. 
Previous studies reported protection from ECM of RAG-1 deficient mice is based on the lack of 
effector B and T cells. The lack of these important lymphocyte populations in RAG deficient mice is 
likely to cause a disintegrated micro-architecture of the spleen (Mebius and Kraal, 2005). Transfer of 
CD8+ effector cells isolated from wild type donors 5 days after PbA infection induced ECM in RAG-1 
deficient recipients (Nitcheu et al., 2003). Here, we show that the generation of effector cells required 
an intact micro-architecture of the spleen as simple reconstitution of RAG-1 deficient mice with CD8+ 
and CD4+ splenocytes isolated from naïve wild type donors did not restore the ability to generate 
detrimental effector responses upon PbA infection (Figure 15). In addition, re-transfer of single-
splenocyte suspension after splenectomy of PbA-infected mice did not cause ECM development (data 
not shown). 
Our findings that depletion of dendritic cells resulted in protection of PbA infected mice from ECM 
pathology (Figure 16), is in line with a recent study (deWalick et al., 2007) and emphasizes the 
importance of DC in the induction of PbA-specific T cell responses as well as the production of 
inflammatory cytokines IL-12 and INF!. Depletion of CD4+ and CD8+ T lymphocytes protected PbA 
infected mice and demonstrated that T cells were critical effectors in ECM (Belnoue et al., 2002; 
Hermsen et al., 1998). However, as parasite-specific CTL responses cannot be determined in the 
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murine PbA infection model, we investigated the generation of CTL responses towards P. falciparum 
infection in vivo in HLA-A2 transgenic mice, which represent a humanized mouse model for P. 
falciparum infection (Ureta-Vidal et al., 1999). Importantly, the data from this thesis provide the first 
evidence that P. falciparum-specific T cell responses can be induced in a mouse model. In the HLA-
A2 transgenic model, the generation of P. falciparum-specific CTL was dependent on the spleen, as 
shown before for mouse model of PbA infection (Figure 22).  
Induction of IFN! depends on IL-12 and represents one of the most important biological activities of 
IL-12 that is linked to induction of a TH1 response (Hsieh et al., 1993; Kobayashi et al., 1989; 
Macatonia et al., 1995; Stern et al., 1990). Major producers of IFN! are activated T cells, but also NK 
cells and DCs. To investigate whether IL-12 was indeed involved in ECM induction, we performed 
experiments in mice deficient for IL-12p35. Interestingly, IL-12p35 deficient mice were protected 
against development of ECM following PbA infection (Figure 17), which indicated that the detection 
of parasites triggered effector mechanisms in an IL-12p35 dependent manner that finally led to 
immuno-pathological complications.  
Although the mechanism how inflammatory cytokines promote ECM is currently unknown, it is 
speculated that the induction of IFN! triggers effector mechanisms destabilizing the integrity of the 
blood-brain barrier. The resulting imbalance between neuroprotective and neurotoxic mediators is 
considered to be the cause of the subsequent brain damage (Medana et al., 2003; Medana et al., 2002). 
Catabolites of the tryptophan metabolism, kynurenic acid and quinolinic acid, are among those 
neurotoxic catabolites (Clark et al., 2005; Hunt et al., 2006; Sanni et al., 1998). The kynurenine 
pathway is activated by IFN! and generates neurotoxic and neuroprotective metabolites (Alberati-
Giani et al., 1996). Indoleamine 2,3 dioxygenase (IDO) is a key enzyme mediating tryptophan 
degradation, which can be blocked with 1-methyl tryptophan (1-MT). Preliminary data from our 
laboratory and work from others indicate that blockage of IDO by oral application of 1-MT can 
protect PbA infected mice against ECM (data not shown and (Clark et al., 2005). The authors 
observed that a shift of the ratio between the neurotoxic metabolite quinolinic acid and the 
neuroprotective metabolite kynurenic acid correlated with the protection from ECM induction (Clark 
et al., 2005).  
Taken together, our data suggest that during Plasmodium infection TLRs trigger a cascade of innate 
and adaptive immune mechanisms culminating in immune-mediated tissue damage.  
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8.2.2 Plasmodium itself inhibits detrimental effector mechanisms upon infection 
A key fining of this thesis was the observation that PbA itself was able to prevent detrimental effector 
responses. Whereas in other infections an increased dose of pathogens accelerates disease progess, 
here, wild type (WT) mice, that received higher doses of PbA (PbAhigh), survived PbA infection almost 
completely, whereas all mice died that were infected with low dose PbA (Figure 23). Our results show 
that TLR2, TLR3 and TLR9 were involved in mediating the protection from ECM and that induction 
of this protection was completely dependent on IL-12/IL-23p40 (Figure 23, Figure 24). In addition, 
mice deficient in IL-10 or iNOS were significantly less well protected against ECM upon infection 
with PbAhigh (Figure 25). A possible protective role for IL-10 and iNOS in prevention of ECM 
pathogenesis was reported by others (Kossodo et al., 1997); (Gramaglia et al., 2006). Both IL-10 and 
iNOS can be induced by IL-12 due to induction of a negative feedback mechanism. Protection against 
ECM is assumed to result from antagonizing pro-inflammatory mediators and inhibition of neurotoxic 
mediators (IDO) supporting a stabilized integrity of the blood brain barrier. 
Our data suggest that a subsequent induction of anti-inflammatory regulatory mediators are likely to 
be responsible for protection as seen in a recent study from Mitchell et al. (Mitchell et al., 2005). 
There, co-infection of C57BL/6 mice with P. berghei ANKA and P. berghei K173 prevented ECM–
related death. The authors determined increased levels of pro-inflammatory cytokines including IL-12 
and IFN! one day after co-infection and attributed this to the increased survival of the mice (Mitchell 
et al., 2005). Excessive production of pro-inflammatory mediators can activate negative feed-back 
mechanisms such as IL-10 to dampen inflammation. IL-10 is a potent inhibitor of IL-12 production by 
blocking transcription of both encoding genes (Aste-Amezaga et al., 1998). The important role of IL-
10 in immune regulation has been shown by uncontrolled, lethal systemic inflammation to various 
microorganisms in IL-10 deficient mice (Gazzinelli et al., 1996). 
 
8.2.3 TLR9 ligand CpG prevented effector mechanisms in Plasmodium infection 
through induction of DC paralysis and T cell suppression 
Protection from ECM induction following high dose PbA infection was partially absent in TLR9 
deficient mice (Figure 23), which emphasizes the impact of TLR-mediated regulation of detrimental 
inflammatory responses. The requirements for the induction of CTL responses were similar in 
Plasmodium ssp. infection and AdOVA infection with respect to the spleen. In both infection models, 
the induction of CTL responses required the spleen and DCs. As in the AdOVA infection model 
adaptive effector responses i.e. antigen-specific CTLs -were inhibited upon systemic application with 
synthetic TLR9 ligand (in a TLR9 dependent manner), we initially hypothesized that the generation of 
detrimental effector immune responses - i.e. inflammatory cytokines and CTLs - culminating in ECM 
following PbA infection, could be inhibited by systemic application of TLR9 ligand CpG.  
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Indeed, PbA-infected mice were protected against ECM if CpG was injected one day prior to or one 
day after PbA infection (Figure 18, Figure 20A). DCs are primary targets of TLR ligation (Reis e 
Sousa, 2006). Our data indicate a key role for these antigen-presenting cells in TLR ligand-induced 
inhibition of immune responses. A single systemic application of CpG led to the maturation of splenic 
DCs, which was characterized by an immediate production of IL-12 and increased expression of co-
stimulatory molecules (Figure 6). In contrast, repeated intravenous injections of mice with CpG 
induced a refractory state in splenic DCs as these cells were unable to produce IL-12, TNF" and 
IFN! (Figure 7). Reduced levels of IL-12 in the serum reflected a systemic down-regulation of 
inflammation (Figure 8D). Similar findings were described in 1999 by Reis e Sousa and coworkers in 
a murine model of Toxoplasma gondii infection. (Reis e Sousa et al., 1999). The inability of DCs to 
sustain IL-12 production after repeated microbial stimulation in vivo was termed “immune paralysis” 
of DCs and was shown to confer protection from IFN! dependent immune damage. In our experiments 
the DC paralysis protected PbA infected mice from immune damage (ECM) and lasted for up to seven 
days and was again in line with the results from Reis e Sousa (Reis e Sousa et al., 1999). Pathogen-
induced counter-regulation of IL-12 expression is not restricted to malaria or toxoplasmosis, as many 
reports exist, which demonstrate that control of IL-12 production can prevent tissue damage caused by 
excessive inflammation. In addition to Toxoplasma gondii, active induction of antigen presenting cell 
paralysis and IL-12 suppression mediated via viral pathogens is described for cytomegalovirus, 
Influenza virus or Measles virus (Andrews et al., 2001; Karp et al., 1996; Noone et al., 2005; Oldstone 
et al., 1999; Schneider-Schaulies et al., 2001; Slifka et al., 2003).  
Taken together, as DC-depleted as well as IL-12p35 deficient mice were protected against ECM upon 
PbA infection, we hypothesize that CpG-mediated protection resulted from the inability of DCs to 
produce IL-12 during PbA infection. TLR9 ligand CpG therefore induced not only a refractory state in 
DCs but inhibited PbA-specific cytotoxic T cell responses. This was strongly supported by the finding 
that TLR9 ligand CpG treatment caused a suppression of Plasmodium-specific CTL responses in 
HLA-A2 transgenic mice, a humanized model of P. falciparum infection (Figure 22). This is the first 
description of TLR ligand mediated inhibition of P. falciparum-specific CTL responses and 
emphasizes the relevance of TLRs in immune regulation of adaptive immune responses to 
Plasmodium infections. 
Overall, our results provide strong evidence for prevention of Plasmodium-induced inflammatory 
processes by systemic application of synthetic TLR ligands. Future therapeutic application of TLR 
ligands during Plasmodium infection requires a decisive staging of disease course and clinical 
progress of Plasmodium infection in humans. Our data show that TLR application in mice proximately 
to ECM onset harbors the risk of acceleration of inflammatory responses, thus therapeutic intervention 
aiming at stabilizing the blood-brain-barrier by regulation the balance between neurotoxic and 
neuroprotective factors may prevent progress in infection. The induction of an anti-inflammatory 
status in the infected host might offer a promising strategy for future therapeutic interventions. 
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8.3 Cellular refractoriness caused by TLR ligands 
 
The TLR ligand mediated immune suppression to virally expressed antigens was observed in a mouse 
model and is similar to a well-known phenomenon in patients that survived septic shock. These 
patients often suffer from insufficient protection against subsequent infections due to induction of 
immune paralysis characterized by lack of immune responses (Volk et al., 1991). This form of 
‘immunological paralysis’ is manifested by suppressed monocyte function, including low levels of 
MHC class II expression, reduced capacity for antigen presentation, and suppressed cytokine 
production (Munoz et al., 1991; Volk et al., 1996; Volk et al., 1991).   
Our observation regarding TLR-ligand-mediated immune suppression raise the question whether this 
negative effect of TLRs can be compared to the so-called “LPS tolerance” that is observed during 
sepsis (Karp et al.; 1998). Suppression of IL-12, loss of DCs and macrophage hypo-responsiveness are 
well-described symptoms of experimental endotoxin tolerance (Karp et al., 1998; Wysocka et al., 
2001). Some studies attribute hypo-responsiveness following repeated LPS challenge to down-
regulated expression and trapping of the receptor TLR4 to the Golgi apparatus (Hornef et al., 2002).  
As TLR 7 and TLR9 are intracellular receptors, an altered receptor expression upon repeated 
stimulation or retaining the receptors in different stages of the endosome/lysosome remain possibilities 
that would require extensive analysis. Recent studies suggest induction of several negative regulators 
to disturb/inhibit cellular responses to TLRs (Liew et al., 2005). These include soluble decoy 
receptors, but also downstream of the receptors several intracellular negative regulators may be 
involved. It remains to be determined whether specific negative regulators are activated by ligands for 
TLR9 or TLR7. 
 
 
8.4 Conclusion and outlook 
 
Our findings support the importance of TLRs in the regulation of immune responses towards 
infections. The data from this thesis provide strong evidence that suppression of T cell responses by 
systemic application of TLR ligands and pathogens is the result of interference in DC-T cell 
interaction. In particular, all TLR ligands examined in this thesis were able to suppress CTL responses 
if they were applied systemically in high doses prior to antigen application. We suggest that the 
induction of immune suppression represents a type of “emergency shutdown” that is induced when 
circumstances of TLR activation or infection represent a serious danger by excessive inflammation.  
We conclude that TLR mediated CTL suppression cannot be attributed to a simple molecular switch 
but rather is the result of multiple factors that interfere with CTL priming.  
Our data suggest that pathogens such as Plasmodium ssp. may benefit from the mechanisms of 
immune suppression - evolved and dedicated for the host as mechanism of protection - as a possibility 
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of immune evasion or silencing. Prevention of detrimental host responses is favorable for 
Plasmodium, as this parasite has to complete its life cycle. 
We hypothesize that TLR dependent induction of immune suppression by recognition of endogenous 
ligands represents an ongoing physiological mechanism to prevent potentially undesired or even 
harmful immune response.  
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10 Appendices 
10.1 Publications and contributions to scientific conferences 
 
Parts of this thesis are published  
•  G. Wingender*, N. Garbi*, B. Schumak*, F. Jüngerkes*, E. Endl, D. von Bubnoff, J. Steitz, J. 
Striegler, G. Moldenhauer, T. Tüting, A. Heit, K. M. Huster, O. Takikawa, S. Akira, D. H. 
Busch, H. Wagner, G. J. Hämmerling, P. A. Knolle and A. Limmer (2006). 
Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via 
induction of IDO. Eur J Immunol 36, 12-20. 
  
*These authors contributed equally to this work 
 
Contribution to other publications: 
• Wingender, G., B. Schumak, A. Schurich, J. E. Gessner, E. Endl, A. Limmer & P. A. Knolle 
(2006). 
Rapid and preferential distribution of blood-borne alphaCD3epsilonAb to the liver is 
followed by local stimulation of T cells and natural killer T cells. Immunology 117 (1); 
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CpG-rich oligonucleotides (CpG-ODN) bind to Toll-like receptor 9 (TLR9) and are used
as powerful adjuvants for vaccination. Here we report that CpG-ODN not only act as
immune stimulatory agents but can also induce strong immune suppression depending
on the anatomical location of application. In agreement with the adjuvant effect,
subcutaneous application of antigen plus CpG-ODN resulted in antigen-specific T cell
activation in local lymph nodes. In contrast, systemic application of CpG-ODN resulted
in suppression of T cell expansion and CTL activity in the spleen. The suppressive effect
was mediated by indoleamine 2,3-dioxygenase (IDO) as indicated by the observation
that CpG-ODN induced IDO in the spleen and that Tcell suppression could be abrogated
by 1-methyl-tryptophan (1-MT), an inhibitor of IDO. No expression of IDO was
observed in lymph nodes after injection of CpG-ODN, explaining why suppression was
restricted to the spleen. Studies with a set of knockout mice demonstrated that the CpG-
ODN-induced immune suppression is dependent on TLR9 stimulation and independent
of type I and type II interferons. The present study shows that for the use of CpG-ODN as
an adjuvant in vaccines, the route of application is crucial and needs to be considered. In
addition, the results indicate that down-modulation of immune responses by CpG-ODN
may be possible in certain pathological conditions.
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Introduction
The immune system has developed mechanisms for
recognition of conserved structures on pathogens [1, 2].
Toll-like receptors (TLR), expressed on various cells of
the innate immune system, are well-known examples for
such pattern recognition receptors. Activation of cells
via TLR ligands leads to the rapid production of
proinflammatory mediators, which control infections
locally and attract leukocytes to the site of infection [1,
3]. TLR9 is expressed on various cells including B cells,
macrophages and DC, and binding of its ligand, CpG-
rich oligonucleotides (CpG-ODN), induces strong pro-
duction of proinflammatory cytokines (e.g. IL-1, IL-6, IL-
12, type I interferons), chemokines (e.g. MCP-1,
RANTES, IP10) and costimulatory molecules (e.g.
CD40, CD80, CD86) [1, 4, 5]. As a result, direct
activation of DC by TLR9 signaling is a prerequisite for
induction of full T cell function [6]. Activation of DC via
TLR thus provides a link between innate and adaptive
immunity [4, 5, 7–10]. Therefore, CpG-ODN applied
locally has been successfully used as an adjuvant for
vaccination in animal models and clinical trials [11–15].
Here we show that in addition to its immune
stimulatory effect, CpG-ODN can also be immunosup-
pressive. Namely, when applied systemically CpG-ODN
inhibited T cell responses in the spleen. The suppressive
effect was mediated by induction of indoleamine 2,3-
dioxygenase (IDO), an enzyme known to suppress T cell
expansion. These results indicate that the route of CpG-
ODN application is critical for regulating T cell
immunity.
Results
Systemic CpG-ODN administration suppresses
CTL activity in vivo
The synthetic TLR9 ligand CpG-ODN, a model for
microbial DNA, is an established adjuvant that augments
immune reactions [7, 9, 16]. Accordingly, we observed
increased ovalbumin (OVA)-specific CTL activity in the
draining lymph node following co-administration of
OVA and CpG-ODN s.c. (Fig. 1A). Injected target cells
loaded with the OVA-derived peptide SIINFEKL were
lysed in the draining lymph node about ten times more
efficiently in mice immunized s.c. with OVA plus CpG-
ODN compared with mice immunized s.c. with OVA
alone. In the spleens of mice immunized s.c. with OVA
plus CpG-ODN, we also observed about 40% specific
cytotoxicity, suggesting that a number of CTL had
migrated from the lymph node to the spleen (data not
shown). It has been previously reported that i.v.
application of soluble (LPS-depleted) OVA induces
CTL activity [17, 18]. Consistent with this, we observed
about 30–40% in vivo CTL activity in mice injected i.v.
with OVA (Fig. 1A). Surprisingly, co-administration of
OVA and CpG-ODN i.v. strongly reduced the specific CTL
response in vivo compared with mice injected i.v. with
OVA alone (Fig. 1A).
The contrasting effects of CpG-ODNapplied locally or
systemically on CTL activity may be explained by the
different routes of administration. Therefore, we next
investigated the effect of CpG-ODN on the generation of
CTL activity in isolated cells fromperipheral lymphnodes
and spleen, because these represent the main lymphoid
organs targeted by s.c. and i.v. application, respectively.
For this, we incubated lymph node cells and splenocytes
Figure 1. Generation of cytotoxicity is inhibited by systemic application of CpG-ODN. (A) C57BL/6 mice were injected with 100 lg
OVAalone or in combinationwith 50 lgCpG-ODN (either s.c. or i.v.). In vivo cytotoxicitywas determined5 days later by quantifying
the lysis of target cells loadedwith the OVA-derived, H2-Kb-restricted SIINFEKL in the draining lymph node (s.c. immunization) or
in the spleen (i.v. immunization) 16 h after target cell transfer into the effectormice. (B) Spleen or lymph node cells fromOT-Imice
were incubated in vitrowith 500 lg/mLOVA alone (light grey) or in the presence of 5 lg/mLCpG-ODN (dark grey), and 4 days later in
vitro cytotoxicitywas determined by a standard [51]Cr-release assay. Shown is specific cytotoxicity at an E:Tratio of 25:1. Results are
expressed as mean  standard error of the mean (SEM). Representative data are shown.
Gerhard Wingender et al. Eur. J. Immunol. 2006. 36: 1–92
f 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji.de
from OT-I mice, which harbor transgenic OVA-specific
CD8+Tcells, withOVA alone or together with CpG-ODN.
Development of CTL activity in the spleen was strongly
suppressed by CpG-ODN (about 10-fold) (Fig. 1B), in
agreement with the reduced CTL activity observed in the
spleenafter i.v. immunization (Fig.1A). In contrast, CpG-
ODNhad only aminor effect on isolated lymphnode cells
with respect to CTL activity (Fig. 1B), suggesting that
organ-resident cells in lymph node and spleen respond
differentially to CpG-ODN. Thus, these results indicate
that the suppressive effect of systemic CpG-ODN
application on CTL generation is mainly due to a
negative effect of CpG-ODN in the spleen.
Systemic CpG-ODN application suppresses anti-
viral T cell responses in a dose-dependent fashion
Next, we studied whether the inhibitory activity of CpG-
ODN on CTL generation also affects virus-specific T cell
responses. CpG-ODN were injected i.v. into mice,
followed 1 day later by i.v. infection with adenovirus
expressing OVA (AdOVA). The generation of CTL specific
Figure 2. Systemic CpG-ODN inhibits generation of anti-viral T cell responses. (A) CpG-ODN or non-CpG-ODN were injected i.v.
into C57BL/6mice 1 day before AdOVA immunization (1  108 pfu i.v.). In vivo cytotoxicity in the spleenwas quantified 5 days later
in a 4-h assay as described in the legend to Fig. 1A. (B) CpG-ODNwere injected i.v. into C57BL/6mice 1 to 5 days before immunizing
mice with AdOVA (1  108 pfu i.v.). In vivo cytotoxicity was analyzed as described in (A). (C) Different doses of CpG-ODN were
injected i.v. into C57BL/6  BALB/c F1 1 day before infection with AdLucGFP (1  108 pfu i.v.). In vivo cytotoxicity was analyzed
5 days later by quantifying lysis of target cells loaded with GFP-derived, H2-Kd-restricted HYLSTQSAL. (D) IgG titers specific for
adenovirus (aAd IgG, top) or OVA (aOVA IgG, bottom) in the plasma of C57BL/6 mice pretreated or not with CpG-ODN i.v. and
immunized 1 day laterwithAdOVAwerequantified by ELISA. Shownare serum IgG levels obtained 21 days after immunization. (E)
C57BL/6  BALB/c F1 mice were injected i.v. with the indicated doses of CpG-ODN 1 day before immunization with AdLucGFP.
Adenovirus-related bioluminescence was quantified 3 days after immunization to determine viral load in the host. ROI is the
region of interest; ROI numbers indicate light intensity in the ROI. Results are expressed as mean  standard error of the mean
(SEM). Representative data are shown.
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for OVA (H2-Kb/SIINFEKL) was again strongly sup-
pressed by systemic CpG-ODN application (Fig. 2A).
This suppressive effect was specific to CpG motifs,
because non-CpG-ODN had no effect on CTL activity
(Fig. 2A), and long-lasting, since a single CpG-ODN
application at least 5 days before infection with AdOVA
inhibited generation of specific CTL activity (Fig. 2B).
We then investigated the dose dependency of the
CpG-ODN-induced T cell suppression. For this purpose,
adenovirus expressing GFP and luciferase (AdLucGFP)
was used for infection of mice so that we could quantify
both CTL responses against GFP (Kd/HYLSTQSAL) as
well as the adenoviral load by bioluminescence imaging.
The suppressive effect of CpG-ODN on CTL generation
was dose-dependent, since a clear inhibition was
observed when a relatively high dose of 50 lg was
injected i.v., but injection of 5 or 0.5 lg CpG-ODN had
no effect (Fig. 2C). Because all doses of CpG-ODN
resulted in reduced adenoviral load in the host (Fig. 2E),
the suppressive effect on CTL generation cannot be
solely attributed to decreased antigen expression.
To investigate whether or not systemic CpG-ODN
administration also suppresses CD4+ T helper cell
function, we quantified anti-adenovirus and anti-OVA
IgG serum titers in mice treated with CpG-ODN i.v. and
infected with AdOVA i.v. 1 day later, since T helper cell
function is required for optimal Ig isotype class switch.
Induction of serum IgM antibodies specific for adeno-
virus or OVA was not negatively affected by systemic
CpG-ODN application (data not shown). However,
systemic application of CpG-ODN dramatically reduced
serum titers of anti-adenovirus and anti-OVA IgG inmice
infected with AdOVA (Fig. 2D).
CpG-ODN treatment impairs antigen-specific
clonal T cell expansion
The reduction in CTL activity caused by systemic CpG-
ODN treatment may have been the result of impaired T
cell expansion. To investigate whether Tcell expansion is
inhibited by CpG-ODN treatment, CFSE-labeled spleen
cell suspensions from OT-I (OVA-specific) TCR-trans-
genic mice were incubated in vitro with OVA alone or in
combination with CpG-ODN. In agreement with the
decreased cytotoxicity described earlier (Fig. 1B), CD8+
T cell proliferation was strongly inhibited by CpG-ODN
treatment (Fig. 3A). Likewise, OVA-specific CD4+ T cell
proliferation was reduced, although to a lesser extent
(Fig. 3A). These results indicate that one mechanism by
which CpG-ODN treatment inhibits T cell function is the
limitation of antigen-specific expansion. Furthermore,
the suppression of cell proliferation was T cell-specific,
because B cells proliferated extensively in response to
CpG-ODN (Fig. 3A), as previously reported [7]. In
agreement with these data on in vitro proliferation,
CD8+ Tcell expansion in vivowas also inhibited, because
the percentage of Kb/SIINFEKL tetramer-positive cells
was strongly reduced in wild-type mice injected i.v. with
CpG-ODN followed by AdOVA 1 day later (Fig. 3B).
Figure 3. Suppression by CpG-ODN
is due to impaired antigen-specific
T cell proliferation. (A) CFSE-labeled
splenocytes fromOT-Imice (left and
right) or OT-II mice (middle) were
incubated in vitro with 500 lg/mL
OVA alone (filled histogram) or in
the presence of 5 lg/mL CpG-ODN
(bold line). The indicated cell po-
pulations were analyzed for prolif-
eration by flow cytometry 4 days
later. (B) Indicated amounts of CpG-
ODN were injected i.v. into C57BL/6
mice 1 day before challenge with
AdOVA (1  108 pfu i.v.). The per-
centage of H2-Kb/SIINFEKL-specific
CD8+ T cells in the spleen was
determined 5 days later by flow
cytometry using specific tetramers.
Results are expressed as mean 
standard error of the mean (SEM).
Representative data are shown.
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Systemic CpG-ODN administration induces IDO
expression in the spleen
It has been reported that activation of the enzyme IDO
can inhibit T cell proliferation via depletion of
tryptophan and/or via generation of suppressive
tryptophan cleavage products [19, 20]. We investigated
whether the suppressive effect of systemic CpG-ODN
application on T cell expansion is linked to IDO activity.
First, the serum of C57BL/6 mice treated with CpG-ODN
i.v. was analyzed for the presence of tryptophan
metabolites. The ratio of the tryptophan cleavage
product kynurenine to tryptophan increased in the
serum shortly after CpG-ODN injection (Fig. 4A),
indicating that IDO activity was induced in vivo by
systemic CpG-ODN challenge.
Next we investigated by immunohistology whether
IDO is expressed in the spleen after systemic application
of CpG-ODN. A dose of 0.5 lg CpG-ODN failed to induce
IDO (data not shown), although it resulted in protective
innate immunity against adenovirus (Fig. 2E). However,
24 h after i.v. injection of 50 lg CpG-ODN, expression of
IDO in the spleen was observed (Fig. 4B). In contrast to
the spleen, no IDO expression was found in peripheral
lymph nodes after i.v. treatment with CpG-ODN
(Fig. 4B). Systemic administration of a single dose of
CpG-ODN did not caused structural changes in the
splenic architecture, as has been reported whenmultiple
doses of CpG-ODN were applied [21].
T cell suppression by systemic CpG-ODN
treatment is mediated by IDO activity
For investigation of the functional relevance of IDO
expression, the tryptophan analogue 1-methyl-trypto-
phan (1-MT), a well-established competitive inhibitor of
IDO [19, 20, 22], was used. OVA-induced proliferation
of CFSE-labeled OT-I cells was blocked by the presence
of CpG-ODN in in vitro culture (Fig. 5A). Addition of 1-
MT interfered with this suppression, resulting in
proliferation of the OT-I cells. Likewise, the in vitro
generation of OVA-specific CTL was inhibited by CpG-
ODN, but not when IDO was blocked with 1-MT
(Fig. 5B). Importantly, by giving mice 1-MT in the
drinking water, antigen-specific CD8+ T cell prolifera-
tion and cytotoxicity to soluble antigen (OVA) was
restored (Fig. 5C, left). As expected, the restoration of
cytotoxicity was accompanied by an increase in the
number of tetramer-positive, OVA-specific CD8+ T cells
(Fig. 5C, right).
Figure 4. Systemic CpG-ODN induce IDO expression
in the spleen. (A) C57BL/6micewere treated i.v. with
50 lg CpG-ODN, and after 24 or 48 h, the amounts of
tryptophan and its cleavage product kynurenine in
serum were determined. Results are expressed as
mean  standard error of the mean (SEM).
(B) C57BL/6 mice were treated i.v. with 50 lg CpG-
ODN. After 24 h, spleen cryosections were stained
for IDO (red) and nuclei counter-stained with
Hoechst 33258 (blue) (size bar =200 lm). Represen-
tative data are shown. No induction of IDO was
obtainedwith a control, non-CpG-ODN (not shown).
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CpG-ODN-mediated immune suppression is
TLR9-dependent but independent of IFNa and
IFNc
Immunostimulatory CpG-ODN are known to bind to
TLR9 [23]. We used TLR9–/– mice to investigate whether
the CpG-ODN-induced suppression is also dependent on
TLR9. No suppression of OVA-specific cytotoxicity by
CpG-ODN was found in TLR9-deficient mice after
immunization with AdOVA (Fig. 6A), indicating a
primary role for TLR9 in the suppressive effect.
Comparable results were obtained in mice infected with
Listeria monocytogenes expressing OVA as a transgene
(LmOVA). Again, CpG-ODN prevented the formation of
OVA-specific CD8+ T cells, whereas no such suppression
occurred in TLR9–/– mice (Fig. 6B).
Tumors and infections have been reported to induce
IDO in an IFNc-dependent way [24, 25]. Therefore we
investigated whether type I and II interferons are
responsible for the CpG-ODN-induced suppression
described here. Strong suppression by systemic CpG-
ODN application was still obtained in IFNaR–/– and
IFNc–/– mice immunized with AdOVA virus (Fig. 6C, D).
These findings argue against a decisive role of type I and
II interferons in CpG-ODN induced suppression.
Discussion
TLR ligands such as CpG-ODN are potent stimulators of
innate and adaptive immune responses and are, there-
fore, used as adjuvants for immunization. The present
study demonstrates that CpG-ODN can also have adverse
effects and suppress Tcell responses. The anatomical site
of application appears to be critical in determining the
immunosuppressive versus stimulatory effects of CpG-
ODN. Stimulation and suppression of immunity are
induced in distinct lymphoid organs. Thus, subcuta-
neous injection of antigen plus CpG-ODN, as performed
for many types of vaccinations, results in a strong T cell
response in the local lymph node. In contrast,
systemically injected CpG-ODN induced suppression
of Tcell proliferation and the generation of effector cells
in the spleen. CpG-ODN did not negatively affect
antigen-presenting DC and effector T cells directly (data
not shown). Rather, this suppression was found to be
mediated by induction of IDO, an enzyme known to
degrade tryptophan, an essential amino acid for
Figure 5. CpG-ODN-induced suppression is mediated by IDO
activity. (A) CFSE-labeled splenocytes from OT-I mice were
incubated in vitrowith 500 lg/mL OVA alone (filled histogram),
together with 5 lg/mL CpG-ODN (dotted line) or together with
5 lg/mL CpG-ODN and 1 mM 1-MT (bold line), and CD8+ T cells
were analyzed for proliferation 3 days later. (B) OT-I spleno-
cytes were incubated in vitro with 500 lg/mL OVA alone or in
combination with 5 lg/mL CpG-ODN and 1 mM 1-MT, and
4 days later cytotoxicity in vitro was determined by [51]Cr-
release assay (E:T =100:1). (C) C57BL/6 mice were treated i.v.
with 100 lg OVA alone or in combination with 50 lg CpG-ODN
and 1-MT (5 mg/mL in the drinking water) as indicated, and
5 days later in vivo cytotoxicity (left panel) and the percentage
of H2-Kb/SIINFEKL-specific CD8+ T cells (right panel) were
determined. Results are expressed asmean standard error of
the mean (SEM). Representative data are shown.
Figure 6. CpG-ODN-mediated immunosuppression is TLR9-
dependent but independent of IFNa and IFNc. TLR9-deficient
mice (TLR9–/–) or wild-type C57BL/6 littermates (wt) were
injected i.v. with 50 lg CpG-ODN 1 day before AdOVA (1  108
pfu i.v.) (A) or OVA-expressing L. monocytogenes (2  103 LmOVA
i.v.) (B) challenge. OVA-specific cytotoxicity in vivo was
quantified in the spleen 5 days after infection (A). OVA-specific
CD8+ T cells were quantified in the spleen using specific
tetramers 7 days after infection (B). IFNc–/– (C) or IFNaR–/– (D)
mice were injected i.v. with 50 lg CpG-ODN 1 day before
AdOVA (1  108 pfu i.v.), and 5 days later OVA-specific in vivo
cytotoxicity was determined in the spleen. Results are
expressed as mean  standard error of the mean (SEM).
Representative data are shown.
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proliferation of CD4+ and CD8+ T lymphocytes [26, 27].
IDO can be produced by various cell types, including
macrophages, immature DC, plasmacytoid DC (pDC)
and non-hematopoietic cells such as trophoblasts and
lung epithelial cells [25, 27]. The nature of the IDO-
producing cell types in the spleen is not yet clear. Their
identification may be complicated, because it is known
that cells can express IDO in a functionally inactive form
[20, 25]. Preliminary experiments indicate that pDC are
not involved (or solely responsible), as in vivo depletion
with a pDC-specific antibody had no effect on suppres-
sion (own unpublished data).
Induction of IDO and Tcell suppression in the spleen
was dose-dependent and observed only at a dose of
50 lg CpG-ODN per mouse. It is interesting to note that
smaller doses of CpG-ODN (0.5 and 5 lg) appear to be
sufficient for induction of innate immunity, as indicated
by the finding that these doses drastically reduced the
load of adenovirus in the host (see Fig. 2E). These
observations suggest that induction of IDO requires
much higher concentrations of CpG-ODN than induction
ofmediators of innate immunity, such as IL-12 and type I
and II interferons, which are likely to be involved in the
protection against virus. Work with various knockout
mice demonstrated that interaction of CpG-ODN with
TLR9 is required for T cell suppression in the spleen.
However, it is not clear if TLR9-positive cells directly
produce IDO uponTLR9 engagement or if IDO induction
is an indirect effect mediated by soluble factors that are
released uponTLR9 stimulation.We could exclude type I
and type II interferons as mediators of suppression,
because CpG-ODN-induced inhibition was still observed
in IFNaR–/– and IFNc–/– mice. It is known that tumors
and infections can induce IDO in various cells types in a
IFNc-dependent manner [24, 25, 27]. The experiments
described here failed to reveal a role for type I and II
interferons in CpG-ODN-induced and IDO-mediated
suppression and therefore argue for a different mode of
IDO induction. Further studies are required for
elucidation of the mechanism of IDO induction by
CpG-ODN.
In conclusion, we have shown that CpG-ODN can be
either immunostimulatory or suppressive, depending
upon the anatomical site of application. These observa-
tions are important with regard to the use of CpG-ODN
in vaccines, and they may explain why in clinical trials,
s.c. immunization was superior to i.v. immunization in
terms of the protection provided [12]. However,
suppression by systemic CpG-ODN application may also
be beneficial in some situations. For example, i.v.
application of CpG-ODN in a mouse model of experi-
mental asthma resulted in induction of IDO in the lung
and amelioration of asthma, but the precise mechanism
of action is not clear [26]. Our results indicate that Tcell
immunity can be regulated depending on the route of
CpG-ODN administration, thus opening up the possibi-
lity to reduce (suppress) unwanted T cell responses.
Materials and methods
Mice
Mice were maintained under specific pathogen-free conditions
at the animal facilities of the ZMBH and DKFZ (Heidelberg,
Germany) and the IMMEI (Bonn, Germany). C57BL/6 and
BALB/c mice were purchased from Jackson Laboratories (Bar
Harbor, Maine, USA) or Harlan Winkelmann (Borchen,
Germany). OVA-specific CD8+ T cell-transgenic OT-I mice
[28], OVA-specific CD4+ T cell-transgenic OT-II mice [29] and
mice deficient for TLR9, IFNaR or IFNc have been described
elsewhere [30] and were all on a C57BL/6 background.
Reagents and antibodies
OVA grade II and VII was purchased from Sigma (Deisenhofen,
Germany). Polymyxin-B columns for the removal of LPS
contamination from soluble OVA were obtained from Pierce
(Bonn, Germany). The peptides SIINFEKL (OVA257–264, H2-K
b-
binding) and HYLSTQSAL (GFP200–208, H2-K
d-binding) were
synthesized by Pineda (Berlin, Germany). CFSE and 7-
aminoactinomycin D (7-AAD) were from Molecular Probes
(Leiden, The Netherlands). LPS-free phosphorothioate-stabi-
lized CpG-ODN 1668 (referred to as CpG-ODN) and mamma-
lian non-CpG-ODN AP-1 [9] were synthesized by TIB MolBiol
(Berlin, Germany). Recombinant adenovirus type 5 expressing
OVA (AdOVA) or AdLucGFP were constructed as previously
described [31]. Fluorochrome-labeled and biotinylated anti-
bodies used for flow cytometry and immunohistology were
from BD Biosciences (Heidelberg, Germany).
Immunizations
For immunizations with soluble OVA, C57BL/6 mice were
injected i.v. or s.c. (intra ear pinna) with 100 lg OVA alone or
in combination with 50 lg CpG-ODN. For adenoviral infec-
tions, the indicated doses of CpG-ODN or mammalian non-
CpG ODNwere applied i.v. 1 day before i.v. immunizationwith
1  108 pfu AdOVA . The dose dependency of CpG-ODN
immunosuppression was investigated by administering CpG-
ODN i.v.1 day before infecting C57BL/6  BALB/c F1mice i.v.
with 1  108 pfu AdLucGFP. Kb/SIINFEKL- or Kd/HYLSTQSAL-
specific cytotoxicity in vivo was quantified in the spleen (i.v.
immunization) or draining lymph nodes (s.c. immunization)
as described below 5 days after immunization. LmOVA were
grown in brain heart infusion broth. For infectionwith LmOVA,
a sublethal dose of 2x103 bacteria was injected into the tail
veins of 8-week-old C57BL/6 mice. OVA-specific T cell counts
(by Kb/SIINFEKL tetramers) were determined 7 days later in
spleens of infected mice.
In vitro cell culture, cell proliferation and cytotoxicity
Spleen cells from C57BL/6, OT-I or OT-II mice were incubated
at 1  106 cells/mL with 500 lg/mL OVA alone or in
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combination with 5 lg/mL CpG-ODN. For proliferation
studies in vitro, spleen cells were labeled with 5 lM CFSE as
described previously [17, 18] before addition of OVA and CpG-
ODN. Proliferation of CD8+ Tcells, CD4+ Tcells and B cells was
analyzed by flow cytometry 3 or 4 days later using a
FACScalibur or LSR II (BD Biosciences). The effect of CpG-
ODN on OVA-specific CD8+ T cell expansion was investigated
in C57BL/6 mice immunized with AdOVA with and without
CpG-ODN as described above. The percentage of H2-Kb/
SIINFEKL-specific CD8+ T cells in the spleen was determined
by flow cytometry using specific tetramers as previously
described [32].
CTL cytotoxicity was measured in vivo as previously
described [17, 18]. Briefly, target spleen cells from C57BL/6
or C57BL/6  BALB/c F1 mice were pulsed with 1 lg/mL
SIINFEKL or HYLSTQSAL for 45 min at 37C and subsequently
labeled with 1 lM CFSE for 15 min at 37C (CFSEhigh, specific
target cells) or were not pulsed with peptide and labeled with
0.1 lM CFSE (CFSElow, non-specific target cells). The two
target cell populations were mixed in equal numbers and
injected i.v. into effector mice. Unless otherwise indicated,
mice were killed 4 h later and the ratio of recovered specific
versus non-specific target cells in spleen or draining lymph
nodes quantified by flow cytometry. The percentage of specific
lysis was calculated using the following equation:
100 – [100  (CFSEhigh / CFSElow)immunized / (CFSEhigh /
CFSElow)non-immunized]
In vitro cytotoxicity was assessed with a standard 5-h [51]Cr-
release assay as previously described [18].
Antibody responses
C57BL/6 mice were immunized with AdOVA alone or in
combination with CpG-ODN as described above. IgG serum
titers specific for adenovirus or for OVA were quantified by
ELISA 21 days after immunization using plates coated with
adenoviral particles or OVA, respectively and using POX-
conjugated goat-anti-mouse-IgG and goat-anti-mouse-IgM
monoclonal antibodies (BD-Biosciences, Heidelberg, Ger-
many)
IDO expression, activity and inhibition
IDO expression was assessed by fluorescent immunohistology
on cryosections of mouse spleens fixed in acetone and stained
with rabbit anti-IDO serum [24] followed by AlexaFluor 647-
conjugated anti-rabbit mAb (Molecular Probes). Nuclei were
counterstained with Hoechst 33258. Sections were analyzed
on an Olympus IX71 invertedmicroscope (Olympus, Hamburg,
Germany). The ratio of L-kynurenine/L-tryptophan in serum,
an indicator of IDO activity, was quantified by HPLC
(Shimadzu, Duisburg, Germany) as previously described
[33]. IDO activity was blocked using the competitive inhibitor
D-isomer of 1-methyl-tryptophan (1-MT; Sigma). For blocking
IDO in vitro, 1 mM 1-MT was added to the cell cultures
simultaneously with OVA and CpG-ODN. For inhibition of IDO
activity in vivo, 5 mg/mL 1-MT was supplied in the drinking
water 1 day before CpG-ODN administration and continued
for 5 days[22].
Bioluminescence imaging
The AdLucGFP load in C57BL/6  BALB/c F1 mice was
quantified by in vivo bioluminescence using the real-time IVIS
Imaging System 200 (Xenogen Corp., Alameda, CA, USA), as
described elsewhere [34]. Briefly, mice were infected i.v. with
1  108 pfu AdLucGFP and analyzed for bioluminescence
measurement 24 h later. Mice were injected with 2.5 mg
luciferin (S039; Synchem, Kassel, Germany) and anesthetized
with isofluran 5 min before quantification of bioluminescence.
Data were analyzed using Living Image 2.50 software
(Xenogen Corp.).
Statistical analysis
Results are expressed as mean  standard error of the mean
(SEM). Comparisons were drawn using a two-tailed Student t-
test (Excel, Microsoft Corporation, Redmond, USA) or a two-
way ANOVA test (Prism, GraphPad Software Inc., San Diego,
USA).
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